Memorial Sloan-Kettering Cancer Center &
Weill Medical College of Cornell University
Required Format for *Curriculum vitae* and Bibliography

Date of preparation: January 17, 2024

A. GENERAL INFORMATION

1.	Name	Steven Mark Larson, MD, FACNP, FACR
2.	Office address	1275 York Avenue, MITS SC-212 New York, NY 10065
	Office telephone	212-717-3263
	Office fax	212
3.	Home address	452 Gilman Street Bridgeport, CT, 06605
	Home telephone	
4.	Cell Phone	917-660-3227
5.	Beeper	N/A
6.	Email	larsons@mskcc.org
7.	Citizenship	USA

B. EDUCATIONAL BACKGROUND

Degree	Institution name and location	Dates attended	Year awarded
BA in Zoology	University of Washington Seattle, Washington	1959-1963	1963
MD	University of Washington Seattle, Washington	1963-1968	1968

C. PROFESSIONAL POSITIONS AND EMPLOYMENT

1. Post-doctoral training including residency/fellowship

Title	Institution name and location	Dates held
Summer Fellowships in Nuclear Medicine	University of Washington Seattle, Washington	1964-1965
Post-Sophomore Fellowship in Nuclear Medicine	University of Washington Seattle, Washington	1965-1966
Straight Medicine Internship	Virginia Mason Hospital Seattle, Washington	1968-1969
Assistant Surgeon	USPHS Commissioned	11/4/1968
Resident in Medicine	Virginia Mason Hospital Seattle, Washington	1969-1970

2. Academic positions **(teaching and research)**

Title	Institution name and location	Dates held
Assistant Professor	Department of Radiologic Sciences Johns Hopkins Medical Institutions Baltimore MD	1972-1975
Associate Professor of Medicine	Oregon Health & Science University Portland, Oregon	1975-1976
Associate Professor of Medicine, Laboratory Medicine and Radiology	University of Washington School of Medicine Seattle, Washington	1976 -1981
Professor of Medicine, Laboratory Medicine & Radiology	University of Washington School of Medicine Seattle, Washington	1980-1983
Professor, Department of Radiology	Uniformed Services University of Health Sciences Bethesda, Maryland	1983-1988
Member	Memorial Sloan-Kettering Cancer Center New York, NY	1988-Present
Professor of Radiology	Weill Cornell Medical College New York, NY	1988-Present
Professor	The Gerstner Sloan-Kettering Graduate School of Biomedical Sciences New York, NY	2011-Present

3. Hospital positions (e.g., **attending physician)**

Title	Institution name, city and state	Dates
Clinical Associate (Nuclear Medicine)	Department of Nuclear Medicine National Institutes of Health; and Surgeon U.S. Public Health Service. Sr. Assistant Surgeon. Active Duty July 1970 Bethesda, MD	1970-1972
Director of Nuclear Medicine Residency & Nuclear Medicine Technologist Training Program	University of Oregon Health Sciences Center Portland, Oregon	1975-1976
Head, Division of Nuclear Medicine	University of Oregon Health Sciences Center Portland, Oregon	1975-1976
Chief, Nuclear Medicine Service	Veterans Administration Medical Center Portland, Oregon	1975-1976
Associate Director of Academic Nuclear Medicine Programs	University of Washington Teaching Hospitals Seattle, Washington	1976-1983
Chief, Radioimmunoassay Unit, Laboratory Service	Veterans Administration Medical Center Medical School Seattle, Washington	1976-1983
Director**,** University of Washington Conjoint PET Program	University of Washington Medical School, Seattle, Washington	1980-1983
Chief, Nuclear Medicine Section Veterans Administration Medical Section	Veterans Administration Medical Center Seattle, Washington	1981-1983
Chief, Department of Nuclear Medicine	National Institutes of Health Bethesda, Maryland	1983-1988
Medical Director(Capt.)	USPHS	1983-1988
Attending Physician	Memorial Hospital for Cancer and Allied Diseases New York, NY	1988-2023
Chief**,** Nuclear Medicine	Department of Radiology Memorial Hospital for Cancer and Allied Diseases New York, NY	1988-2012
Chief, Radioisotope Service	Department of Medical Physics Memorial Hospital for Cancer and Allied Diseases New York, NY	1988-1992

Attending Physician Division of Hematologic Oncology	Department of Medicine Memorial Sloan-Kettering Cancer Center New York, NY	1990-Present
Visiting Clinician Courtesy Staff Division of the Medical Staff	Clinical Research Center (CRC) Brookhaven National Laboratory Long Island, NY	1990-Present
Director, Laurent and Alberta Gerschel PET Center	Memorial Hospital for Cancer and Allied Diseases New York, NY	1995-2012
Attending Radiologist	The New York Hospital-Cornell Medical Center New York, NY	1996-1997
Director of Radiology Research	Memorial Hospital for Cancer and Allied Diseases New York, NY	
Vice Chair for Research	Department of Radiology Memorial Hospital for Cancer and Allied Diseases New York, NY	2006-2012
Emeritus-Member	Department of Radiology Memorial Sloan-Kettering Cancer Center New York, NY	2023-Present

D. LICENSURE, BOARD CERTIFICATION, MALPRACTICE

1. Licensure

a.

State	Number	Date of issue	Date of Expiration
Washington	MD00010901	08/18/69	11/30/20
New York	173588-1	02/04/88	10/31/21
New Jersey	25MA08143000	06/12/11	06/30/21

b. If no license:
   (1) Do you have a temporary certificate?
   (2) Have you passed the examination for foreign medical school graduates?

c. DEA number: BL 2487141

d. NPI number: 1841277001

2. Board Certification

Full Name of Board	Certificate #	Date (MM/DD/YY)
American Board of Internal Medicine	42321	1972
American Board of Nuclear Medicine	01176	1973

3. Malpractice insurance

Do you have Malpractice Insurance? **Yes**

Name of Provider: **MSK Insurance US, Inc.**

Premiums paid by: *(choose one)*

a. a. self b. group (name) c. institution (Memorial Sloan-Kettering Cancer Center)

E. PROFESSIONAL MEMBERSHIPS (medical and scientific societies) (in chronological order)

Member/officer	Name of Organization	Dates Held
Fellow	Society of Nuclear Medicine	1964
Fellow	American College of Nuclear Physicians	1980
Member	Radiological Society of North America	1980
Member	American Society of Clinical Oncology	1988
Member	American Association for Cancer Research	1990
Fellow	American College of Radiology	1991
Member	Institute for Clinical PET, Academy of Molecular Imaging	1991
Fellow	New York Academy of Medicine	1995
Member	American Thyroid Association	2009
Member	Society of Nuclear Medicine Committee on Publications	2011-2012
Member	Society of Nuclear Medicine Committee on Publications	2016-2017

F. HONORS AND AWARDS

Name of award	Date awarded
Outstanding Zoology Undergraduate, University of Washington, Seattle	1963
Phi Beta Kappa	1967
Smith-Kline Instrumentation Prize	1968
Zetein Award, Nuclear Medicine	1968
Commissioner's Special Citation, Food and Drug Administration, Department of Health and Human Services	1982
The Society of Nuclear Medicine, in Commemoration of the First Annual S SNM Lectureship "Imaging with Radiolabeled Antibodies"	1984
Distinguished Alumnus Award, Division of Nuclear Medicine, Johns Hopkins Medical Institutions	1985
Rockwell Memorial Lecturer, Univ. of Iowa College of Medicine	1985
Distinguished AMA Lecturer in Medical Sciences	1986
Honorary Member, Sociedade Paulista de Radiologia, Sao Paulo, Brazil	1986
Eugene Pendergrass Award, New Horizons Lecture, Given by Radiological Society of North America	1986
G.V. Hevesy Lecture-Medal, in Budapest, Hungary	1987
The Louise and Lionel Berman Foundation, Inc. award for accomplishments in the field of nuclear medicine involving the peaceful use of atomic energy	1990
First Ralph G. Robinson Lecture Award, ACNP, San Juan, Puerto Rico	1996

Elis Berven Lecture, Annual Meeting of the Swedish Medical Society, Stockholm, Sweden	1999
Martin Lindgren Lecture, Lund University, Lund, Sweden	1999
Marquis Who's Who in Science and Engineering Certificate of Recognition	2000-2001
Berson Yalow Award, New England Chapter of The Society of Nuclear Medicine, Newport, RI	
Wagner Lecture, Society of Nuclear Medicine, Toronto	2001
Directors Commendation Letter for Contributions to Anti-terrorism Special Task Force, NYPD	2004
Radiological Society of North America Researcher of the Year	2004
IOM of National Academy of Sciences	2005
Fellow, American College of Nuclear Medicine	2005
Hevesy Award, Society of Nuclear Medicine	2005
Shining Spirit Award for Cancer Care, Paul Robert Carrey Foundation	2005
Peter Valk Award as the Distinguished Clinical Scientist of the Year	2007
Donna and Benjamin M. Rosen Chair in Radiology	2008
Benedict Cassen Prize for Research in Nuclear Medicine	2012
Saul Hertz Prize for Targeted Radiotherapy of the Society of Nuclear Medicine	2016
Challenge Award, Prostate Cancer Foundation	2017
Gold Medal Award, American College of Nuclear Medicine	2018
Ajit Pathy Oration Warmth Professor Award, ISRT	2018
Paul Aebersold Award	2021

Media/Public Recognition

How to Find The Best Doctors: New York Metro Area 2nd Edition	April 1, 1997
New York Magazine "Best Doctors"	June 8,1998
How to Find The Best Doctors: New York Metro Area 3rd Edition	April 1, 1999
New York Magazine "Best Doctors"	June 7, 1999
New York Magazine "Best Doctors"	April 1, 2000
How to Find The Best Doctors: New York Metro Area 4th Edition	April 1, 2000
Top Doctors: New York Metro Area 5th Edition	April 1, 2001
America's Top Doctors 1st Edition	April 1, 2001
New York Magazine "Best Doctors"	June 4, 2001
Top Doctors: New York Metro Area 6th Edition	April 1, 2002
America's Top Doctors 2nd Edition	April 1, 2002
New York Magazine "Best Doctors"	June 10, 2002
New York Magazine "Best Doctors"	April 1, 2003
Top Doctors: New York Metro Area 7th Edition	April 1, 2003
America's Top Doctors 3rd Edition	April 1, 2003
Top Doctors: New York Metro Area 8th Edition	May 5, 2004
America's Top Doctors 4th Edition	May 5, 2004
New York Magazine "Best Doctors"	June 1, 2004
New York Magazine "Best Doctors"	May 17, 2005
America's Top Doctors 5th Edition	May 23, 2005
Top Doctors: New York Metro Area 9th Edition	May 23, 2005
America's Top Doctors for Cancer 2005	June 2, 2005
RT Image's Most Influential in Radiology	2006

America's Top Doctors for Cancer 2006 2nd Edition	May 22, 2006
New York Magazine "Best Doctors"	June 6, 2006
Top Doctors: New York Metro Area 10th Edition	September 14, 2006
America's Top Doctors 6th Edition	September 14, 2006
New York Magazine "Best Doctors"	June 1, 2007
America's Top Doctors for Cancer	July 3, 2007
America's Top Doctors	October 9, 2007
Top Doctors: New York Metro Area's	October 29, 2007
New York Magazine "Best Doctors"	May 28, 2008
America's Top Doctors for Cancer	October 1, 2008
America's Top Doctors 8th Edition	January 9, 2009
Top Doctor in New York	February 5, 2009
Top Doctors: New York Metro Area 12th Edition	February 5, 2009
Top Cancer Doctor in America	October 1, 2009
Top Doctors: New York Metro Area's	January 1, 2010
Castle Connolly New York Magazine 10th Anniversary 2007	February 1, 2010
Top Doctors: New York Metro Area's	February 1, 2010
5th Anniversary America's Top Doctor, 2006	May 1, 2010
Top Doctors in New York Magazine	May 1, 2010
New York Metro Area's Top Doctors	July 1, 2010
America's Top Doctors For Cancer	October 1, 2010
New York Metro Area's Top Doctors 15th Edition	January 1, 2011
New York Metro Area's Top Doctors 14th Edition	January 1, 2011
America's Top Doctors 10th Edition	January 1, 2011
5th Anniversary-America's Top Doctors for Cancer 2009	January 1, 2011
America's Top Doctors	September 1, 2011
America's Top Doctors For Cancer	October 1, 2011
New York, Super Doctor	2011
America's Top Doctors 11th Edition	January 1, 2012
Castle Connolly Top Doctor in 2012	March 1, 2012
Saul Hertz Award 2016	June 6, 2016
Director Scientific Leadership Award 2017	June 2017
Gold Medal Award 2018	January 26, 2018
Ajit Padhy Oration of WARMTH ISRT 2018	November 18, 2018

G. INSTITUTIONAL/HOSPITAL AFFILIATION

1. Primary Hospital Affiliation	**Memorial Hospital for Cancer and Allied Diseases**
2. Other Hospital Affiliations	None
3. Other Institution Affiliations	None

H. EMPLOYMENT STATUS

1. Name of Current Employer(s): **Memorial Sloan-Kettering Cancer Center**
2. Employment Status *(choose one):* **Full-time**
   a. Full-time salaried by Cornell
   b. Full-time salaried at Cornell-affiliated hospital
   c. Part-time salaried at Cornell

d. Part-time salaried at Cornell-affiliated hospital
e. Voluntary (self-employed or member of a P.C.)
f. Other salaried
g. Other non-salaried

I. CURRENT AND PAST INSTITUTIONAL RESPONSIBILITIES AND PERCENT EFFORT *(in chronological order; specify below whether an activity involves WMC and/or MSK students/researchers)*

1. Teaching/Mentoring (e.g., specific teaching and mentoring activities, courses taught, dates)

Mentees. For R25T program, MSKCC	
Elmer Santos	1998-Present
Mark Dunphy	2004-Present
Michelle Bradbury	2008-Present
Gary Ulaner	2017-Present

2. Clinical care (duties, dates)

PET and Therapy; MSKCC	1998-Present

3. Administrative duties, including committees, dates

Chief of Nuclear Medicine	1988-2012
Director Gerschel PET Center	1994-2012
Director Animal Imaging CORE	2000-Present
Executive Committee MPC	2001-Present
Co-Leader Imaging and Radiation Sciences Program (IMRAS)	2004-Present
Chairman, PET Research Steering Committee	2008-Present

4. Research

Vice Chairman for Radiology (Research)	2003-2012

	Current Percent Effort (%)	Does the activity involve WMC students or researchers? (Y/N)	Does the activity involve MSK trainees or researchers? (Y/N)
Teaching/Mentoring:	10%	N	Y
Clinical Care:	20%	N	Y
Administration:	20%	N	Y
Research:	50%	N	Y
TOTAL:	**100%**		

J. RESEARCH SUPPORT

Active Other Support

1 R01 CA233896-01 (PI: Cheal) 12/10/2018 - 11/30/2023 1.20 calendar
NCI $ 404,997
DOTA-based pre-targeting of alpha emitters
We have developed a targeted theranostic molecular radiotherapy method known as the

DOTA-PRIT platform that is based on antibodies suitable for use in treating common human tumors. Our studies in animal models have shown superior therapeutic index (TI), i.e., the ratio of tumor radiation dose to radiation to normal tissues. We propose using animal models of human colorectal cancer and human breast cancer to adapt the DOTA- PRIT platform for safe and effective tumor-targeting of actinium-225

5 P50 CA172012-05 (PI: Fagin/ Fagin) 9/19/2014 - 8/31/2020 NCE 1.20 calendar
NCI $ 265,830
SPORE in Thyroid Cancer (Project 2: Maximizing effectiveness of radioiodine therapy by inhibiting MAPK signaling)
The goals of this SPORE on thyroid cancer are to leverage new insights on disease pathogenesis to improve the outcomes of patients
with thyroid cancer at all stages of presentation.

5 P50 CA172012-05 (PI: Fagin/ Fagin) 9/19/2014 - 8/31/2020 NCE 0.60 calendar
NCI $ 83,306
SPORE in Thyroid Cancer (Core C: Administrative Core)
The goals of this SPORE on thyroid cancer are to leverage new insights on disease pathogenesis to improve the outcomes of patients
with thyroid cancer at all stages of presentation.

GC223928 (PI: Larson) 1/1/1994 - 12/31/2099 0.00 calendar
General Electric $ 370,370
General Electric Research Fund

GC238048 (PI: Larson) 1/1/2019 - 12/31/2019 0.60 calendar
Center for Experimental Therapeutics $ 250,000
Ac-225 DOTA Proteus for Pre-targeted Radioimmunotherapy (PRIT) of Solid Tumors
We seek additional funding to follow up on promising early results in mouse tumor models with alpha therapy to find optimized regimens for cure with minimal toxicity in both HER2 antigen (Breast and GE junction) and GPA33 antigen (colon)-expressing human tumors. We will also incorporate recently developed novel imaging biomarker adaptations, such as the use of 111In- and 68Ga-PrDOTA, into this ongoing research. In addition, studies will be completed in cynomolgus monkey gut to overcome binding to GPA33 during alpha and beta radiotherapeutic radio-hapten capture as a basis for developing high therapeutic index (TI) of pre-targeted radioimmunotherapy (PRIT) to human colon cancer.

GC238879 (PI: Larson) 3/1/2019 - 2/29/2020 0.60 calendar
Imaging and Radiation Sciences Program Seed Grant $ 99,999
Evaluation of a novel 203Pb/212Pb theranostic pretargeted alpha-particle radiotherapy strategy for treatment of solid tumors
Synthesize a novel anti-tumor/anti-DOTA-based pretargeting proteus-DOTA (PrDOTA) hapten designed for use with Pb-isotopes, develop and optimize a labeling method for the addition of Pb-203 (203 Pb), and demonstrate that the 203 Pb-hapten is recognized with high affinity by the anti-DOTA-hapten pretargeting antibody platform. Characterize the immunokinetics of 203 Pb-PrDOTA compounds to identify a radiohapten that exhibits rapid renal clearance and exceptionally low whole-body retention. Demonstrate in vivo 203 Pb-DOTA-PRIT with the aim of achieving simultaneous high tumor uptake with low normal tissue activity. Determine dosimetry for 203 Pb-DOTA-PRIT (and by extrapolation, 212 Pb-DOTA-PRIT) in a model DOTA-PRIT system (herein, we propose to use anti-GPA33 tumor antigen targeting of GPA33-expressing human

colorectal cancer).

5 R01 CA201250-04 (PI: Larson / Humm / Tuttle) 8/5/2016 - 7/31/2021 1.20 calendar
NCI $ 131,158
124I-NaI PET: Building block for precision medicine in metastatic thyroid cancer
While treatment with RAI has been life-saving for many patients with advanced thyroid cancer, not all patients benefit, and side effects can be serious and, in some cases, life-threatening.
Role: Principal Investigator

GC238563 (PI: Morris) 12/31/2017 - 12/30/2019 1.20 calendar
Prostate Cancer Foundation (formerly CaP CURE) $ 500,000
Characterizing mechanisms of sensitivity and resistance to anti-androgen therapy with whole-body

2 P30 CA008748-53 (PI: Thompson/ Larson) 1/20/2017 - 12/31/2023 1.80 calendar
NCI
Cancer Center Support Grant (Imaging and Radiation Sciences)
Memorial Sloan Kettering Cancer Center (MSK) is a free-standing institution dedicated to the control of cancer through inpatient and outpatient care, clinical and research training programs, and a broad spectrum of research activities. Through these activities, MSK seeks to reduce the burden of cancer throughout our catchment area and the nation.

5 P50 CA192937-04 (PI: Younes/ Brentjens) 8/30/2016 - 7/31/2021 0.00 calendar
NCI
MSK SPORE in Lymphoma (RP-2: Autologous CD19 targeted 19-28z+ Tcells for the treatment of relapsed diffuse large B cell lym)
We have assembled a collaborative team of basic, translational, and clinician scientists, from major institutions in the NYC area to accelerate the translation of the current scientific knowledge into new innovative treatment strategies for patients with diffuse large B cell lymphoma.

2 P50 CA086438-11 (PI: Larson/Blasberg) 06/01/2000 - 06/30/2016 1.2 calendar
NIH/NCI (NIH) $191,250
MSKCC Center for Molecular Imaging in Cancer (Project 4 - Refining Antiandrogen Therapy for Prostate Cancer through Positron Emission Tomography)
The central theme of Research Project 4 (RP4) is to refine the current use of Positron Emission Tomography (PET) in prostate cancer as pharmacodynamic and predictive biomarkers during antiandrogen therapy. During ICMIC-3, we shall exploit MI imaging study results, as well as human tissue samples obtained from image-directed biopsy analysis and animal models to better understand the molecular basis for these MI phenotypes.

P01 CA94060 (Norton) 09/01/2002–04/30/2013 0.6 calendar
NIH/NCI $195,967
Program project in models of breast cancer (Imaging Core)
Direct the Imaging Core that supports research projects in animal models of breast cancer.

R25 CA96945 (Hricak) 08/16/2002–07/31/2014 0.6 calendar
NIH/NCI $488,250
Molecular Imaging: Training for Oncology
Co-PI assisting Dr. Hricak in the management of the program. He will act as Co-Chairman of the Internal Advisory Committee, with a particular emphasis on curriculum development and experimental research project oversight. Plays a key role in the tracking and monitoring of fellows' progress as well as oversee mentor and trainee relations.

I3- A152 (PI: Larson) 08/01/2009 - 07/31/2013 1.20 calendar
Starr Cancer Consortium $350,000

Clinical and Molecular Correlates of Positron Emission Tomography (PET) with Zr-89 J591 in Metastatic Castrate Resistant Prostate Cancer

Perform a clinical imaging in 50 patients with castrate resistant prostate cancer.

1R21CA162602-01A1 (PI: Larson) 09/26/2011 – 08/31/2013 1.2 calendar
NIH/NCI (NIH) $207,000

124I-cG250 ImmunoPET Imaging of Sunitinib Treatment Response in Renal Cell Cancer

The central theme of this R21 is to extend the use of Positron Emission Tomography (PET) immunoPET imaging of 124I-cG250 to improve management of individual patients with advanced renal cell cancer who are undergoing targeted therapy with Sunitinib regimens. We will explore the following hypothesis: In advanced clear cell renal cancer, detection of CA9 antigen expression, based on 124I-cG250 ImmunoPET, will provide improved staging in comparison to the combination of standard CT and bone scan, and changes in 124I-cG250 ImmunoPET uptake will provide earlier and more accurate assessment of treatment response in advanced RCC, in comparison to RECIST 1.1, and assessment of time to progression and overall survival as our principal endpoint.

PENDING

I13-0046 (PI: Larson) 1/1/2020 - 12/31/2021 0.60 calendar
Starr Cancer Consortium $ 239,951

Optimizing Targeted Radiotherapy for CURE in Prostate Cancer

To optimize imaging and therapeutic regimens using PSMA-expressing prostate cell lines and patient-derived xenografts passaged in radiation-tolerant immune-deficient DKO mice with 177Lu/86Y/90Y aminobenzylDOTA and 225Ac/111In proteus DOTA-PRIT, and 18F/Cy3 proteus DOTAPRIT, either alone or in combination.

1 R01 CA173592-01 (PI: Fagin) 07/01/2013 – 06/30/2018 0.60 calendar
NIH/NCI $250,000

Maximizing effectiveness of radioiodine therapy by inhibition of MAPK signaling

We will build on recent experimental and clinical breakthroughs by our research group that show that in a large fraction of patients RAI refractoriness can be reversed by blocking ERK pathway activity.

Patents

Synthesis and Utilization of 17-methyl and 17-cyclo-propylmethyl-3, 14-Di-hydroxy-4, 5-Epoxy 6 b-Fluoromorphines (Foxy and cyclofoxy) as (18F)-labeled opiate ligands for positron emission transaxial tomography. (PET) Rice KC, Pert CB, Burke TR, Jr., **Larson SM,** Eckelman WC, Channing MA. October 4, 1988. US Patent No. 4,775,759

Antigen-Specific Composition and In Vivo Methods for Detecting and Localizing an Antigenic Site and for Radiotherapy. **Larson SM,** Finn R, Carrasquillo JA, Reynolds JC, Neumann RD, Graham MC, Pentlow KS. U.S. Patent No. 5,185,142. Date: Feb. 9, 1993.

Non-invasive imaging and Quantification of Specific Antigen and Uses Thereof. Smith-Jones, P and Larson **SM**. Provisional Patent Application. Registration Number 28,325. Date 1/06/03.

Single chain Fv polynucleotide or peptide construct of anti-ganglioside GD2 antibodies, cells expressing same and related methods NK Cheung, **SM Larson**, HF Guo, K Rivlin, M. Sadelain US Patent No. 6,451,995.

Small-Molecule HSP90 Inhibitors, Chiosis, Gabriela; Huazhong He, Llauger-Bufi, Laura; Kim Joungnam; **Larson, Steve**; Smith-Jones, Peter. US Patent No. 7,834,181. Date 11/16/10.

Uses of labeled HSP90 Inhibitors, Chiosis, Gabriela, Pillarsetty N, Lewis, J, **Larson S,** Taldone T, Alpaugh, Mary US Patent No. 61,506010. Date 08/07/2011.

Method for Diagnosing or Treating Tumors Using Sphingomylin Containing Liposomes. **Larson, Steve.** US Patent No. 61,756116. Date 02/24/2013.

Multimodal Silica-Based Nanoparticles. **Larson SM.** US Patent No. 61,794414. Date 03/15/2013.

Herceptin - C825 conjugate for Pretargeted Radioimmunotherapy and application as a theranostic product. Sarah Marie Cheal; Nai-Kong V Cheung; Hong-Fen Guo; **Steven M Larson** *; Karl Dane Wittrup; Hong Xu. US Patent No. 62,641,645. Date 2014.

Multi-Specific Antibodies with Affinity for Human A33 Antigen and DOTA Metal Complex and Uses Thereof. Cheal S, Hong Xu, **Larson SM**, NK Cheung. US Patent No. 62,113,988. Date 2/09/2015.

Systems and Methods for Determining Optimum Patient-Specific Antibody Dose for Tumor Targeting. Zanzonico P, Cheal SM, **Larson SM**, Osborne J, Fung Edward K. US Patent No. 62,165699. Date 5/22/2015.

Fluorescent silica-based nanoparticles for detection, characterization, monitoring and treatment of a disease such as cancer. Bradbury, Michelle; Wiesner, Ulrich; Penate, Medina Oula; Ow, Hoosweng; Burns, Andrew; Lewis, Jason; **Larson, Steven**. US Patent No. 9625456. Date 4/18/2017.

A N-acetylgalactosamino dendron-clearing agent for DOTA-pretargeted radioimmunotherapy. Sarah Marie Cheal; Nai-Kong V Cheung; **Steven M Larson *;** Ouathek Ouerfelli. US Patent 62,697,956. Date 2018.

HSP90-TARGETED CARDIAC IMAGING AND THERAPY US Patent 10,201,623 Date 2/12/2019

Fluorescent Silica-Based Nanoparticles US Patent 10,548,998 Date 2/4/2020

Small-molecule HSP90 Inhibitors US Patent 10,676,476 Date 6/9/2020

SYSTEMS AND METHODS FOR DETERMINING OPTIMUM PATIENT-SPECIFIC ANTIBODY DOSE FOR TUMOR TARGETING US Patent 10,806,808 Date 10/20/2020

MULTI-SPECIFIC ANTIBODIES WITH AFFINITY FOR HUMAN A33 ANTIGEN AND DOTA METAL COMPLEX AND USES THEREOF US Patent 10,988,534 Date 4/27/2021

Applications

Application #: WO 2009045535
Title: Fluorine-18 derivative of dasatinib and uses thereof.
Inventors: Veach D, Pillarsetty N, Dunphy M, **Larson S**, Santos E, Namavari M.
PCT Int. Appl. (2009),35pp. CODEN: PIXXD2 WO 2009045535 A2 20090409 CAN 150:392331 AN 2009:422420 CAPLUS

Application #: WO 2010005697
Title: ^{18}F-labeled 3- and 4-carbon acids for PET imaging.
Inventors: Pillarsetty, Nagavarakishore; **Larson, Steven**.

Application #: PCT/US2016/017141
Title: A33-C825 Conjugate for Pretargeted Radioimmunotherapy and application as a theranostic product.
Inventors: Sarah Marie Cheal; Nai-Kong Cheung; Hong-Fen Guo; **Larson, Steven;** Karl Dane Wittrup; Hong Xu.

Application #: PCT/US2016/033217
Title: PET-based compartmental modeling for individualizing tumor targeting of antibodies.
Inventors: Sarah Marie Cheal; Edward Komin Fung; **Larson, Steven;** Joseph Osborne; Pat Zanzonico.

Application #: PCT/US2016/062818
Title: A Molecular Specific Theranostic Platform for Androgen Receptor positive Breast Cancer.
Inventors: Mary Alpaugh; Anson Ku; **Larson, Steven;** Michael McDevitt; Sven-Erik Strand; Daniel Thorek; Hans David Staffan Ulmert; Darren Veach.

Application #: PCT/US2017/21092
Title: Bone Marrow, RETICULOENDOTHELIAL SYSTEM-, AND/OR LYMPH NODE-Targeted Radiolabeled Liposomes and Methods of Their Diagnostic and Therapeutic Use
Inventors: **Larson, Steven;** Sang-Gyu Lee; Nagavarakishore Pillarsetty.

Application #: SK2018-045
Title: Re-humanized (>85%) anti-GPA33 antibodies
Inventors: Mahuiddin Ahmed, Sarah Marie Cheal; Nai-Kong Cheung; Megan Dacek; **Larson, Steven**.

Application #: PCT/2018/0409011
Title: Small Molecule Hapten Chelates for Pretargeted Radioimmunotherapy with Anti-DOTA (lanthanide) Bispecific Antibodies (Proteus)
Inventors: Sarah Marie Cheal; Nai-Kong Cheung; **Larson, Steven;** Michael McDevitt; Ouathek Ouerfelli; Nagavarakishore Pillarsetty.

Application #: 63/193,700

Title: LESIONAL DOSIMETRY METHODS FOR TAILORING TARGETED RADIOTHERAPY IN CANCER
Inventors: **Larson, Steven**

Application #: 63/257,694
Title: ANTI-TSHR MULTI-SPECIFIC ANTIBODIES AND USES THEREOF
Inventors: **Larson, Steven**

Application #: 17/259,663
Title: N-ACETYLGALACTOSAMINO DENDRON-CLEARING AGENT FOR DOTA-PRETARGETED RADIOIMMUNOTHERAPY
Inventors: **Larson, Steven**
Application #: PCT/US2020/048524
Title: NOVEL THERANOSTIC AGENTS FOR PSMA POSITIVE CANCERS
Inventors: **Larson, Steven**

Application #: 17/640,598
Title: ANTI-STEAP1 ANTIBODIES AND USES THEREOF
Inventors: **Larson, Steven**

Application #: 17/274,952
Title: BONE MARROW-, RETICULOENDOTHELIAL SYSTEM-, AND/OR LYMPH NODE-TARGETED RADIOLABELED LIPOSOMES AND METHODS OF THEIR DIAGNOSTIC AND THERAPEUTIC USE
Inventors: **Larson, Steven**

Application #: 17/229,007
Title: MULTI-SPECIFIC ANTIBODIES WITH AFFINITY FOR HUMAN A33 ANTIGEN AND DOTA METAL COMPLEX AND USES THEREOF
Inventors: **Larson, Steven**

K. EXTRAMURAL PROFESSIONAL RESPONSIBILITIES

1. National Institute of Health/National Cancer Institute

In Vivo Cellular and Molecular Imaging Centers, "Imaging Targeted Therapy w/ PET". Washington, DC	November 2006
NCI Phase 0 Workshop "Phase 0 Imaging Example (Herceptin)" Bethesda, MD	September 2007
NCI Site visit, Reviewer. Experimental Transplantation & Immunology Branch & Jacek Capala, Ph. D (Radiation Oncology Branch), Bethesda, MD	October 2008
NCI, Grant Reviewer. Quantitative Imaging. Bethesda, MD	July 2009
NCI, Grant Reviewer. Radiation Oncology Branch. Bethesda, MD	July 2009
NCI, Grant Reviewer. Washington, DC	October 2009
Inaugural NCI-PCF Treatment Science, Speaker. Washington, DC	April 2010
NIH, Scientific Advisor. External Advisory Board Meeting. Bethesda, MD	October 2010
NIH Review, Chairman of Study Section	October 2010
NCI Lecturer, Prostate Cancer Androgen Receptor Meeting. Arlington, VA	December 2010
NIH, Chairman of Study Section. Bethesda, MD	February 2011

NCI, ACRIN Mid-Term Review	May 2011
NCI, Investigational Drug Steering Committee, Bethesda, MD	October 2011-Present
NCI, Clinical Imaging Steering Committee, Co-Chair, Bethesda, MD	November 2011-Present

2. Meeting/ Conferences

Meeting/Conference	Title of Lecture/Rose	Date
ABNM Marcos Island, FL.	Finance Committee Meeting	01/12-01/16/06
RSNA, BIROW IV	"Molecular Imaging"	02/24-02/25/06
NCMHID Society of Fellows And Scholars	Scholar	02/27/06
Novartis, Clinical Development in Lung Cancer Investigators Meeting, New York, NY	Consultant	03/03/06
FDG-PET Lymphoma Investigational Workshop, Bethesda, MD	"PET/CT in Staging Lymphoma"	03/20/06
75th ABNM Teton Village, WY	Oncology, Chairperson	06/17-06/20/06
SNM, Molecular Imaging: Shaping the Future, Miami, FL	"Molecular Imaging in Clinical Area"	07/27-07/30/06
National Academies Committee Meeting	"Future Needs and Directions"	08/23-08/24/06
ASCO's Development of Molecular Therapies in Breast Cancer Conference Aspen, CO	"Functional or Molecular Imaging"	08/10-08/13/06
RSNA/SNM Imaging in Molecular Medicine, Waikoloa, HI	Meeting Participant	08/26-09/02/06
CCR Grand Rounds Bethesda, MD	"Molecular Imaging and Targeted Radiotherapy in Oncology"	09/11-09/12/06
New Trends on PET St. Petersburg, Russia	"Molecular Energy and Target Therapy"	09/16-09/20/06
11th Conference on Cancer Therapy w/ Antibodies and Immunoconjugates Parsippany, NJ	Meeting Participant	10/12-10/14/06
BERAC Meeting Bethesda, MD	Committee Member	10/15-10/16/06
PET and PET/CT Imaging New York, NY	"What Does the Future Hold for PET and PET/CT"	11/02-11/05/06
NCCN PET Task Force Chicago, IL	"Overview of PET in Oncology: What is coming in the future?"	11/09-11/10/06
Symposium Copenhagen, Denmark	"Exploratory IND Applications in the Development of Cancer Therapeutic Drugs"	12/11-12/13/06

Meeting/Conference	Title of Lecture/Rose	Date
St. Jude Grand RoundsMemphis, TN	Visiting Professor	12/13-12/14/06
76th ABNM Meeting New Orleans, LA	Meeting Participant	01/25-01/28/07
UPENN Grand Rounds Philadelphia, PA	Visiting Professor	01/30/07
Keystone Symposia on Molecular and Cellular Biology Lake Louis, AB Canada	"Imaging and Therapy with Radiolabeled Antibodies"	02/01-02/06/07
NAS Committee Medical Isotope Production Washington, DC	Member	02/15-02/16/07
Cellectar Science Advisory Milwaukee, WI	Consultant	02/19-02/20/07
Prostate Cancer Symposium Orlando, FL	"General Session X: Imaging and Novel Therapeutics"	02/23-02/24/07
Cellectar Meeting Chicago, IL	IND	03/06/07
Fox Chase Cancer Center Grand Rounds Philadelphia, PA	"Targeted Radiotherapy of thyroid Cancer"	04/05/07
Medical Isotope Production Committee Meeting, IOM Washington, DC	"Welcome, Introduction and Objectives"	04/10-04/11/07
98th Annual Meeting of the AACR Los Angeles, CA	"Advances in Clinical PET Imaging"	04/14-04/18/07
Nobel Symposium Stockholm, Sweden	"Molecular Imaging In Oncology"	05/05-05/10/07
SNM 54th Annual Meeting Washington, DC	"Need for Quantitative SPECT in Molecular Imaging"	06/01-06/03/07
NAS: Comm. Medical Isotope Production w/out Highly Enriched Uranium Washington, DC	Committee Member, Site Visit	06/10-06/12/07
19th Annual Pezcoller Symposium Trento, Italy	"Molecular Imaging for Drug Discovery and Treatment Response in Oncology"	06/14-06/16/07
NRC- Medical Isotope Production w/o Uranium Ottawa/Chalk River, Canada	Site Visit	08/19-08/22/07

Meeting/Conference	Title of Lecture/Rose	Date
Pre-Conference Symposium/Joint Molecular Imaging Providence, Rhode Island	Moderator: "Novel Imaging for Clinical Studies"	09/07-09/10/07
New Frontiers of Science: DOE Fueling the Future of Nuclear Medicine Boston, MA	BERAC Subcommittee on Radiopharmaceutical Research Final Recommendations	09/10-09/11/07
4th AdMeTech Foundation Conference Washington, DC	"Nuclear Medicine & PET Imaging"	09/16-09/18/07
Improving the Quality of Cancer Clinical Trials Workshop Washington, DC	"PET/CT for Treatment Response in Oncology"	10/04-10/05/07
National Research Council Committee on Medical Isotope Production w/o Uranium St. Louis, MO	Committee Member, Site Visit	10/14-10/17/07
MIP Advisory Board Meeting Bethesda, MD	Reviewer	10/25-10/26/07
Wilkinson Lecturer/Grand Rounds, Duke University Durham, NC	"Molecular Imaging in Oncology"	11/01/07
RSNA (MIC) Chicago, IL	"Molecular Imaging in Oncology: Drug Development"	11/27-11/28/07
BERAC Meeting Washington, DC	Biological and Environmental Research Advisory Committee	11/29-11/30/07
Nuclear Medicine Grand Rounds, North Shore Hospital Manhasset, NY	"Tumor Targeting with Radiopharmaceuticals"	12/10/07
NNSA-ANSTO Workshop on the Production of Mo-99 Using Low Enriched Uranium. Medical Isotopes Committee Australia	Committee Member, Site Visit	12/14-12/19/07
78th ABNM Meeting St. Thomas, VI	Sub-Committee Chair	01/17-01/21/08
The National Academies Irvine, CA	Committee Member, National Research Council Committee on Medical Isotope Production w/o HEU	01/28-01/29/08
Brigham and Women's Hospital Boston, MA	Opening Celebration of the Cyclotron and Radiopharmaceutical Chemistry Laboratories	03/04-03/05/08

Meeting/Conference	Title of Lecture/Rose	Date
New York Academy of Medicine New York, NY	"Oncologic Applications of PET Imaging"	03/17/08
Jonsson Comprehensive Cancer Center, UCLA	"GU Leaders in the Field", Lecture Series	04/07-04/08/08
BOD GE Healthcare Hilton Head, SC	Consultant	04/09-04/11/08
The National Academies Irvine, CA	Committee Member, National Research Council Committee on Medical Isotope Production w/o HEU	04/20-04/22/08
PET/CT Symposium Brazil	"PET/CT in Esophageal Cancer-Staging, Restaging and Evaluation of Treatment Response"	04/28-05/01/08
Clinical Nuclear Medicine Course Boston, MA	"Radionuclide Therapy"	05/13-05/14/08
PET-CT in Cancer Management at UPENN	"The Role of PET-CT for the Medical Oncologist"	05/15-05/16/08
Japanese SMI Tokyo, Japan	"Radiotracers for Molecular Imaging and Drug Development", Lecturer	05/20-05/25/08
National Academies, CNEA & INVAP Buenos Aeries, Argentina	Committee Member	06/03-06/07/08
SNM 55th Annual Meeting New Orleans, LA	"Need for Quantitative SPECT & PET in Molecular Imaging"	06/13-06/16/08
Ca Research UK/EPSRC: Ca Imaging Committee London, United Kingdom	Reviewer	06/16-06/19/08
Issues in Clinical Prostate Cancer Meeting Washington, DC	"Radionuclide Bone Scanning vs. ^{18}Fluoro-2-Deoxyglucose-Positron"	06/24-06/25/08
Medical Isotopes Meeting # 7 Seattle, WA	Meeting of NAS Committee	07/07-07/09/08
ABNM 79th Annual Meeting Kennebunkport, MI	Committee Member	07/10-07/13/08
Division of Medical Chemistry Philadelphia, PA	"Molecular Imaging in Drug Development and Chemistry I"	08/18/08
Amgen Los Angeles, CA	Consultant	08/20-08/21/08
Fall BERAC	Committee Member	09/05/08
World Molecular Imaging Congress Nice, France	"Antibody PET Imaging in Cancer Detection and Treatment"	09/10-09/13/08
NSACI Meeting Washington, DC	Committee Member	12/15-12/16/08

Meeting/Conference	Title of Lecture/Rose	Date
National Academies Briefing Washington, DC	Vice Chairman	12/18/08
80th ABNM Meeting Park City, UT	Committee Member	01/08-01/12/09
NSAC Isotope Meeting Bethesda, MD		01/13-01/15/09
DOD PCRP Pre-Award Mtg Fort Detrick, Maryland	Consultant	03/06/09
Prostate Cancer Program Retreat Baltimore, Maryland	Presenter	03/25-03/27/09
DOE Nuclear Science Advisory Bethesda, Maryland	Committee Member	03/26/09
Uppsala Vth Spring Meeting Uppsala, Sweden	Speaker	04/05-04/08/09
AACR Annual Meeting Denver, Colorado	Speaker	04/18-04/22/09
21st National Congress of Turkish SNM Istanbul, Turkey	Presenter, Reviewer	04/29-05/05/09
Clinical Nuclear Medicine/PET Harvard Course	Speaker	05/12-05/15/09
SNM 56th Annual Meeting Toronto, Canada	Speaker	06/12-06/16/09
Cyclotron Opening Cermony Copenhagen, Denmark	Keynote Speaker	06/20-06/24/09
Congress, Committee on Enrgy & Commerce Washington, DC	Testified a legislative hearing	09/09/09
Starr Cancer Consortium Retreat Cold Spring, NY	Poster Presenter	09/21-09/22/09
Damon Runyon-Rachleff Innovation Award New York, NY	Reviewer	10/23/09
RSNA Annual Meeting Chicago, IL	Committee Member	11/30-12/02/09
ACNM/ACNP Mid Winter Meeting Albuquerque, NM	Lecturer	01/27-01/31/10
IBA Visit & Collaboration Paris, France	Consultant	02/10-02/15/10
ICMIC's Washington, DC	Reviewer	03/08-03/09/10

Meeting/Conference	Title of Lecture/Rose	Date
Molecular Imaging Meeting Washington, DC	Lecturer	03/12-03/13/10
Cancer Vaccine Consortium Washington, DC	Lecturer	03/17-03/19/10
MD Anderson Visit Houston, TX	Consultant	03/28-03/29/10
Geoffrey Beene Cancer Research Retreat Skytop Lounge, Pennsylvania	Participant	04/08-04/09/10
FDA/SNM/RSNA Meeting Bethesda, MD	Participant	04/13-04/14/10
AACR 2010 Annual Meeting Washington, DC	Speaker	04/16-04/12/10
Stakeholder's Meeting Washington, DC	Participant	05/20-05/21/10
Washington University Visit St. Louis, MO	Consultant	06/01-06/02/10
PCCTC Semi-Annual Review Chicago, IL	Speaker	06/03/10
SNM 57th Annual Meeting Salt Lake City, UT	Participant	06/05-06/10/10
Study Stage Review Washington, DC	Chairman of Review Committee	06/13-06/14/10
2010 Whitney Symposium, GE Niskayuna, NY	Speaker	06/28-06/29/10
WHO Conference on Prostate Ca, Stockholm, Sweden	Speaker	09/08-09/10/10
PCF's 17 Annual Scientific Retreat Washington, DC	Invited Expert	09/14-09/16/10
Starr Cancer Consortium Retreat Cold Spring Harbor Laboratory	Presenter/Investigator	09/20-09/21/10
DR-Rachleff Innovation Award Review New York, NY	Reviewer	10/22/10
Nuclear Medical Colloquia Munich, Germany	Chairman of Molecular Committee	11/09-11/11/10
RSNA Annual Meeting Chicago, IL	Visiting Professor	11/30-12/03/10
SNM Mid Winter Meeting Palm Springs, CA	"Bone Scans for Prostate Cancer Metastasis"	01/20-01/22/11
Molecular Med TRI-CON San Francico, CA	Speaker	02/23-02/25/11

Meeting/Conference	Title of Lecture/Rose	Date
(Johns Hopkins Medical Institute) JHMI Course Baltimore, MD	Speaker	03/11-03/12/11
CTEP Early Drug Development Meeting Bethesda, MD	Participant	03/14-03/15/11
EAG Workshop on 99m Tc Future Paris, France	Committee Member	04/02-04/06/11
Novartis Visit Boston, MA	Participant	04/19-04/20/11
Sandler Lecture at Vanderbilt Nashville, TN	Lecturer	05/05-05/07/11
Geoffrey Beene Ca Research Retreat Skytop, PA	Lecturer	05/19-05/20/11
SNM 58th Annual Meeting San Antonio, TX	"Promising Novel Techniques in Molecular Imaging and Targeted Therapy of Cancer"	06/02-06/09/11
WCIO New York, NY	Lecturer	06/09/11
World Molecular Imagign Congress, San Diego, CA	"Molecular Imaging Beyond FDG: A tool for In Vivo Study of Human Cancer Biology and Pharmacology"	09/07-09/10/11
Prostate Cancer Foundation Lake Tahoe, NV	Participant	09/20-09/24/11
Starr Cancer Consortium Retreat Cold Spring Harbor Lab, NY	Presenter/Investigator	09/26-09/27/11
ACR Image Metrix Philadelphia, PA	Consultant	Oct.& Nov. 2011
RSNA Annual Meeting Chicago, IL	Committee Member	11/28-11/30/11
Ontario Institue for Cancer Research Toronto, Canada	Reviewer	03/06-03/08/12
AACR Chicago, IL	"Molecular Imaging for advanced practice oncology"	03/31-04/04/12
Cancer Immunotherapy Consortium 2012 National Harbor, MD	"Quantative PET imaging for the development of antibodies as drugs"	04/19-04/21/12
SNM 59th Annual Meeting Miami, FL	Cassen Lectureship & Prize "Molecular Imaging and Therapy in Advanced Prostate and Thyroid Cancer"	06/9-06/13/12
National Clinical Trials Network Bethesda, MD	Committee Member	07/10-07/11/12

Meeting/Conference	Title of Lecture/Rose	Date
Molecular Imaging Scientific Advisory Board Ann Arbor, MI	Committee Member	07/11-07/12/12
Investigational Drug Steering Committee Meeting (IDSC) Chicago, IL	Committee Member	07/12-07/13/12
Karolinska University Hospital Stockholm, Sweden	"Prostate Cancer Imaging"	08/26-08/28/12
ECOG-ACRIN Imaging Researchers Workshop Pentagon City, VA	Programs Advancing Imaging Research: "CISC; NCI Imaging Steering Committee"	10/04/12
Damon Runyon Cancer Research Foundation New York, NY	Damon Runyon-Rachleff Innovation Award Meeting	10/19/12
RSNA 2012 Annual Meeting Chicago, IL	"Supporting Radiology Research: Imaging Cores, Faculty Development"	11/25-11/28/12
National Clinical Trials Network (NTCN) Working Group Bethesda, MA	Committee Member	12/15-12/17/12
New Jersey Medical School – Univeristy Hospital Cancer Center, Newark, NJ	"Molecular imaging and targeted therapy in oncology"	01/28/13
EMIT- 2nd World Targeted Radiotherapy Washington DC	"Radio-Antibodies as Theranostics: The Role of PET Imaging"	01/29-01/31/13
2013 Genitourinary Cancers Symposium Orlando, FL	"State of the Art: Imaging in Prostate Cancer"	02/14-02/16/13
AACR-SNMMI Joint Conference on State-Of-The-Art Molecular Imaging in Cancer Biology and Therapy San Diego, CA	Session Chairperson "Pleanary Session 4: Cancer Metabolism and Tumor Physiology"	2/28-03/01/13
Enabling Technologies for Cancer Research: Imaging and Diagnostics Berverly, MA	"Targeted radionuclides as theranostics: the role of PET imaging"	03/4-03/05/13
RSNA-Molecular Imaging Committee Chicago, IL	MIC-In person meeting, Committee Member	03/13/13
NCI-SNMMI Worshop on Targeted Radionuclide Therapy Bethesda, MD	"Breakout Session: Solid Tumors"	03/18-03/19/13
NCI National Clinical Trials Network (NCTN) Working Group Bethesda, MD	Committee Member	03/27-03/28/13
SNMMI 60th Annual Meeting, Vancouver, Canada	Participant	06/08-06/10/13

Meeting/Conference	Title of Lecture/Rose	Date
NCI Intramural Research Program Bethesda, MD	Reviewer	06/12-06/14/13
NCI National Clinical Trials Network (NCTN) Working Group Summer Meeting Bethesda, MD	Committee Member	06/28-06/29/13
NCI National Clinical Trials Network (NCTN) Working Group Rockville, MD	Committee Member	06/30-7/3/13
Investigatgational Drug Steering Committee Bethesda, MD	Committee Member	09/16-09/17/2013
2013 STARR Cancer Consortium Cold Spring, NY	Participant	09/23-09/24/2013
20th Annual Scientific Retreat National Harbor, MD	Participant	10/24-10/26/2013
Cardiovascular Molecular Imaging Symposium Santa Monica, CA	Participant	11/14-11/15/2013
Etta Kalin Moskowitz Lectureship Stanford, CA	Participant	11/20-11/22/2013
NIH/NCI Bethesda, MD	Committee Member	01/07-01/08/2014
SU2C- Lustgarten Founcation Pancreatic Cancer Philadelphia, PA	Participant	02/23-02/24/2014
NCTN Meeting Bethesda, MD	Committee Member	03/25-3/26/2014
AUA Annual Meeting Orlando, FL	Participant	05/19-05/20/2014
NIH- Ad Hoc Member of Board of Counselors of NUBIB	Committee Member	06/01-06/03/2014
SNMMI 2014 Mid-winter Meeting St. Louis, Missouri	Participant	06/06-06/07/2014

Meeting/Conference	Title of Lecture/Rose	Date
Scientific Committee Europe, Italy	Participant	09/10-09/14/2014
2014 Coleman Lecture at the SNMMI Southeastern Chapter Annual Meeting Orlando, FL	Participant	10/10-10/11/2014
NCI_SNMMI Workshop on Targeted Raionuclide Therapy Bethesda, MD	Committee Member	10/23-10/24/2014
NIH Meeting	Participant	01/29-01/30/2015
Keystone Symposia on Molecular and Cellular Biology Banff, Alberta, Canada	Tumor Immunology-Multidisciplinary Science Driving Combination Therapy	02/08-02/11/2015
Definition of a paradign for Validation	Participant	02/15-02/16/2015
Yale West Campus Symposium New Haven, CT	Harnessing the Power of the Atom for the Theranostics of Oncology: Targeted Radiotherapy and diagnosis	04/23/2015
Prostate Cancer Clinical Trials Consortium Scientific Oversight Committee Chicago, Illinois	Participant	05/29/2015
SNMMI Annual Meeting Baltimore, MD	"Androgen Receptor Imaging Agents" "Current Role of RAI Imaging and Therapy: Potential for I124 Imaging"	06/04-06/09/2015
Bone Only Disease in Metastic Breast Cancer Symposium Silver Spring, MD	"Imaging"	09/15/2015
The Inaugural International Cancer Immunotherapy Conference New York, NY	Participant	09/16-09/19/2015
NHLBI RFA Review-Molecular Imaging of the Lung-Phase 2 (R01)	Participant	11/01-11/02/2015
Washington, DC SNMMI Review Committee Orlando, FL	Committee Member	01/28-01/30/2016

Meeting/Conference	Title of Lecture/Rose	Date
OHSU Cancer Center Meeting Portland, OR	"Molecular Imaging in Castrate Resistant Prostate Cancer and Theranostics as the future of Nuclear Medicine"	02/11-02/15/2016
UT Southwestern Medical Center Dallas, TX	"Theranostics in Nuclear Medicine Combining Diagnosis with Therapy"	04/25-04/26/2016
University of Iowa Coralville, IA	"Theranostics: The Future of Nuclear Medicine"	04/27-4/29/2016
TRIUMF Vancouver, Canada	"Theranostics: The Future of Nuclear Medicine"	05/03-05/05/2016
FDA Vancouver, Canada	Plenary Lecture: Evaluation of response in metastatic bone disease – experience from prostate cancer	05/05-05/06/2016
SNMMI Annual Meeting San Diego, CA	Participant –Received Saul Hertz Award	06/10-06/13/2016
University of Victoria Victoria, Canada	Participant	06/16-06/17/2016
First Global Summit Boston, MA	"Molecular Imaging" and Poster Judge	09/16-09/19/2016
Washington University School Of Medicine St. Louis, MO	"Theranostics: The Future of Nuclear Medicine"	09/19-09/20/2016
Tenth International Workshop on Pharmacodynamics of anticancer agents Stevenson, WA	"PET-based Compartmental Modeling"	09/23-09/29/2016
SPORE Thyroid EAB Meeting New York, NY	Participant	09/29-09/30/2016
Stanford Cancer Institute Symposium Menlo Park, CA	"Intergrating Diagnosis and Therapy for Radionuclide Targeted Treatment of Solid Tumors'	10/31-11/01/2016
Massachussets General Hospital Grand Rounds Boston, MA	"Molecular Imaging for Oncology: Application to Precision Medicine and Theranostics'	01/18-01/19/2017

Meeting/Conference	Title of Lecture/Rose	Date
Frontier in Oncology Symposium Miami, FL	"Curing Solid Tumors: A Role for Molecular Targeted Radionuclides in Prostate, Thyroid and Colon Cancer"	01/26-01/28/2017
CFI Innovation Funds Review Committee Montreal, Canada	Reviewer	01/29-1/30/2017
Duke Cancer Institute Durham, NC	Speaker	02/21-02/23/2017
Lahey Hospital and Medical Center Boston, MA	Speaker	03/30-03/31/2017
John Hopkins University School of Medicine Baltimore, MD	"Molecular Imaging: Rise of Theranostic"	05/09-05/10/2017
Armed Forces Radiobiology Research Institute Bethesda, MD	Guest of Honor	05/25/2017
SNMMI Annual Meeting Denver, CO	Participant	06/08-06/14/2017
IDSC Meeting Washington, D.C.	Participant	09/26/2017
PCF 2017 Annual Retreat Washington, D.C.	"Targeting PSMA with Antibodies and Antibody Forms"	10/04-10/07/2017
NAM 2017 Annual Meeting Washington, D.C.	Member	10/14-10/16/2017
IEEE 2017 Annual Symposium Atlanta, GA	"Advances in Oncology and Imaging Needs"	10/24-10/26/2017
Executive Advisory Board Meeting Bethesda, MD	Participant	11/06-11/07/2017
SNMMI Annual Meeting Orlando, FL	Participant -Received ACNM gold medal award	01/25-01/28/2018

Meeting/Conference	Title of Lecture/Rose	Date
Miami Thyroid Oncology Symposium Miami, FL	"Radioactive Iodine Theranostic"	02/01-02/04/2018
TFRI 2018 PPG Review Meeting Toronto, Canada	Reviewer	03/27-3/28/2018
NCI-CISC Workshop Meeting Shady Grove, MD	Participant	04/17-04/18/2018
NCI-Improving Brain Tumor Characterization with Advanced Neuroimaging Methods Shady Grove, MD	Committee Reviewer	04/18-04/19/2018
World Federal Nuclear Medicine-Biology Melbourne, Australia	"Molecular Imaging for Oncology Drug Development"	04/20-04/25/2018
Oncopole EMc^2 Montreal, Canada	Committee Reviewer	05/01-05/03/2018
PEGS Summit Boston, MD	"Anti-Tumor x Anti-DOTA Bispecific Antibodies Pre-targeted Radioimmunotherapy"	05/04/2018
Oliver Press Memorial Symposium Seattle, WA	"Treating Solid tumor xenograft for Cures with Pre-targeted Radioimmunotherapy"	09/26-10/1/2018
38th Annual Scientific Meeting of Japanese Society of Nuclear Medicine Okinawa, Japan	Speaker	11/15-11/17/2018
Helsinki International Symposium on Radiopharmaceutical Therapy Helsinki, Finland	Speaker	11/17-11/21/2018
NCI Workshop on Lineage Plasticity and Androgen Receptorindependent Prostate Cancer Bethesda, MD	Participant	12/6-12/7/2018
Emerson Collective Retreat Carmel, CA	Participant	03/18-03/21/2019
SNMMI Annual Anaheim, CA	Committee Reviewer	06/20-06/25/2019

Meeting/Conference	Title of Lecture/Rose	Date
Targeted Radionuclide Therapy Consortium Madison, WI	Speaker	09/20-09/23/2019
NAM 2019 Annual Washington DC	Participant	10/18-10/21/2019
PCF 26th Annual Retreat Carlsbad, CA	Participant	10/23-10/26/2019
PCF Theranostics Scientific Working Group New York, NY	Moderator	11/18/2019
International Symposium on the occasion of 20th Anniversary of Molecular Radiotherapy 2019 Bad Berka, Germany	Participant	12/12-12/15/2019
PEGS Boston Virtual Summit	Speaker	8/31/2020- 9/4/2020
Emerson Collective MICTRL grand rounds Virtual Lecture	Speaker	2/2/2021

3. Institutional Committees

Member, Seattle Veterans Administration Medical Center Research and Development Committee and Chairman, Space Sub-Committee	1978-1980
Member, Seattle Veterans Administration Medical Center Radiation Safety Committee	1978-1983
Member, Search Committee for Director of Nuclear Medicine, Harborview Medical Center	1978-1979
Member, Radiology Research Development Committee, University of Washington	1978-1983
Member, Standing Committee on the Cancer Institutional Grant, University of Washington	1979-1983
Chairman, Laboratory Utilization Review Committee, VA Medical Center	1980-1983
Chairman Research and Development Scientific Review and Evaluation Subcommittee, VA Medical Center	1981-1983
Co-Chairman, Radiation Safety Committee, National Institutes of Health	1983-1988
Member, Medical Board, Clinical Center, National Institutes of Health	1984-1986
Member, Positron Emission Tomography Advisory Committee, NIH	1983-1986
Member, Program of Molecular Pharmacology and Therapeutics, Sloan-Kettering Institute	1990-Present
Investigational Drug Committee, MSKCC (July 1990)	1990-Present
Department of Medicine Ad Hoc Review Committee, MSKCC (September 1990)	1990-Present

Member, Molecular Pharmacology and Therapeutics Program Executive Committee	1991-Present
Member, Scientific Advisory Board, Research & Therapeutics Program in Prostate Cancer, MSKCC	1994-Present
Co-Leader of the Imaging and Radiation Sciences Bridge Program	2002-Present
Member, Institute of Medicine of the National Academies of Science	2005-Present
Chairman of Radiation Oncology, Search Committee, MSKCC	2006-2007
Chairman, Radiochemistry Director Search Committee, MSKCC	2007-2008
HOPP Advisory Committee, Member, MSKCC	2007-2008
MPC, Imaging Faculty Search Committee	2007-Present
Medical Physics Search Committee	2008
Cyclotron Steering Committee Meeting, MSKCC	2008-Present

4. Consultant Activities

Member, Food and Drug Administration, Radiopharmaceutical Advisory Committee	1972-1982
Consultant in Nuclear Medicine for the National Library of Medicine	1972-1974
Consultant in Nuclear Medicine to the National Institutes of Health, Clinical Center	1972-1974
Chairman, Radiopharmaceutical Advisory Committee, Food and Drug Administration	1978-1982
Member, Nuclear Medicine Review Committee, Department of Energy	1982-Present
Member, Biological Response Modifier Decision Network Committee	1983-1987
Member, Editorial Board of the Journal of Computer Assisted Tomography	1984-1995
Member, Brookhaven Linac Isotope Producer User's Committee, Brookhaven National Laboratory	1984-Present
Member, Editorial Board of the American Journal of Physiologic Imaging	1985-1988
Member, Editorial Board of the Journal of the National Cancer Institute	1986-1990
Member, Editorial Board of the International Journal of Biological Markers	1986-Present
Member, Radiology Study Section, NIH	1986-1992
Member, Editorial Board of the Journal: Antibody, Immunoconjugates and Radiopharmaceuticals	1987-1996
Member, Positron Emission Tomography Panel of the Council on Scientific Affairs of the American Medical Association	1987-1988
Associate Editor, The Journal of Nuclear Medicine	1989-1996
Member, National Institutes of Health Reviewers Reserve (NRR)	1990-Present
Member, Editorial Board, The Journal of Nuclear Medicine	1994-Present
Associate Editor, Clinical Cancer Research	1995-Present
Member, Associated Universities, Inc., Visiting Committee for Brookhaven National Laboratory Division of Life Sciences	1995-Present
Member, Scientific Advisory Committee for the Nuclear Medicine Research Program, National Research Council, University of Naples	1995-2001
Editor-in-Chief, Clinical Positron Imaging - Official Journal of the Institute for Clinical PET	1997-2000
Consultant in Nuclear Medicine, INSERM, Nantes Cyclotron Project	1999-2000
Member, Medical Advisory Committee for Counter-terrorism NYPD	2001-2004
Member, Biological and Environmental Research Advisory Committee (BERAC) of the Office of Science, Department of Energy	2001-Present
Member, Council on Molecular Imaging, American College of Radiology	2001-Present
Chairman, Publications Committee, Society of Nuclear Medicine	2002-2005
Director, American Board of Nuclear Medicine	2002-2008
Chairman, Berac Sub-committee on Radiopharmaceutical Development	2002-Present
Study Investigator, GE Amersham	2003-2004

Advisor on Radiopharmaceuticals and PET, CPS	2004
Consultant, Wilex	2006-Present
Consulting for PET Imaging and Study Investigator, Novartis	2006-Present
Clinical Cancer Research Journal, Editorial Board	2007
Study Investigator, CTI Siemens	2007
Consultant, Bayer HealthCare	2007
Study Investigator, Genentech	2007
Consultant, Aposense	2007-11/2008
Consultant, Philips ADAC	2007-Present
Consultant, Imaginab	2008-Present
Member, NCI Panel to review Radiation Oncology Intramural	2009-Present
Medivation Prostate Cancer Study	2010-Present

5. Committee Assignments

Chairman, Scientific Exhibit Committee, Society of Nuclear Medicine	1973-1974
Member of the Board of Regents, American College of Nuclear Physicians	1973-1975
Co-Chairman, Scientific Exhibit Committee, Society of Nuclear Medicine	1974-1975
Member, Scientific Program Committee, Society of Nuclear Medicine	1974-1977
Member, Commercial Exhibit Committee, Society of Nuclear Medicine	1975-1976
Chairman, PSRO Standards on Nuclear Medicine, American College of Nuclear Physicians	1975-1976
Secretary-Treasurer, Pacific Northwest Society of Nuclear Medicine	1976-1978
Trustee, Society of Nuclear Medicine	1976-1980
President-Elect, Pacific Northwest Chapter, Society of Nuclear Medicine	1980-1982
President, Pacific Northwest Chapter, Society of Nuclear Medicine	1982-1984
Member, Society of Nuclear Medicine Publications Committee	1983-Present
Joint Committee on Positron Emission Tomography	1987-Present
Member, Charles F. Kettering Selection Committee, General Motors Cancer Research Foundation	1990-1996
Member, New York County Medical Society	1990-Present
Member, American College of Radiology	1991-Present
Chairman, 1992 Kettering Selection Committee, General Motors Cancer Research Foundation	1991-1992
Member, Board of Directors, Institute for Clinical PET	1993-1994
Member, Scientific Committee of Research Center, University "Federico II", Naples	1994-2001
Chair, Colorectal Cancer Recurrence Task Force, Institute for Clinical PET	1994-1995
Annual Conference Chairman, Institute for Clinical PET	1994-1995
President, Institute for Clinical PET	1995-1996
Fellowship, New York Academy of Medicine	1995-Present
Chairman, Board of Directors, Light of Life Foundation (patient support group, thyroid cancer survivors)	2000-Present
Co-Chair, Investigational Drug Steering Committee, National Cancer Institute	2010-Present
Chairman, Center for Scientific Review, DTCS-A(81)	2011-Present
Co-Chair, Clinical Imaging Steering Committee, National Cancer Institute	2011-Present
Member, Radioactive Drug Research Committee (RDRC)	2012-Present

6. The National Academies

Speaker, Biomarkers in Clinical Trials	2007

Vice Chairman, Committee on Medical Isotope Production W/out Highly Enriched Uranium	2008
Reviewer, An Assessment of the National Institute of Standards & Technology Physics Laboratory	2008
Chairperson, Center for Scientific Review Special Emphasis Panel: Radiation Oncology	2009
Member, Nuclear Energy Agency Advisory Group	2010-Present

7. Research Appointments

Member, Sloan-Kettering Institute New York, NY	07/1988-2023
Laboratory Head, Molecular Pharmacology and Chemistry Program, Sloan Kettering Institute	07/1988-2023
Co-Head, Animal Imaging CORE, SKI	07/2000
Co-Head Imaging and Radiation Sciences Bridge Program	2002-2023

L BIBLIOGRAPHY

Peer Review Articles *(633 from 660 publications)*

1. **Larson SM,** Nelp WB. Visualization of the placenta by radioisotope photoscanning using Tc-99m labeled albumin. Am J Ob Gyn 1965; 93:950.
2. **Larson SM,** Nelp WB. Radiopharmacology of a simplified Tc-99m radiocolloid for photoscanning. J Nucl Med 1966; 7:817.
3. Nelp WB, **Larson SM**. Diagnosis of placenta previa by photoscanning with Tc-99m labeled albumin. JAMA 1967; 200:2.
4. Nelp WB, **Larson SM,** Lewis RJ. Distribution of the erythron and the bone marrow organ. J Nucl Med 1967; 8:430.
5. Nelp WB, Gohil M, **Larson SM,** Bower RE. Long term effect of local irradiation of the marrow on the rythrone and RE cell function. Blood 1970; 36:617.
6. **Larson SM,** Tuell SH, Moores KD, and Nelp WB. Dimensions of the normal spleen and prediction of spleen weight. J Nucl Med 1971; 12:123.
7. **Larson SM,** Schall GL, Di Chiro G. The influence of previous lumbar puncture and pneumoencephalography on the incidence of unsuccessful radioisotope cisternography. J Nucl Med. 1971 Aug;12(8):555-7.
8. **Larson SM,** Nelp WB. The radiocolloid bone marrow scans in malignant disease. J Surg Oncol 1971; 3:685-687.
9. Schall GL, and **Larson SM**. The pathologic basis of the positive bone scan and its implications for the detection of metastatic osteosarcoma. J Surg Oncol 1971; 3:275.
10. Griffith JM, Schall GL, and **Larson SM**. An improved detector for video systems used in radionuclide studies. Radiology 1971; 100:669.
11. **Larson SM,** Schall GL. Gallium-67 concentration in human breast milk. Letter to the Editor, JAMA 1971; 218:217.

12. **Larson SM,** Schall GL, Johnston GS. The value of 67Ga scanning in the evaluation of liver involvement in Hodgkin's disease: comparison with 99m-Tc sulfur colloid. Nuklear Medizin 1971; 10:241.
13. Soloway MS, **Larson SM,** Myers GH. Evidence against a vesicorenal reflex. J Urol 1972; 107:751.
14. Schall GL, **Larson SM,** Anderson L, Griffith JM: Quantification of parotid gland uptake of pertechnetate using a gamma scintillation camera and a "region of interest" system. Amer. J. Roentgenol. Rad Ther Nucl Med 1972; 115:689.
15. Soloway MS, **Larson SM,** Johnston GS, Myers GH. Radioisotope renography in patients with ileal conduit: The importance of position. J Urol 1972; 108:202.
16. **Larson SM,** Graff KS, Tretner IH, Henderson EA, Johnston GS. Positive Gallium-67 photoscan in myeloblastoma. JAMA 1972; 222:321.
17. **Larson SM,** Bailey JJ, Griffith JM, Schall GL, Johnston GS. Radioisotope technique for measuring regional perfusion. Int J Appl Rad Isotopes 1972; (18) 223:388.
18. Soloway MS, **Larson SM,** Myers GL, Johnston GS, Ketcham AS. Value of renography in following radical pelvic surgery. J Surg Oncol 1972; 4:306.
19. **Larson SM,** Schall GL, Johnston GS, Bailey JJ, Griffith JM. Radioisotope technique for measuring regional organ blood flow. Int J Appl Radiat Isot. 1972 Aug; 23(8):388-90.
20. Milder MS, **Larson SM**, Swann SJ, Johnston GS. False-positive liver scan due to breast prosthesis. J Nucl Med. 1973 Mar;14(3):189.
21. Milder MS, **Larson SM,** Bagley CM, DeVita VT, Johnson RE, Johnston GS. The liver spleen scan in Hodgkin's. Cancer 1973; 31:826.
22. **Larson SM,** Milder MS, Tretner IH, Johnston GS. Interpretation of Gallium-67 photoscans. J Nucl Med 1973; 14:208.
23. **Larson SM,** Johnston GS, Ommaya A, Jones AE, DiChiro G. The radionuclide ventriculogram. JAMA 1973; 224:853.
24. Oldham RK, **Larson SM,** Givelber HM, Johnson AE. A preliminary study of 51 Cr-labeled platelets for the evaluation of splenic sequestration in chronic lymphocytic leukemia. J Nucl Med 1973; 14:219.
25. Milder MS, **Larson SM**, Swann SJ, Johnston GS. Liver scan artifact due to breast prosthesis. Letter to the Editor, J Nucl Med 1973; 14:189.
26. DiChiro G. **Larson SM,** Harrington T, Johnston GS, Green MV, Swann SJ. Descent of cerebrospinal fluid to spinal subarachnoid space. Acta Radiologica 1973; 14:379.
27. **Larson SM,** Charache P, Chen M, Wagner HN Jr. Automated detection of hemophilus influenza. J Appl Microbiol 1973; 25:1011.
28. Milder MS, Aptekar RG, **Larson SM**, Decker JL, Johnston GS. Letter: Spleen size in SLE. Arthritis Rheum. 1974 Mar-Apr;17(2):190-1.
29. **Larson SM,** Chen M, Charache P, Wagner HN Jr. Inhibition of the metabolism of streptococcus and salmonella by type specific antisera. Appl Microbiol 1974; 27:351.
30. Amrein PC, **Larson SM,** Wagner HN Jr. An automated system for the study of leukocyte metabolism. J Nucl Med 1974; 15:352.

31. Amrein PC, **Larson SM,** Wagner HN Jr. A rapid automated system for measurement of antibody titers. J Nucl Med 1974; 15:1145.

32. McIntyre PA, **Larson SM,** Eikman EA, Colman M, Scheffel U, Hodkinson BA. Comparison of the metabolism of iron labeled transferrin (Fe TF) and indium labeled (In TF) by the erythropoietic marrow. J Nucl Med 1974; 15:856.

33. Camargo EE, **Larson SM,** Tepper BS, Wagner HN Jr. Radiometric measurement of metabolic activity of mycobacterium lepraemurium. J Appl Microbiol 1974; 28:452.

34. Chen M, Rhodes BA, **Larson SM,** Wagner HN Jr. Sterility testing of radiopharmaceuticals. J Nucl Med 1974; 15:1142.

35. Vessal K, Montali R, **Larson SM,** Chaffee V, James AE Jr. Evaluation of barium and gastrografin as contrast media for diagnosis of esophageal ruptures and perforations. Amer J Roentgenol Rad Ther Nucl Med 1975; 123:307.

36. **Larson SM,** Chen M. Charache P, Wagner HN Jr. Radiometric identification of streptococcus group A in throat cultures. J Nucl Med 1975; 16:1085.

37. Oster ZH, **Larson SM,** Strauss HW, Wagner HN Jr. Analysis of liver scanning in a general hospital. J Nucl Med 1975; 16:450.

38. Cummings DM, Ristroph D, Camargo EE, **Larson SM,** Wagner HN Jr. Radiometric detection of the mycobacterial tuberculosis. J Nucl Med 1975; 16:1189.

39. Camargo EE, Charache P, **Larson SM,** Hwangbo CL, Wagner HN Jr. Mycobacterium tuberculosis: Radiometric testing of susceptibility to drugs. J Nucl Med 1975; 16:1189.

40. Yeung W, Haines JE, **Larson SM**. Diagnosis of posterolateral congenital diaphragmatic (Bochdalek) hernia by liver scintigram. J Nucl Med 1975; 17:110.

41. Yeung W, **Larson SM,** Haines JE. Letter to the Editor: A simple method for zero extrapolatin in plasma volume determination. J Nucl Med 1975; 16:1207.

42. Camargo EE, **Larson SM,** Tepper BS, Wagner HN Jr. A radiometric method for predicting effectiveness of chemotherapeutic agents in murine leprosy. Int J Leprosy 1975; 43:234.

43. Camargo EE, **Larson SM,** Charache P, Tepper BS, Wagner HN Jr. Current status of radiometric detection of M. tuberculosis and M. lepraemurium. J Nucl Med 1975; 16:518.

44. Kim HR, Buchanan JW, D'Antonio R, **Larson SM,** Morgan RP, Thorell JI, McIntyre PA, Wagner HN Jr. The use of toadfish serum for in vitro assay of Vitamin Bl2. J Nucl Med 1976; 17:737.

45. D'Antonio N, Tsau M, Charache P, **Larson SM,** Wagner HN Jr. Simple radiometric techniques for rapid detection of herpes simplex virus Type I-In 111 38 cell culture. J Nucl Med 1976; 17:503.

46. Oster ZH, **Larson SM,** Wagner HN Jr. Possible enhancement of Gallium 67 citrate imaging by iron dextran. J Nucl Med 1976; 17:356.

47. Harrowe D, Kessler S, Jansen A, **Larson SM**. Gallium-67 uptake by a malignant fibrous histiocytoma. J Nucl Med 1976; 17:630.

48. Van Kirk OC, Burry MT, Jansen AA, Barnett D, **Larson SM**. A simplified approach to radionuclide venography. J Nucl Med 1976; 17:696-671.

49. Camargo EE, **Larson SM,** Tepper BS, Wagner HN Jr. Radiometric studies of m. lepraermurium. Int J Leprosy 1976; 44:294-300.

50. Hegge FN, Mahler DJ, **Larson SM**. The incorporation of 67Ga into the ferritin fraction of rabbit hepatocytes in vivo. J Nucl Med 1977; 18:937-939.

51. Johnston GS, Go MF, Benua RS, **Larson SM,** Andrews GA, Hubner KF. Gallium-67 citrate imaging in Hodgkins' disease: Final report of cooperative group. J Nucl Med 1977; 18:692.

52. Folland ED, Hamilton GW, **Larson SM,** Kennedy JW, Williams DL, Ritchie JL. The radionuclide ejection fraction: A comparison of three radionuclide techniques with contrast angiography. J Nucl Med 1977; 18:1159-1166.

53. Hegge FN, Hamilton GW, **Larson SM,** Ritchie JL, Richards P. Cardiac chamber imaging: A comparison of red blood cells labeled with Tc-99m in vitro and in vivo. J Nucl Med 1978; 19:129-134.

54. Van Kirk OC, Chafetz N, Cooke S, Taylor A Jr, **Larson SM**. Imaging the bowel with technetium -- an aid in gallium studies. J Nucl Med 1978; 19:69-70.

55. **Larson SM,** Mahler D, Allen DR. Iron-dextran enhancement of 67Ga concentration in abscess relative to normal tissue Nuklearmedizin 1978; 17:95-98.

56. **Larson SM,** Allen DR, Grunbaum Z, Rasey JS. Kinetics of binding of carrier-free 67Ga to human transferrin. J Nucl Med 1978; 19:1245-1249.

57. Hubbard TW, **Larson SM,** Allen DR. Effect of phenobarbital on liver uptake of Ga-67. Letter to the Editor. J Nucl Med 1978; 19:1089.

58. **Larson SM,** SM, Hamilton GW, Richards P, Ritchie JL. Kit labeled Technetium 99m red blood cells for clinical cardiac chamber imaging. European J Nucl Med 1978; 3:227-231.

59. **Larson SM,** Rasey JS, Grunbaum Z, Allen DR. Pharmacologic enhancement of Gallium-67 tumor-to-blood ratios for EMT-6 sarcoma (BALB/c mice). Work in Progress. Radiology 1979; 130:241-243.

60. Hayden PW, **Larson SM,** Lakshminarayanan S. Atropine clearance from human plasma. J Nucl Med 1979; 20:366-367.

61. **Larson SM,** Rasey JS, Allen DR, Nelson NJ. A transferrin-mediated uptake of Gallium-67 by EMT-6 sarcoma. I. Studies in tissue culture. J Nucl Med 1979; 20:837-842.

62. **Larson SM**, Rasey JS, Allen DR, Grunbaum Z. A transferrin-mediated uptake of Gallium-67 by EMT-6 sarcoma. II. Studies in vivo (BALB/c mice): concise communication. J Nucl Med 1979; 20:843-846.

63. Camargo EE, Kertcher JA, **Larson SM,** Tepper BS. Radiometric measurement of fatty acids by mycobacterium lepraemurium. Int J Leprosy 47:161-179.

64. **Larson SM,** Rasey JS, Allen DR, Nelson JH, Grunbaum Z, Harp GD, Williams DL. Common pathway for tumor cell uptake of Gallium-67 and Iron-59 via a transferrin receptor. J Natl Cancer Inst 1980; 64:41-53.

65. **Larson SM,** Grunbaum Z, Rasey JS. Positron imaging feasibility studies: l. Selective tumor concentration of 3H-thymidine, 3H-uridine, and 14C-2-deoxyglucose, based on the characteristic metabolism of malignancy. Radiology 1980; 134(3):771-773.

66. Rasey JS, **Larson SM.** Tumor detection by gallium-67 scintiscanning: Source of success and cause of failure. Brit J Cancer 1980; 41(suppl. IV):50.

67. Queener SF, Bell NH, **Larson SM**, Henry DP, Slatopolsky E. Comparison of the regulation of calcitonin in serum of old and young Buffalo rats. J Endocrinol. 1980 Oct;87(1):73-80.

68. Cummings CW, **Larson SM,** Dobie RA, Weymuller EA, Rudd TG, Merello A. Assessment of cobalt 57 tagged bleomycin as a clinical aid in staging of head and neck carcinoma. Laryngoscope 1981; 91:529-537.

69. Kradjan WA, Lakshminarayan S, Hayden PW, **Larson SM,** Marini JJ. Serum atropine concentrations after inhalation of atropine sulfate. Am Rev Respir DIS 1981; 123:471-472.

70. Nelp WB, **Larson SM,** Hamilton GW. Radionuclide venography. In Clinical Nuclear Cardiology, Berman DS, Mason DT, eds., Grune & Stratton, Inc., New York, 1981.

71. **Larson SM,** Weiden PL, Grunbaum Z, Rasey JS, Kaplan HG, Graham MM, Harp GD, Sale GE, Williams DL. Positron imaging feasibility studies. I. Characteristics of 3H-thymidine uptake in rodent and canine neoplasms. J Nucl Med 1981; 22:869-874.

72. **Larson SM,** Weiden PL, Grunbaum Z, Kaplan HG, Rasey JS, Graham MM, Sale GE, Harp GD, Williams DL. Positron imaging feasibility studies. II. Characteristics of 2-deoxyglucose uptake in rodent and canine neoplasms. Concise communication. J Nucl Med 1981; 22:875-879.

73. **Larson SM,** Grunbaum Z, Rasey JS. The role of transferrins in gallium uptake. Int J Nucl Med Biol 1981; 8:257-266.

74. Rasey JS, Nelson NJ, **Larson SM**. Relationship of iron metabolism to tumor cell toxicity of stable gallium salts. Int J Nucl Med Biol 1981; 8:303-314.

75. Camargo EE, Kertcher JA, **Larson SM,** SM, Tepper BS and Wagner Jr. HN. Radiometric measurement of differential metabolism of fatty acid by mycobacteria. In. J Lepr 1982; 50:200-204.

76. Rasey JS, Nelson NJ, **Larson SM**. Tumor cell toxicity of stable GA nitrate. Enhancement by transferrin protection iron. Eur J Cancer Clin Oncol 1982; 18:661-668.

77. **Larson SM,** Brown JP, Wright PW, Carrasquillo JA, Hellstrom I, Hellstrom KE. /ZX Imaging of melanoma with I-131-labeled monoclonal antibodies. J Nucl Med 1983; 24:123-129.

78. **Larson SM,** Carrasquillo JA, Krohn KA, McGuffin RW, Hellstrom I, Hellstrom KE, Lyster D. Diagnostic imaging of malignant melanoma with radiolabeled anti-tumor antibodies. JAMA 1983; 249:811-812.

79. Graham MM, Spence AM, **Larson SM**. Glucose metabolic rates in transplanted astrocytic gliomas in rats. J. Cereb Blood Flow Metab 3 1983; (suppl 1): S41-S42.

80. Carrasquillo JA, Rogers JV, Williams DL, Shuman WP, Olson DO, **Larson SM**. Single photon emission computerized tomography of the normal liver. AJR 1983; 141:937-941.

81. **Larson SM,** Carrasquillo JA, Krohn KA, Brown JP, McGuffin RW, Fevens JM, Graham MM, Hill LD, Beamier PL, Hellstrom KE and Hellstrom I: Localization of 131-I-labelled p97-specific Fab fragments in human melanoma as a basis for radiotherapy. JCI 1983; 72:2101-2114.

82. Bacharach SL, Green MV, Vitale D, White G, Douglas MA, Bonow RO, **Larson SM**. Optimum fourier filtering of cardiac data: a minimum-error method: concise communication. J Nucl Med. 1983 Dec;24(12):1176-84.

83. Ferens JM, Krohn KA, Beaumier PL, Brown JP, Hellstrom I, Hellstrom KE, Carrasquillo JA, and **Larson SM**. High-level iodination of monoclonal antibody fragments for radiotherapy. J Nucl Med 1984; 25:367-370.

84. Carrasquillo JA, Krohn KA, Beaumier PL, McGuffin RW, Brown JP, Hellstrom KE, Hellstrom J, **Larson SM**. Diagnosis of and therapy for solid tumors with radiolabelled antibodies and immune fragments. Cancer Treat Rep, January 1984; vol. 68, no. 1, 317-328.

85. Shields AF, **Larson SM,** Grunbaum Z, Graham MM. Short term thymidine uptake in normal and neoplastic tissues: studies for PET. J Nucl Med 1984; 25:759-764.

86. East IJ, Keenan AM, **Larson SM,** Dean J. Scintigraphy of normal mouse ovaries with monoclonal antibodies to ZP-2, the major zona pellucida protein. Science, August 31, 1984; 225:938-941.

87. Keenan AM, Colcher D, **Larson SM,** Schlom J. Radioimmunoscintigraphy of human colon cancer xenografts in mice with radioiodinated monoclonal B72.3. J Nucl Med 1984; 25:1197-1203.

88. Green MV, Jones-Collins BA, Bacharach SL, Findley SL, Patterson RE, **Larson SM**. Scintigraphic quantification of asynchronous myocardial motion during the left ventricular isovolumic relaxation period: A study in the dog during acute ischemia. JACC 1984; 4:72-27.

89. Pert CB, Danks JA, Channing MA, Eckelman WC, **Larson SM,** Bennett JM, Burke TR, Jr., Rice KC: 3-[18F]Acetylcyclofoxy: A useful probe for the visualization of opiate receptors in living animals. FEBS Letters, November 1984; vol. 177, no. 2.

90. Bunn PA, Carrasquillo JA, Keenan AM, Schroff RW, Foon KA, Hsu SM, Gazdar AF, Reynolds JC, Perentesis P, **Larson SM**. Successful imaging of malignant non-Hodgkin's lymphoma using radiolabelled monoclonal antibody. Lancet, November 24, 1984; 1219-1221.

91. Hou D-Y, Hoch H, Johnston GS, Tsou KC, Jones AE, Miller EE, **Larson SM**. A new tumor imaging agent-111-In-bleomycin complex: Comparison with 67Ga-citrate and 57Co-Bleomycin in tumor bearing animals, J Surgical Oncology 1984; 27:189-195.

92. Colcher D, Keenan AM, **Larson SM,** Schlom J. Prolonged binding of a radiolabelled monoclonal antibody (B72-3) used for the on-site radioimmunodetection of humans. Colon Carcinoma Xenografts. Cancer Research 1984; 44:5744-5751.

93. Bacharach SL, Green MV, Bonow RO, **Larson SM**. Maximal LV filling rate during exercise: R-R interval normalization, IEEE Computers in Cardiology, 1984, pp. 207-210.

94. **Larson SM**. Radiolabeled monoclonal anti-tumor antibodies in diagnosis and therapy. J Nucl Med. 1985 May;26(5):538-45.

95. **Larson SM,** Carrasquillo JA, McGuffin RW, Krohn KA, Ferens JM, Hill LD, Beaumier PL, Reynolds JC, Hellstrom KE, Hellstrom I. Preliminary clinical experience using an I-131 labelled, murine Fab against a high molecular weight antigen of human melanoma, Radiology 1985; 155:487-492.

96. Zeeberg BR, Soucaille JF, Carson R, Bacharach S, Green MV, **Larson SM**. An efficient algorithm for reconstruction of SPECT images in the presence of spatially varying attenuation, IEEE Trans Nucl Sci April 1985; vol. NS-32, no. 2, pp. 1190-1197.

97. Petronas JF, Di Chiro G, Kufta C, Bairamian D, Kornblith PL, Simon R, **Larson SM**. Prediction of survival in glioma patients by means of positron emission tomography (PET), J Neurosurgery 1985; 62:816-822.

98. Hou, DY, Hoch, H, Johnston GS, Tsou KC, Jones AE, Farkas RJ, Miller EE, **Larson SM**. A new 111 In-Bleomycin complex for combined radiotherapy and chemotherapy. J Surgical Oncology 1985; 29:91-98.

99. **Larson SM,** Di Chiro G. Comparative anatomo functional imaging of two neuroreceptors and glucose metabolism: A PET study performed in the living baboon. J Computer Assisted Tomography July/August 1985; 9(4):676-681.

100. Beaumier PL, Krohn KA, Carrasquillo JA, Eary J, Hellstrom I, Hellstrom KE, Nelp WB, **Larson SM**. Melanoma localization in nude mice with monoclonal Fab against p97. J Nucl Med 1985; 26:1172-1179.

101. Bairamian D, Di Chiro G, Theodore WH, Holmes MD, Dorwart RH, **Larson SM**. MR imaging and Positron Emission Tomography of cortical heterotopia, J Computer Assisted Tomography November/December 1985; 9(6):1137-1139.

102. **Larson SM**. A tentative biological model for the localization of radiolabeled antibody in tumor: The importance of immunoreactivity. Nucl Med Biol 1986; 13:393-399.

103. Kiesewetter DO, Eckelman WC, Cohen RM, Finn RD, **Larson SM.** Syntheses and D2 receptor affinities of derivatives of spiperone containing aliphatic halogens. Int J Rad Appl Instrum A. 1986;37(12):1181-8.

104. McManaway ME, Jagoda EM, Eckelman WC, **Larson SM**, Francis BE, Gibson RE, Reba RC, Lippman ME. Binding characteristics and biological activity of 17 alpha-[125I]iodovinyl-11 beta-methoxyestradiol, an estrogen receptor-binding radiopharmaceutical, in human breast cancer cells (MCF-7). Cancer Res. 1986 May;46(5):2386-9

105. Lotze MT, Carrasquillo, JA, Weinstein JN, Bryant GJ, Perentesis P, Reynolds JC, Matis LA, Eger RR, Keenan AM, Hellstrom I, Hellstrom KE, **Larson SM**. Monoclonal antibody imaging of human melanoma: Radioimmunodetection by subcutaneous or systemic injection. Ann Surg 1986; 204:19-31.

106. Theodore WH, Bairamian D, Newmark ME, DiChiro G, Porter RJ, **Larson SM,** Fishbein D. Effect of phenytoin on human cerebral glucose metabolism, J Cerebral Blood Flow and Metabolism Raven Press, New York. 1986; 6:315-320.

107. Carrasquillo JA, Bunn PA, Jr, Keenan AM, Reynolds JC, Schroff RW, Foon KA, Ming-Hsu S, Gazdar AF, Mulshine JL, Oldham RK, Perentesis P, Horowitz M, Eddy J, James P, **Larson SM**. Radioimmunodetection of cutaneous T-cell lymphoma with 111 In-labeled T101 monoclonal antibody. NEJM Sept. 11, 1986; 315:673-680.

108. Duara R, Grady C, Haxby J, Sundaram M, Cutler NR, Heston L, Moore A, Schlageter N, **Larson SM,** Rapoport SI: Positron Emission Tomography in Alzheimer's Disease, Neurology 1986; 36: 879-887.

109. *Kiesewetter DO, Eckelman WC, Cohen RM, Finn RD, **Larson SM**. Syntheses and D2 receptor affinities of derivatives of spiperone containing aliphatic halogens, Submitted to Int J Appl Radiol Isot 1986; 37:1181-1188.

110. Keenan AM, Weinstein JN, Mulshine JL, Carrasquillo JA, Bunn PA, Jr., Reynolds JC, **Larson SM.** Immunolymphoscintigraphy in patients with lymphoma after subcutaneous injection of indium-111 labeled T101 monoclonal antibody, J Nucl Med 1987; 28:42-46.

111. Woolfenden JM, Carrasquillo JA, **Larson SM,** Simmons JT, Masur H, Smith PD, Shelhamer JH, Ognibene FP: Acquired Immunodeficiency Syndrome: Ga-67 Citrate Imaging, Radiology 1987; 162: 383-387.

112. Yarchoan R, Brouwers P, Spitzer AR, Grafman J, Safai B, Perno CF, **Larson SM,** Berg G, Fischl MA, Wichman A, Thomas RV, Brunetti A, Schmidt PJ, Myers CE, Broder S. Response of human immunodeficiency-virus-associated neurological disease to 3'-azido-3'Deoxythymidine, The Lancet, January 17, 1987; pp. 132-135.

113. Brooks RA, Di Chiro G, Zukerberg BW, Bairamian D, **Larson SM**. Test-retest studies of cerebral glucose metabolism using Fluorine-18 Deoxyglucose: Validation of Method, J Nucl Med 1987; 28: 53-59.

114. Carrasquillo JA, Mulshine JL, Bunn PA, Reynolds JC, Foon KA, Schroff RW, Perentesis P, Steis RG, Keenan AM, Horowitz M, **Larson SM**. Tumor uptake of 111 in T-101 monoclonal antibody is superior to 131-I T-101 in cutaneous T-cell lymphoma. JNM 1987; vol. 28, 3:281-287.

115. Esteban JM, Colcher D, Sugarbaker P, Carrasquillo JA, Bryant G, Thor A, Reynolds JC, **Larson SM,** Schlom J: Quantitative and qualitative aspects of radiolocalization in colon cancer patients of intravenously administered Mab B72.3, Int J Cancer 1987; 39: 50-59.

116. Fishbein DS, Chrousos GA, Di Chiro G, Wayner RE, Patronas NJ, **Larson SM**: Glucose utilization of visual cortex following extra-occipital interruptions of the visual pathways by tumor: A Positron Emission Tomography Study, J Clin Neuro-Opthalmology 1987; 7(2):63-68.

117. Agui T, Bryant G, Kebabian JW, **Larson SM,** Saavedra JM, Shigematsu K, Yamamoto T, Yokoyama K: 125 I-Iodinated benzazepines bind to melanin: Implications for the noninvasive localization of pigmented melanomas, Nucl Med Biol 1987; vol. 14, no. 2, pp. 133-141, Int J Radiat Appl Instrum Part B.

118. Schapiro MB, Haxby JV, Grady CL, Duara R, Schlageter NL, White B, Moore A, Sundaram M, **Larson SM,** Rapoport SI. Decline in cerebral glucose utilization and cognitive function with aging in Down syndrome, Jrn of Neurology, Neurosurgery, and Psychiatry, 1987, 50: 766-774.

119. Neuwelt EA, Specht HD, Barnett PA, Dahlborg SA, Miley A, **Larson SM,** Brown P, Eckerman KF, Hellstrom KE, Hellstrom I. Increased delivery of tumor specific monoclonal antibodies to brain after osmotic blood-brain barrier modification in patients with melanoma metastatic to the central nervous system. Neurosurgery 1987; vol. 20, no. 6:885-895.

120. *Kiesewetter DO, Eckelman WC, Cohen RM, Finn RD, **Larson SM**. Syntheses and D2 receptor affinities of derivatives of spiperone containing aliphatic halogens, Submitted to Int J Appl Radiol Isot 1986; 37:1181-1188.

121. Brooks RA, Hatazawa J, Di Chiro G, **Larson SM,** Fishbein DS: Human cerebral glucose metabolism determined by Positron Emission Tomography: A Revisit, J Cerebral Blood Flow and Metabolism 1987; 7:427-432.

122. Keenan AM, Weinstein JN, Mulshine JL, Carrasquillo JA, Bunn PA Jr, Reynolds JC, **Larson SM.** Immunolymphoscintigraphy in patients with lymphoma after subcutaneous injection of indium-111-labeled T101 monoclonal antibody. J Nucl Med. 1987 Jan;28(1):42-6.

123. Esteban JM, Colcher D, Sugarbaker P, Carrasquillo JA, Bryant G, Thor A, Reynolds JC, **Larson SM,** Schlom J. Quantitative and qualitative aspects of radiolocalization in colon cancer patients of intravenously administered MAb B72.3. Int J Cancer. 1987 Jan 15;39(1):50-9.

124. Di Chiro G, Oldfield E, Wright DC, De Michele D, Katz DA, Patronas NJ, Doppman JL, **Larson SM,** Ito M, Kufta CV: Cerebral necrosis following radiotherapy and/or intra-arterial chemotherapy for brain tumors: PET and Neuropathological Studies, AJNR 1987; 8:1083-1091.

125. Colcher D, Carrasquillo JA, Esteban JM, Sugarbaker P, Reynolds JC, Siler K, Bryant G, **Larson SM**, Schlom J. Radiolabeled monoclonal antibody B72.3 localization in metastatic lesions of colorectal cancer patients. Int J Rad Appl Instrum B. 1987;14(3):251-62.

126. Colcher D, Esteban J, Carrasquillo JA, Sugarbaker P, Reynolds JC, Bryant G, **Larson SM,** Schlom J: Quantitative analyses of selective radiolabeled monoclonal antibody localization in metastatic lesions of colorectal cancer patients, Ca Res 1987; 47:1185-1189.

127. McManaway ME, Jagoda EM, Kasid A, Eckelman WC, Francis BE, **Larson SM,** Gibson RE, Reba RC, Lippman ME: [125 I] 17-Iodovinyl 11-Methoxyestradiol interaction in vivo with estrogen receptors in hormone-independent MCF-7 human breast cancer transfected with the v-rasH oncogene, Ca Res 1987; 47:2945-2949.

128. Eger RR, Covell DG, Carrasquillo JA, Abrams PG, Foon KA, Reynolds JC, Schroff RW, Morgan AC, **Larson SM,** Weinstein JH: Kinetic model for the biodistribution of an 111 In-Labeled monoclonal antibody in humans, Ca Res 1987; 47:3328-3336.

129. Mulshine JL, Keenan AM, Carrasquillo JA, Walsh T, Linnoila RI, Holton OD, Harwell J, **Larson SM,** Bunn PA, Weinstein JN: Immunolymphoscintigraphy of pulmonary and mediastinal lymph nodes in dogs: A new approach to lung cancer imaging, Ca Res 1987; 47:3572-3576.

130. Blacklock JB, Oldfield EH, DiChiro G, Tran D, Wright DC, **Larson SM**. Effect of barbiturate coma on glucose utilization in normal brain versus gliomas: PET studies. J Neurosurg 1987; 67:71-75.

131. Colcher D, Simpson J, Ohuchi N, Carrasquillo J, Reynolds J, **Larson SM,** Scholm J. Potential use of monoclonal antibody B72.3 for the diagnosis and management of gastrointestinal malignancies. "New Trends in Gastroenterology", 1987; pp. 153-165.

132. O'Gara PT, Bonow RO, Maron BJ, Damske BA, Van Lingen A, Bacharach SL, **Larson SM,** Epstein SE: Myocardial perfusion abnormalities in patients with hypertrophic cardiomyopathy: Assessment with Thallium-201 emission computed tomography, circulation 1987; 76(6):1214-1223.

133. Keenan AM, Weinstein JN, Carrasquillo JA, Bunn PA, Reynolds JC, Foon KA, Smarte NC, Ghosh B, Fejka RM, **Larson SM,** Mulshine JL: Immunolymphoscintigraphy and the dose-dependence of Indium-111-labeled T101 monoclonal antibody in patients with cutaneous T-cell lymphoma. Ca Res 1987; 47:6093-6099.

134. Colcher D, Esteban J, Carrasquillo JA, Sugarbaker P, Reynolds JC, Bryant G, **Larson SM,** Schlom J: Complementation of intracavitary and intravenous administration of a monoclonal antibody (B72.3) in patients with carcinoma. Ca Res 1987; 47: 4218-4224.

135. Stevenson HC, Miller JP, Beman JA, Ottow R, Abrams PG, Keenan AM, **Larson SM,** Woodhouse C, Sugarbaker P: Fate of gamma interferon activated killer blood monocytes adoptively transfered into the abdomenal cavity of patients with peritoneal carcinomatosis. Ca Res 1987; 47:6100- 6103.

136. Finn R, Plascjak P, Sheh Y, Yamashita Y, Yoshida H, Adams R, Simpson N, **Larson SM**. Modification and integration of JSW cyclotron gas targets at The National Institutes of Health Cyclotron Facility. Nucl Instruments & Methods in Physics Research B24/25, North-Holland, Amsterdam, 1987; 954-956.

137. Theodore WH, Rose D, Patronas N, Sata S, Holmes M, Bairamian D, Porter RJ, Di Chiro G, **Larson SM,** Fishbein D. Cerebral glucose metabolism in the Lennox-Gastaut Syndrome. Ann Neurol 1987; 21:14-21.

138. Di Chiro G, Oldfield E, Wright DC, De Michele D, Katz DA, Patronas NJ, Doppman JL, Larson SM, Ito M, Kufta CV. Cerebral necrosis after radiotherapy and/or intraarterial chemotherapy for brain tumors: PET and neuropathologic studies. AJR Am J Roentgenol. 1988 Jan;150(1):189-97.

139. Rodgers GP, Clark CM, **Larson SM,** Rapoport SI, Nienhuis AW, Schechter AN. Brain glucose metabolism in neurologically normal patients with sickle cell disease: regional alterations. Archives of Neurology 1988; 45:78-82.

140. Kern KA, Brunetti A, Norton JA, Chang AE, Malawer M, Lack E, Finn RD, Rosenberg SA, **Larson SM**. Metabolic imaging of human extremity musculoskeletal tumors by PET. J Nucl Med 1988; 29:181-186.

141. Carrasquillo JA, Abrams PG, Schroff RW, Reynolds JC, Woodhouse CS, Morgan AC, Keenan AM, Foon KA, Perentesis P, Marshall S, Horowitz M, Szymendera J, Englert J, Oldham RK, **Larson SM**. Effect of antibody dose on the imaging and biodistribution of Indium-111 9.2.27 anti-melanoma monoclonal antibody. J Nucl Med 1988; 29:39-47.

142. Yarchoan R, Thomas RV, Grafman J, Wichman A, Dalakas M, McAtee N, Berg G, Fischl M, Perno CF, Klecker RW, Buchbinder A, Tay S, **Larson SM,** Myers CE, Broder S. Long-term administration of 3'-Azido-2',3'-Dideoxythymidine to patients with AIDS-related neurological disease. Ann Neurol 1988; 23(suppl):S82-S87.

143. Carrasquillo JA, Sugarbaker P, Colcher D, Reynolds JC, Esteban J, Bryant G, Perentesis P, Yokoyama K, Rotman M, Schlom J, **Larson SM**. Peritoneal carcinomatosis: Imaging of peritoneal carcinomatosis with intraperitoneal injection of I-131 labeled B72.3 monoclonal antibody. Radiology 1988; 167:35-40.

144. **Larson SM,** Carrasquillo JA Advantages of radioiodine over radioindium labelled monoclonal antibodies for imaging of solid tumors. Nucl Med Biol, Int J of Rad Instrum 1988; 15(3):231-233.

145. Bacharach SL, Green MV, Bonow RO, Findley SL, Daube-Witherspoon ME, **Larson SM**. The effect of energy window on cardiac ejection fraction. J Nucl Med 1988; 29:385-391.

146. Mulshine JL, Avis I, Treston AM, Dsaprzyk PG, Nakanishi Y, Mobley C, Carrasquillo JA, **Larson SM,** Merchant B, Cuttitta F. In vivo diagnosis and therapy of human tumors with monoclonal antibodies: selection of antibodies and preliminary clinical studies in small cell carcinoma of the lung. Nuc Med Biol Int J Appl Radiat Instrum. Part B. Suppl 1989; 16(2):159-162.

147. Schlom J, Colcher D, Roselli M, Carrasquillo JA, Reynolds JC, **Larson SM,** Sugarbaker P, Tuttle SE, Martin EW. Tumor targeting with monoclonal antibody B72.3. Nuc Med Biol Int J Appl Radiat Instrum 1989; 16(2);137-142.

148. Carrasquillo JA, Sugarbaker P, Colcher, Reynolds JC, Esteban J, Bryant G, Keenan AM, Perentesis P, Yokoyama K, Simpson DE, Ferroni P, Farkas R, Schlom J, **Larson SM**. Radioimmunoscintigraphy of colon cancer with Iodine-131 labeled B72.3 monoclonal antibody. J Nucl Med 1988; 29:1022-1033.

149. Del Vecchio S, Reynolds JC, Blasberg RG, Neumann RD, Carrasquillo JA, Hellstrom I, **Larson SM**. Measurement of local p97 and p250 antigen concentration in sections of human melanoma tumor using in vitro quantitative autoradiography. Cancer Res 1988; 48:5475-5481.

150. Brunetti A, Blasberg RG, Finn RD, **Larson SM**. Gallium transferrin as a molecular tracer of vascular permeability. Nucl Med Biol, Int J Radiat Appl Instrum Part B, 1988; l5(6):665-672.

151. Mulshine JL, Avis I, Treston AM, Mobley C, Kaspryk P, Carrasquillo JA, **Larson SM,** Nakanishi Y, Merchant B, Minna JD, Cuttitta F. Clinical use of a monoclonal antibody to bombesin-like

peptide in patients with lung cancer. Annals New York Academy of Sciences, Science Press 1988; 547:360-372.

152. **Larson SM,** Raubitschek A, Reynolds JC, Neumann RD, Hellstrom KE, Hellstrom I, Colcher D, Schlom J, Glatstein E, Carrasquillo JA. Comparison of bone marrow dosimetry and toxic effect of high dose I-131 labelled monoclonal antibodies administered to man. Nuc Med Biol Int J Appl Radiat Instrum Part B, 1989; 16(2):153-158.

153. Yokoyama K, Carrasquillo JA, Chang AE, Colcher D, Roselli M, Sugarbaker P, Sindelar W, Reynolds JC, Perentesis P, Gansow OA, Francis B, Adams R, Finn R, Schlom J, **Larson SM**. Differences in biodistribution of Indium-111- and Iodine-131-labeled B72.3 monoclonal antibodies in patients with colorectal cancer. J Nucl Med 1989; 30:320-327.

154. Del Vecchio S, Reynolds JC, Carrasquillo JA, Blasberg RG, Neumann RD, Lotze MT, Bryant GJ, Farkas RJ, **Larson SM**. Local distribution and concentration of intravenously injected 131 I-9.2.27 monoclonal antibody in malignant melanoma. Cancer Research 1989; 49: 2783-2789.

155. Fisher B, Packard BS, Read EJ, Carrasquillo JA, Carter CS, Topalian SL, Yang JC, Yolles P, **Larson SM,** Rosenberg SA. Tumor localization of adoptively transferred Indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma. J Clin Oncology 1989; 7(2):250-261.

156. Brunetti A, Berg G, DiChiro G, Cohen RM, Yarchoan R, Pizzo PA, Broder S, Eddy J, Fulham MJ, Finn RD, **Larson SM**. Reversal of brain metabolic abnormalities following treatment of AIDS Dementia Complex with 3' -azido-2',3'-Dideoxythymidine (AZT, Zidovudine): A PET-FDG Study. J Nucl Med 1989; 30:581-590.

157. Reynolds JC, Del Vecchio S, Sakahara H, Lora ME, Carrasquillo JA, Neumann RD, **Larson SM**. Anti-murine antibody response to mouse monoclonal antibodies: Clinical findings and implications. Nucl Med Biol 1989; vol. 16, no. 2, Int J Radiat Appl Instrum Part B, pp. 121-125.

158. Sakahara H, Reynolds JC, Carrasquillo JA, Lora ME, Maloney PJ, Lotze MT, **Larson SM,** Neumann RD. In vitro complex formation and biodistribution of mouse antitumor monoclonal antibody in cancer patients. J Nucl Med 1989; 30:1311-1317.

159. Steis RG, Carrasquillo JA, McCabe R, Bookman M, Reynolds JC, **Larson SM,** Smith II JW, Clark J, Dailey V, Pinsky C, Urba W, Haspel M, Perentesis P, Paris B, Longo DL, Hanna, Jr, MG. Toxicity, immunogenicity, and tumor radioimmunodetecting ability of two human monoclonal antibodies in patients with metastatic colorectal carcinoma. Journal of Clinical Oncology 1990; vol. 8, no. 3, pp. 476-490.

160. Paik CH, Yokoyama K, Reynolds JC, Quadri SM, Min CY, Shin SY, Maloney PJ, **Larson SM,** Reba RC. Reduction of background activities by introduction of a diester linkage between antibody and a chelate in radioimmunodectection of tumor. J Nucl Med 1989; 30:1693-1701.

161. Pace L, Bacharach SL, Bonow RO, Cannon III, RO, Green MV, **Larson SM**. Diagnosis of coronary artery disease by radionuclide angiography: Effect of combining indices of left ventricular function. J Nucl Med 1989; 30:1966-1971.

162. Schlom J, Colcher D, Szpak CA, Johnston WW, Sugarbaker P, Carrasquillo JA, Reynolds JC, **Larson SM**. A monoclonal antibody (B72.3) to adenocarcinoma of the colon and related tumors. Prog Clin Biol Res. 1989;288:63-72.

163. Yokoyama K, Reynolds JC, Paik CH, Sood VK, Maloney PJ, **Larson SM**, Reba RC. Immunoreactivity affects the biodistribution and tumor targeting of radiolabeled anti-P97 Fab Fragment. J Nucl Med 1990; 31:202-210.

164. Schlom J, Hand PH, Greiner JW, Colcher D, Shrivastav S, Carrasquillo JA, Reynolds JC, **Larson SM,** Raubitschek A. Innovations that influence the pharmacology of monoclonal antibody guided tumor targeting. Cancer Resea rch (suppl.) 1990; 50:820s-827s.

165. Naruki Y, Jorge CA, James CR, Maloney PJ, Frincke JM, Neumann RD, **Larson SM**. Differential cellular catabolism of 111-In, 90Y and 125-I radiolabeled T101 Anti-CD5 monoclonal antibody. Nucl Med Biol, Int J Radiat Appl Instrum 1990; part B, vol. 17, no. 2, pp.201-207.

166. Colcher D, Milenic DE, Ferroni P, Carrasquillo JA, Reynolds JC, Roselli M, **Larson SM,** Schlom J. In vivo fate of monoclonal antibody B72.3 in patients with colorectal cancer. J Nucl Med 1990; 31:1133-1142.

167. Sawada Y, Hiraga S, Francis B, Patlak C, Pettigrew K, Ito K, Owens E, Gibson R, Reba R, Eckelman W, **Larson SM,** Blasberg RD. Kinetic analysis of 3-quinuclidinyl 4-[125] iodobenzilate transport and specific binding to muscarinic acetylcholine receptors in rat brain in vivo: implications for human studies. Journal of Cerebral Blood Flow and Metabolism (MCBFM),Raven Press, Ltd. 1990; 10:781-807.

168. Eastman RC, Carson RE, Gordon MR, Berg GW, Lillioja S, **Larson SM**, Roth J. Brain glucose metabolism in noninsulin-dependent diabetes mellitus: a study in Pima Indians using positron emission tomography during hyperinsulinemia with euglycemic glucose clamp. J Clin Endocrinol Metab. 1990 Dec;71(6):1602-10.

169. Steis RG, Carrasquillo JA, McCabe R, Bookman MA, Reynolds JC, **Larson SM**, Smith JW 2nd, Clark JW, Dailey V, Del Vecchio S, et al. Toxicity, immunogenicity, and tumor radioimmunodetecting ability of two human monoclonal antibodies in patients with metastatic colorectal carcinoma. J Clin Oncol. 1990 Mar;8(3):476-90.

170. **Larson SM**. First reports from unexplored seas: radiolabeled antibodies and cancer. Cancer Invest. 1990;8(3-4):443-4.

171. Schmall B, Finn RD, Rapoport SI, Noronha JG, DeGeorge JJ, Kiesewetter DO, Simpson NR, **Larson SM.** Synthesis of a fluorinated fatty acid, dl-erythro-9,10-[18F]difluoropalmitic acid, and biodistribution studies in rats. Int J Rad Appl Instrum B. 1990;17(8):805-9.

172. Divgi CR, Welt S, Kris M, Real FX, Yeh SDJ, Gralla R, Merchant B, Schweighart S, Unger M, **Larson SM,** Mendelsohn J. Phase I and imaging trial of Indium-111 labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma. J Natl Cancer Inst 1991; vol. 83, no. 2, pp. 97-104.

173. Finn R, Cheung NKV, Divgi C, St. Germain J, Graham M, Pentlow K, **Larson SM**. Technical challenges associated with the radiolabeling of monoclonal antibodies utilizing short-lived, positron emitting radionuclides. Nucl Med Biol 1991; vol. 18, no. 1, pp. 9-13.

174. Mulshine JL, Carrasquillo JA, Weinstein JN, Keenan AM, Reynolds JC, Herdt J, Bunn PA, Sausville E, Eddy J, Cotelingam JD, Perentesis P, Pinsky C, **Larson SM**. Direct intralymphatic injection of radiolabeled 111In-T101 in patients with cutaneous T-Cell lymphoma. Cancer Research 1991; 51:688-695.

175. Eastman RC, Carson RE, Gordon MR, Berg GW, Lillioja S, **Larson SM,** Roth J, Cassibry AL, Baker KL. Brain glucose metabolism in noninsulin-dependant diabetes mellitus: A study in Pima Indians using Positron Emission Tomography during hyperinsulinemia with euglycemic glucose clamp. J Clin Endocrinol Metab 1990; 71:1602-1610.

176. Schmall B, Finn RD, Rapoport SI, Noronha JG, DeGeorge JJ, Kiesewetter DO, Simpson NR, **Larson SM**. Synthesis of a fluorinated fatty acid, dl-Erythro-9, 10[F-18] difluoropalmitic acid, and biodistribution. Nucl Med Biol 1990; vol. 17, no. 8, pp. 805-809.

177. Scheinberg DA, Lovett D, Divgi CR, Graham MC, Berman E, Pentlow K, Feirt N, Finn R, Clarkson BD, Gee TS, **Larson SM,** Oettgen HF, Old LJ. A phase trial of monoclonal antibody M195 in acute myelogenous leukemia: Specific bone marrow targeting and internalization of radionuclide. J Clin Oncol 1991; vol. 9, no. 3, pp. 478-490.

178. Yeh SDJ, **Larson SM,** Burch L, Kushner BH, Laquaglia M, Finn R, Cheung NKV. Radioimmunodetection of neuroblastoma with iodine-131-3F8: Correlation with biopsy, iodine-131-metaiodobenzylguanidine and standard diagnostic modalities. J Nucl Med 1991; 32:769-776.

179. Batte, Jr., WG, Yeh SDJ, **Larson SM**. Diffuse lung uptake of Tc-99m MDP associated with pneumocystis carinii pneumonia in a patient with neuroblastoma. Clin Nucl Med 1991; vol. 16, no. 5, pp. 321-324.

180. Pentlow KS, Graham MC, Lambrecht RM, Cheung N-KV, **Larson SM**. Quantitative imaging of I-124 using Positron Emission Tomography with applications to radioimmunodiagnosis and radioimmunotherapy. Medical Physics 1991; 18(3):357-366.

181. **Larson SM**. Editorial: Receptors on tumors studied with radionuclide scintigraphy. J Nucl Med 1991; vol 32, no 6, pp. 1189-1191.

182. **Larson SM.** Choosing the right radionuclide and antibody for intraperitoneal radioimmunotherapy. J Natl Cancer Inst. 1991 Nov 20;83(22):1602-4.

183. **Larson SM**. Biologic characterization of melanoma tumors by antigen-specific targeting of radiolabeled anti-tumor antibodies. J Nucl Med. 1991 Feb;32(2):287-91.

184. Finn RD, Tirelli S, Sheh Y, Knott A, Gelbard AS, **Larson SM,** Dahl JR. Consequences of electroplated targets on radiopharmaceutical preparations. Nucl Instruments & Methods in Physics Research B56/57 1991; pp. 1284-1286.

185. **Larson SM,** Carrasquillo JA, Colcher DC, Yokoyama K, Reynolds JC, Bacharach SA, Raubitchek A, Pace L, Finn RD, Rotman M, Stabin M, Neumann RD, Sugarbaker P, Schlom J. Estimates of radiation absorbed dose for intraperitoneally administered I-131 radiolabelled B72.3 monoclonal antibody in patients with peritoneal carcinomatoses. J Nucl Med 1991; 32:1661-1667.

186. Batte WG, Yeh SDJ, Rosenblum MK, **Larson SM**. Intense muscle uptake of Ga-67 citrate and Tc-99m MDP in a patient with aplastic anemia. Clin Nucl Med 1991; vol. 16, no. 6, pp. 421-424.

187. Calluser C, Healey J, Macapinlac HA, Kostakoglu L, Abdel-Dayem HM, **Larson SM,** Yeh SDJ. T1-201 uptake in recurrent pigmented villonodular synovitis correlation with three-phase bone imaging. Clin Nucl Med 1992; vol. 7, no. 9, pp. 751-753.

188. Kostakoglu L, Yeh SDJ, Portlock C, Heelan R, Yao Tzy-Jyun, Niedzwiecki D, **Larson SM**. Validation of Ga-67-citrate, single-photon emission computed tomography (SPECT) in biopsy-confirmed residual Hodgkin's disease in the mediastinum. J Nucl Med. 1992; 33:345-350.

189. Divgi CR, McDermott K, Johnson D, Schnobrich KE, Finn R, Cohen AM, **Larson SM**. Detection of hepatic metastases from colorectal carcinoma using 111In-labeled monoclonal antibody C110. Int J Radiat Appl Instrum (Part B) Nucl Med Biol 1991; 18:705-710.

190. Schlom J, Siler K, Colcher D, Carrasquillo JA, Reynolds JC, Sugarbaker P, **Larson SM**. Binding of radiolabeled MAb B72.3 administered intravenously and intraperitoneally in colorectal cancer patients. An overview. Acta Radiologica 1990; Supplentum 374:123-128.

191. Mulshine JL, Shuke N, Daghighian F, Carrasquillo J, Ghosh B, Walsh T, Ingalill A, Reynolds JC, Cuttitta F, **Larson SM**. The correct dose: Pharmacologically guided end point for anti-growth factor therapy. Cancer Research (Suppl.) 1992; 52:2743s-2746s.

192. Cheung NK, Yeh SD, Gulati S, LaQuaglia M, Burch L, Kushner BH, **Larson S.** 131I-3F8: clinical validation of imaging studies and therapeutic applications. Prog Clin Biol Res. 1991;366:409-15.

193. Scott AM, Kostakoglu L, O'Brien JP, Straus DJ, Abdel-Dayem HM, **Larson SM**. Comparison of Technetium-99m-MIBI and Thallium-201-Chloride uptake in primary thyroid lymphoma. J Nucl Med 1992; 33:1396-1398.

194. Mehta BM, Rosa E, Fissekis JD, Bading JR, Biedler JL, **Larson SM**. In vivo identification of multidrug resistance with radiolabeled Tritium-3-Colchicine. J Nucl Med 1992; 33:1373-1377.

195. **Larson SM,** Pentlow KS, Volkow ND, Wolf AP, Finn RD, Lambrecht RM, Graham MC, DiResta G, Bendriem B, Daghighian F, Yeh SDJ, Wang GJ, Cheung NKV. PET scanning of iodine-124-3F8 as an approach to tumor dosimetry during treatment planning for radioimmunotherapy in a child with neuroblastoma. J Nucl Med 1992; 33:2020-2023.

196. Caluser C, Macapinlac HA, Healey J, Gravimi F, Meyers P, Wollner N, Kalaigian J, Kostakoglu L, Abdel-Dayem HM, Yeh SDJ, **Larson SM**. The relationship between Thallium uptake, blood flow, and blood pool activity in bone and soft tissue tumors. Clin Nucl Med 1992; vol. 17, no. 7, pp. 565-572.

197. Scher HI, Curley T, Yeh SDJ, Iversen JM, O'Dell M, **Larson SM**. Therapeutic alternatives for hormone-refractory prostatic cancer. Sem Urol 1992; 10:55-64.

198. Kostakoglu L, Yeh SD, Portlock C, Heelan R, Yao TJ, Niedzwiecki D, **Larson SM**. Validation of gallium-67-citrate single-photon emission computed tomography in biopsy-confirmed residual Hodgkin's disease in the mediastinum. J Nucl Med. 1992 Mar;33(3):345-50.

199. Mulshine JL, Shuke N, Daghighian F, Carrasquillo J, Ghosh B, Walsh T, Avis I, Reynolds JC, Cuttitta F, **Larson SM**. The correct dose: pharmacologically guided end point for anti-growth factor therapy. Cancer Res. 1992 May 1;52(9 Suppl):2743s-2746s.

200. Schwartz MA, Lovett DR, Redner A, Finn RD, Graham MC, Divgi CR, Dantis L, Gee TS, Andreeff M, Old LJ, **Larson SM,** Scheinberg DA. Dose-escalation trial of M195 labeled with Iodine 131 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias. J Clin Oncol 1993; 11:294-303.

201. Rubin SC, Kairemo KJA, Brownell A-L, Daghighian F, Federici MG, Pentlow KS, Finn RD, Lambrecht RM, Hoskins WJ, Lewis JL, **Larson SM**. High resolution Positron Emission Tomography of human ovarian cancer in nude rats using 124 I-labeled monoclonal antibodies. Gynecologic Oncology 1993; 48:61-67.

202. Rubin SC, Kostakoglu L, Divgi C, Federici MG, Finstad CL, Lloyd KO, **Larson SM**, Hoskins WJ. Biodistribution and intraoperative evaluation of radiolabeled monoclonal antibody MX35 in patients with epithelial ovarian cancer. Gynecol Oncol. 1993 Oct;51(1):61-6.

203. Sgouros G, Graham MC, Divgi CR, **Larson SM,** Scheinberg DA. Modeling and dosimetry of monoclonal antibody M195 (anti-CD33) in acute myelogenous leukemia. J Nucl Med 1993; 34:422-430.

204. Oosterwijk E, Bander Bh, Divgi CR, Welt S, Wakka JC, Finn RD, Carswell EA, **Larson SM,** Warnaar SO, Fleuren GJ, Oettgen HF, Old LJ. Antibody localization in human renal cell carcinoma: A phase I study of monoclonal antibody G250. J Clin Oncol 1993; 11:738-750.

205. Boonkitticharoen V, James H, Cheung N-K, **Larson SM,** Finn RD. Optimizing the recovery of chemicaly reduced monoclonal antibody for site-specific technetium-99m radiolabeling. BioTechniques 1993; 14(5):706-708.

206. Carrasquillo JA, Reynolds JC, Bunn Jr. PA, Foon KA, Shuke N, Schroff RW, Mulshine JL, Perentesis P, Szymendera J, Horowitz M, **Larson SM**. Pharmacokinetics of In-111 T101 (Anti-CD5) monoclonal antibody in patients with cutaneous T-cell lymphoma. Antibody Immunoconj Radiophar 1993; vol. 6, no. 2, pp. 111-126.

207. Daghighian F, Pentlow K, **Larson SM,** Graham M, DiResta G, Yeh SDJ, Macapinlac HA, Finn R, Arbit E, Cheung N-KV. Development of a method to measure kinetics of radiolabelled monoclonal antibody in human tumour with applications to microdosimetry: Positron Emission Tomography studies of iodine-124 labelled 3F8 monoclonal antibody in glioma. Eur J Nucl Med 1993; 20:402-409.

208. Sgouros G, Chiu S, Pentlow KS, Brewster LJ, Kalaigian H, Baldwin B, Daghighian F, Graham MC, **Larson SM,** Mohan R. Three-dimensional dosimetry for radioimmunotherapy treatment planning. J Nucl Med 1993; 34:1595-1601.

209. Bergman I, Arbit E, Rosenblum M, **Larson SM,** Heller G, Cheung N-KV. Treatment of spinal epidural neuroblastoma xenografts in rats using anti-GD2 monoclonal antibody 3F8. J Neur-Oncol 1993; 15:235-242.

210. Rusch V, Macapinlac HA, Heelan R, Kramer E, **Larson SM,** McCormack P, Burt M, Martini N, Ginsberg R. NR-LU-10 monoclonal antibody scanning: A helpful new adjunct to CT in evaluating non-small cell lung cancer. J Thoracic and Cardiovascular Surgery 1993; vol. 106, no. 2, pp. 200-204.

211. DiResta GR, Lee J, **Larson SM,** Arbit E. Characterization of neuroblastoma xenograft in rat flank. I. Growth, interstitial fluid pressure, and interstitial fluid velocity distribution profiles. Microvascular Research 1993; 46:158-177.

212. Schneider JA, Divgi CR, Scott AM, Macapinlac HA, Sonenberg M, Goldsmith SM, **Larson SM**. Hiatal hernia on whole-body radioiodine survey mimicking metastatic thyroid cancer. Clin Nucl Med 1993; 9:751-753.

213. **Larson SM,** Daghighian F, Shenderov P, Pentlow KS, Graham MC, Melcher CL, Schweitzer JS: Evaluation of cerium doped lutetium oxyorthosilicate (LSO) scintillation crystal for PET. IEEE Trans Nucl Sci 1993; 40:1045-1047.

214. Divgi CR, McDermott K, Giffin TW, Johnson DK, Schnobrich KE, Fallone PS, Scott AM, Hilton S, Cohen AM, **Larson SM**. Lesion-by-lesion comparison of computerized tomography and indium-111-labeled monoclonal antibody C110 radioimmunoscintigraphy in colorectal carcinoma: A multicenter trial. J Nucl Med 1993; 34:1656-1661.

215. Rubin SC, Kostakoglu L, Divgi C, Federici MG, Finstad CL, Lloyd KO, **Larson SM,** Hoskins WJ. Biodistribution and intraoperative evaluation of radiolabeled monoclonal antibody MX35 in patients with epithelial ovarian cancer. Gyn Oncol 1993; 51:61-66.

216. Czuczman MS, Straus DJ, Divgi CR, Graham M, Garin-Chesa P, Finn RD, Myers J, Old LJ, **Larson SM,** Scheinberg DA. Phase I dose-escalation trial of iodine 131-labeled monoclonal antibody OKB7 in patients with non-Hodgkin's lymphoma. J Clin Oncol 1993; 11:2021-2029.

217. **Larson SM.** A model for others: a strategy for improving diagnosis and therapy of human malignancies using monoclonal antibodies targeting TAG-72 oncofetal antigen. Cancer Invest. 1993;11(2):235-8.

218. Divgi CR, Scott AM, McDermott K, Fallone PS, Hilton S, Siler K, Carmichael N, Daghighian F, Finn RD, Cohen AM, Schlom J, **Larson SM**. Clinical comparison of radiolocalization of two monoclonal antibodies (mAbs) against the TAG-72 antigen. Nucl Med Biol 1994; 21:9-15.

219. Levenson D, Gulec S, Sonenberg M, Lai E, Goldsmith SJ, **Larson SM**. Peripheral facial nerve palsy after high-dose radioiodine therapy in patients with papillary thyroid carcinoma. Ann Intern Med 1994; 120:576-578.

220. Cheung N-K V, Cheung IY, Canete A, Yeh SDJ, Kushner B, Bonilla MA, Heller G, **Larson SM**. Antibody response to Murine Anti-GD2 monoclonal antibodies: Correlation with patient survival. Cancer Research 1994; 54:2228-2233.

221. Caron PC, Jurcic JG, Scott AM, Finn RD, Divgi CR, Graham MC, Jureidini IM, Sgouros G, Tyson D, Old LJ, **Larson SM,** Scheinberg DA. A phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immunogenicity. Blood 1994; 83:1760-1768.

222. Welt S, Divgi CR, Scott AM, Garin-Chesa P, Finn RD, Graham M, Carswell EA, Cohen A, **Larson SM,** Old LJ, Rettig WJ. Antibody targeting in metastatic colon cancer: A phase I study of monoclonal antibody F19 against a cell surface protein of reactive tumor stromal fibroblasts. J Clin Oncol 1994; 12:1193-1203.

223. Mehta B, Rosa E, Fissekis JD, Bading JR, Biedler JL, **Larson SM**. In vivo uptake of Carbon-14-Colchicine for identification of tumor multidrug resistance. J Nucl Med 1994; 35:1179-1184.

224. Kostakoglu L, Divgi CR, Hilton S, Cordon-Cardo C, Scott AM, Kaliagian H, Finn RD, Schlom J, **Larson SM**. Pre-selection of patients with high TAG-72 antigen expression leads to targeting of 94% of known metastatic tumor sites with monoclonal antibody I-131-CC49. Cancer Invest 1994; 12(6):551-558.

225. Welt S, Divgi, CR, Kemeny N, Finn RD, Scott AM, Graham M, St. Germain J, Carswell Richards, E, **Larson SM,** Oettgen HF, Old LJ. Phase I/II study of iodine 131-labeled monoclonal antibody A33 in patients with advanced colon cancer. J Clin Oncol 1994; 12(8):1561-1571.

226. Tjuvajev JG, Macapinlac HA, Scott AM, Daghighian F, Ginos JZ, Finn RD, Kothari P, Desai R, Zhang J, Beattie B, Graham M, **Larson SM,** Blasberg RS. Imaging of the brain tumor proliferative activity with [131]-Iododeoxyuridine. J Nucl Med 1994; 35:1407-1417.

227. Bading JR, Sigurdson ER, Finn RD, Yeh SDJ, Ginos J, Kemeny NE, **Larson SM**. Transport limits cellular entry of hepatic arterially injected 5-[18F] Fluoro-2-Deoxyuridine in human intrahepatic tumors. Drug Metabolism and Disposition 1994; 22(4):643-650.

228. Schneider JA, Divgi CR, Scott AM, Macapinlac HA, Seidman AD, Goldsmith SJ, **Larson SM**. Flare on bone scintigraphy following Taxol chemotherapy for metastatic breast cancer. J Nucl Med 1994; 35(110):1748-1752.

229. Kostakoglu L, Roistacher N, Kalaigian H, Abdel-Dayem H, **Larson SM**. Simultaneous gallium-67 citrate and technetium-99m sestamibi SPET in a case of myocardial lymphoma: comparison with echocardiography before and after chemotherapy. Eur J Nucl Med 1994; 21:1013-1016.

230. Caluser CI, Abdel-Dayem HM, Macapinlac HA, Scott AM, Healy JH, Huvos A, Kalaigian H, Yeh SDJ, **Larson SM**. The value of thallium and three-phase bone scans in the evaluation of bone and soft tissue sarcomas. Eur J Nucl Med 1994; 21(11):1198-1205.

231. Scott AM, Macapinlac HA, Divgi CR, Zhang JJ, Kalaigian H, Pentlow K, Hilton S, Graham MC, Sgouros G, Pelizzari C, Chen G, Schlom J, Finn R, Goldsmith SJ, **Larson SM**. Clinical validation

of SPECT and CT/MRI image registration in radiolabelled monoclonal antibody studies of colorectal carcinoma. J Nucl Med 1994; 35:1976-1984.

232. Caron PC, Schwartz MA, Co MS, Finn RD, Graham MC, Divigi CR, **Larson SM,** Scheinberg DA. Murine and humanized constructs of onoclonal antibody M195 (anti-CD33) for the therapy of acute myelogenous leukemia. Cancer 1994 Feb 1;73(3 Suppl): 1049-1056.

233. Cheung NK, Kushner BH, Yeh SJ, **Larson SM**. 3F8 monoclonal antibody treatment of patients with stage IV neuroblastoma: a phase II study. Prog Clin Biol Res. 1994;385:319-28.

234. **Larson SM**, Divgi CR, Scott A, Sgouros G, Graham MC, Kostakoglu L, Scheinberg D, Cheung NK, Schlom J, Finn RD. Current status of radioimmunotherapy. Nucl Med Biol. 1994 Jul;21(5):785-92.

235. Macapinlac HA, Scott AM, **Larson SM**, Divgi CR, Yeh SD, Goldsmith SJ. Gallium-67-citrate imaging in nuclear oncology. Nucl Med Biol. 1994 Jul;21(5):731-8.

236. **Larson SM**, Divgi C, Scott A, Daghighian F, Macapinlac H, Welt S. Current status of radioimmunodetection. Nucl Med Biol. 1994 Jul;21(5):721-9.

237. **Larson SM**. Cancer or inflammation? A Holy Grail for nuclear medicine. J Nucl Med. 1994 Oct;35(10):1653-5.

238. Scott AM, Macapinlac HA, Zhang J, Daghighian F, Montemayor N, Kalaigian H, Sgouros G, Graham MC, Kolbert K, Yeh SDJ, Lai E, Goldsmith SJ, **Larson SM**. Image registration of SPECT and CT images using an external fiduciary band and three dimensional surface fitting in metastatic thyroid cancer. J Nucl Med 1995; 36:100-103.

239. Ugur O, Scott AM, Kostakoglu L, Hui ET, Masterson ME, Febo R, Sgouros G, Rosa E, Mehta BM, Fisher DR, Cheung N-KV, **Larson SM**. Calculated and TLD-based absorbed dose estimates for I-131-labeled 3F8 antibody in a human neuroblastoma xenograft nude mouse model. Nucl Med Biol 1995; 22(1):87-93.

240. Divgi CR, Scott AM, Dantis L, Capitelli P, Siler K, Hilton S, Finn RD, Kemeny N, Kelsen, D, Kostakoglu L, Schlom J, **Larson SM**. Phase I radioimmunotherapy trial with I-131 CC49 in metastatic colon carcinoma. J Nucl Med 1995; 36(4):586-592.

241. Kothari PJ, Finn RD, **Larson SM,** SM. Syntheses of colchicine and isocolchicine labeled with carbon-11 or carbon-13. J Labeled Compounds and Radio-pharmaceuticals 1995; 36(6):522-528.

242. Arbit E, Cheung N-KV, Yeh SDJ, Daghighian F, Zhang JJ, Cordon-Cardo C, Pentlow K, Canete A, Finn R, **Larson SM**. Quantitative studies of monoclonal antibody targeting to disialogangioside GD2 in human brain tumors. Eur J Nucl Med 1995; 22:419-426.

243. Scott AM, Rosa E, Mehta BM, Divgi CR, Finn RD, Biedler JL, Kalaigian H, **Larson SM**. In vivo quantitation and specific targeting of P-glycoprotein expression in multidrug resistant nude mice xenografts with [I-125] MRK-16 monoclonal antibody. Nucl Med Biol 1995; 22(4):497-504.

244. Yukihiko N, Maloney PJ, Reynolds JC, **Larson SM,** Carasquillo JA. Selective cytotoxicity of Y-90 labelled T101 monoclonal antibody on human malignant T-cells lines. Antibody Immunoconj Radiophar 1995; 8(2):81-92.

245. Reinsel RA, Veselis RA, Feshchenko VA, DiResta GR, Mawlawi O, Beattie B, Silbersweig D, Stern E, Blasberg, R, Macapinlac HA, Finn RD, Goldsmith S, **Larson SM**. Target detection and the prefrontal cortex: A PET scan study of the P300 event-related potential. Ann NY Acad Sci 1995; 769:393-397.

246. Kostakoglu L, Panicek DM, Divgi CR, Botet J, Healy J, **Larson SM,** Abdel-Dayem HM. Correlation of the findings of thallium-201 chloride scans with those of other imaging modalities and histology following therapy in patients with bone and soft tissue sarcomas. Eur J Nucl Med 1995; 22:1232-1237.

247. Finn RD, Sheh Y, Bui V, **Larson SM,** Schlyer D. Refinements with targetry to overcome accelerator energy constraints. Nucl Instrum Methods 1995; B99, pp. 814-816.

248. Jurcic JG, Caron PC, Miller WH, Yao TJ, Maslak P, Finn RD, **Larson SM,** Warrell RP, Scheinberg, DA. Sequential targeted therapy for acute promyelocytic leukemia with ALL-Trans Retinoic acid and anti-CD33 monoclonal antibody M195. Leukemia 1995; 9:244-248.

249. Welt S, Scott AM, Divgi, CR, Kemeny NE, Daghighian F, Finn RD, **Larson SM,** Old LJ. Radio-Immunotherapy of colon cancer with monoclonal antibody A33. (Letter) Tumor Targeting 1995; 1:299-300.

250. **Larson SM**. Improving the balance between treatment and diagnosis: A role for radioimmunodetection. Cancer Res 1995; 55(23):5756S-5758S.

251. Divgi CR, Scott AM, Gulec S, Broussard EK, Levy N, Young C, Capitelli P, Daghighian F, Williams JM, Finn RD, Kemeny N, Hilton S, Kelson D, Milenic D, Lora ME, Schlom J, **Larson SM**. Pilot radioimmunotherapy trial with I-131 murine monoclonal antibody (MAB) CC49 and deoxyspergualin (DSG) in metastatic colon carcinoma. Clin Ca Res 1995; 1:1503-1510.

252. Jurcic JG, Caron PC, Nikula LTK, Papadopoulos EB, Finn RD, Gansow OA, Miller Jr WH, Geerlings MW, Warrell Jr RP, **Larson SM,** Scheinberg DA. Radiolabeled anti-CD33 monoclonal antibody M195 for myeloid leukemia. Cancer Res 1995; (suppl)55:5908s-5910s.

253. Caluser C, Scott AM, Macapinlac HA, Yeh SDJ, Rosenfeld N, Farid B, Abdel-Dayem H, **Larson SM,** Kalaigian H. Extramedullary hematopoiesis assessment in a patient with osteopetrosis. Clin Nucl Med 1995 Jan, 20(1):75.

254. Goldenberg DM, **Larson SM**, Reisfeld RA, Schlom J. Targeting cancer with radiolabeled antibodies. Immunol Today. 1995 Jun;16(6):261-4.

255. Wu D, Landsberger S, **Larson SM**. Evaluation of elemental cadmium as a marker for environmental tobacco smoke. Environ Sci Technol. 1995 Sep 1;29(9):2311-6. doi: 10.1021/es00009a024.

256. Katzenellenbogen JA, Coleman RE, Hawkins RA, Krohn KA, **Larson SM**, Mendelsohn J, Osborne CK, Piwnica-Worms D, Reba RC, Siegel BA, et al. Tumor receptor imaging: proceedings of the National Cancer Institute workshop, review of current work, and prospective for further investigations. Clin Cancer Res. 1995 Aug;1(8):921-32.

257. Dimotakis ED, Cal MP, Economy J, Rood MJ, **Larson SM**. Chemically treated activated carbon cloths for removal of volatile organic carbons from gas streams: evidence for enhanced physical adsorption. Environ Sci Technol. 1995 Jul 1;29(7):1876-80. doi: 10.1021/es00007a027.

258. Ugur O, Kostakoglu L, Hui ET, Fisher DR, Garmestani K, Gansow OA, Cheung N-KV, **Larson SM**. Comparison of the targeting characteristics of various radioimmunoconjugates for radio-immunotherapy of neuroblastoma: dosimetry calculations incorporating cross-organ beta-doses. Nucl Med Biol 1996; 23(1):1-8.

259. Grant SC, Kostakoglu L, Kris MG, Yeh SDJ, **Larson SM,** Finn RD, Oettgen HF, Cheung N-KV. Targeting of small-cell lung cancer using the anti-GD2 ganglioside monoclonal antibody 3F8: a pilot trial. Eur J Nucl Med 1996; 23:145-149.

260. Mehta BM, Levchenko A, Rosa E, Kim SW, Winnick Sm, Zhang JJ, Kalaigian H, **Larson SM**. Evaluation of 14C-Colchicine biodistribution with whole-body quantitative autoradiography in colchicine-sensitive and resistant xenografts. J Nucl Med 1996; 37(2):312-314.

261. Sgouros G, Jureidini IM, Scott AM, Graham MC, **Larson SM,** Scheinberg DA. Bone marrow dosimetry: Regional variability of marrow-localizing antibody. J Nucl Med 1996; 37:695-698.

262. Macapinlac HA, Kemeny N, Daghighian F, Finn R, Zhang J, Humm J, Squire O, **Larson SM**. Pilot clinical trial of 5-[I-125]iodo-2'-deoxyuridine in the treatment of colorectal cancer metastatic to the liver. J Nucl Med 1996; 37(suppl):25S-29S.

263. Daghighian F, Humm JL, Macapinlac HA, Zhang J, Izzo J, Finn RD, Kemeny N, **Larson SM**. Pharmacokinetics and dosimetry of iodine-125-IUdR in the treatment of colorectal cancer metastatic to liver. J Nucl Med 1996; 37(suppl):29S-32S.

264. Levchenko A, Mehta BM, Spengler BA, Narkar AA, Fonti R, Biedler JL, Tsuruo T, **Larson SM**. Measurement of P-glycoprotein expression in multidrug-resistant human neuroblastoma cell lines using self-competitive binding assay. Analytical Biochemistry 1996; 236:338-343.

265. Welt S, Scott AM, Divgi CR, Kemeny NE, Finn RD, Daghighian F, St Germain J, Richards EC, **Larson SM,** Old LJ. Phase I/II study of iodine 125-labeled monoclonal antibody A33 in patients with advanced colon cancer. J Clin Oncol 1996; 14:1787.

266. Yeh SDJ, Imbriaco M, **Larson SM,** Garza D, Zhang JJ, Kalaigian H, Finn RD, Reddy D, Horowitz SM, Goldsmith SJ, Scher HI. Detection of bony metastases of androgen independent prostate cancer by PET-FDG. Nucl Med Biol 1996; 23:693-697.

267. Daghighian F, Barendswaard E, Welt S, Humm JL, Scott A, Willingham MC, McGuffie E, Old LJ, **Larson SM**. Enhancement of radiation dose to the nucleus by vesicular internalization of iodine-124-labeled A33 monoclonal antibody. J Nucl Med 1996; 37:1052-1057.

268. Tjuvajev JG, Finn RD, Watanabe K, Joshi R, Oku T, Kennedy J, Beattie B, Koutcher J, **Larson SM,** Blasberg RG. Non-invasive imaging of herpes virus thymidine kinase gene transfer and expression: a potential method for monitoring clinical gene therapy. Cancer Res 1996; 56:4087-4095.

269. Pentlow KS, Graham MC, Lambrecht RM, Daghighian F, Bacharach SL, Bendriem B, Finn RD, Jordan K, Kalaigian H, Karp JS, Robeson WR, **Larson SM**. Quantitative imaging of iodine-124 with PET. J Nucl Med 1996; 37:1557-1562.

270. Yeung WD, Imbriaco M, Zhang JJ, Macapinlac HA, Goldsmith SJ, **Larson SM**. Visualization of myocardial metastasis of carcinoid tumor by Indium-111-Pentetreotide. J Nucl Med 1996; 37:1528-1530.

271. Kostakoglu L, Panicek DM, Divgi CR, Botet J, Healy J, **Larson SM**, Abdel-Dayem HM. Correlation of the findings of thallium-201 chloride scans with those of other imaging modalities and histology following therapy in patients with bone and soft tissue sarcomas. Eur J Nucl Med. 1996 Nov;23(11):1558.

272. **Larson SM**. RIGS: surgery. Talking the talk and (just possibly) walking the walk. Cancer Invest. 1996;14(6):637-9.

273. Imbriaco M, Yeh SD, Yeung H, Zhang JJ, Healy JH, Meyers P, Huvos AG, **Larson SM**. Thallium-201 scintigraphy for the evaluation of tumor response to preoperative chemotherapy in patients with osteosarcoma. Cancer 1997;80(8): 1507-1512.

274. Finstad CL, Lloyd KO, Federici MG, Divgi CR, Venkatraman E, Barakat RR, Finn RD, **Larson SM,** Hoskins WJ, Humm JL. Distribution of radiolabeled monoclonal antibody MX35F(ab')2 in tissue samples by storage phosphor screen image analysis: evaluation of antibody localization to micrometastatic disease in epithelial ovarian cancer. Clin Can Res 1997; 3:1433-1442.

275. El-Shirbiny AM, Yeung HW, Imbriaco M, Michaeli J, Macapinlac HA, **Larson SM**. Technetium-99m-MIBI versus fluorine-18-FDG in diffuse multiple myeloma. J Nucl Med 1997; 38:1208-1210.

276. Kothari PJ, Finn RD, Bornmann WG, Agus DB, Vera JC, **Larson SM**. Chemical consequences resulting from multi-millicurie preparation of 6-[18F]-Fluoro-6-deoxy-L-ascorbic acid. Radiochimica Acta 1997; 77:87-90.

277. Erdi YE, Humm JL, Imbriaco M, Yeung HW, **Larson SM**. Quantitative bone metastases analysis based on image segmentation. J Nucl Med 1997; 38:1401-1406.

278. El-Shirbiny AM, Stavrou SS, Dnistrian A, Sonenberg M, **Larson SM,** Divgi CR. Jod-basedow syndrome following oral iodine and radioiodinated-antibody administration. J Nucl Med 1997; 38:1816-1817.

279. Veselis RA, Reinsel RA, Beattie BJ, Mawlawi OR, Feshchenko VA, DiResta GR, **Larson SM,** Blasberg RG. Midazolam changes cerebral blood flow in discrete brain regions. Anesthesiology 1997; 87:1106-1117.

280. **Larson SM,** El-Shirbiny AM, Divgi CR, Sgouros G, Finn RD, Tschmelitsch J, Picon A, Whitlow M, Schlom J, Zhang J, Cohen AM. Single chain antigen binding protein (sFv CC49) first human studies in colorectal carcinoma metastatic to liver. CA 1997; 80(suppl):2458-2468.

281. Erdi YE, Mawlawi O, **Larson SM,** Imbriaco M, Yeung HWD, Finn RD, Humm JL. Segmentation of lung lesion volume by adaptive Positron Emission Tomography image thresholding. CA 1997; 80(suppl):2505-2509.

282. Graham MC, Pentlow KS, Mawlawi O, Finn RD, Daghighian F, **Larson SM**. An investigation of the physical characteristics of Ga-66 as an isotope for PET imaging and quantification. Med Phys 1997 Feb;24(2):317-326.

283. Furhang EE, Chui CS, Kolbert KS, **Larson SM,** Sgouros. Implementation of a Monte Carlo dosimetry method for patient-specific internal emitter therapy. Med Phys 1997 Jul;24(7):1163-1172.

284. Kramer K, Cheung NK, Humm J, DiResta G, Arbit E, **Larson SM,** Finn R, Rosenblum M, Nguyen H, Gonzalez G, Liu C, Yang YF, Mendelsohn ME, Gillio AP. Pharmacokinetics and acute toxicology of intraventricular 131 I-monoclonal antibody targeting disialoganglioside in non-human primates. J Neurooncol 1997;35(2):101-111.

285. Kolbert KS, Sgouros G, Scott AM, Bronstein JE, Malane RA, Zhang J, Kalaigian H, McNamara S, Schwartz L, **Larson SM**. Implementation and evaluation of patient-specific three-dimensional internal dosimetry. J Nucl Med. 1997 Feb;38(2):301-8.

286. Macapinlac HA, **Larson SM**. Positron emission tomography (PET)--measured biochemical response to radiotherapy of laryngeal tumors. Cancer J Sci Am. 1997 Nov-Dec;3(6):333-5.

287. Hughes A, **Larson SM**, Hanson RN, DeSombre ER. Uptake and interconversion of the Z and E isomers of 17 alpha-iodovinyl-11 beta-methoxyestradiol in the immature female rat. Steroids. 1997 Feb;62(2):244-52.

288. Barendswaard EC, Scott AM, Divgi CR, Williams Jr. C, Coplan K, Riedel E, Yao T-J, Gansow OA, Finn RD, **Larson SM,** Old LJ, Welt S. Rapid and specific targeting of monoclonal antibody A33 to a colon cancer xenograft in nude mice. Int'l J of Oncol 1998;12:45-53.

289. Divgi CR, Bander NH, Scott AM, O'Donoghue JA, Sgouros G, Welt S, Finn RD, Morrissey F, Capitelli P, Williams JM, Deland D, Nakhre A, Oosterwijk E, Gulec S, Graham MC, **Larson SM,** Old LJ. Phase I/II radioimmunotherapy trial with iodine-131 labeled monoclonal antibody (MAB) G250 in metastatic renal cell carcinoma. Clin Cancer Research 1998;4(11): 2729-2739.

290. Sgouros G, O'Donoghue JA, **Larson SM,** Macapinlac H, Larson JJ, Kemeny N. Mathematical model of 5-[125I]iodo-2'-deoxyuridine treatment: continuous infusion regimens for hepatic metastases. Int J Radiat Oncol Biol Phys 1998 15;41(5):1177-1183.

291. Yeung HW, Macapinlac HA, Karpeh M, Finn RD, **Larson SM**. Accuracy of FDG-PET in gastric cancer- preliminary experience. Clin Pos Imaging 1998; 1(4):213-221.

292. Slovin SF, Scher HI, Divgi CR, Reuter V, Sgouros G, Moore M, Weingard K, Pettengall, Imbriaco M, El-Shirbiny A, Finn R, Bronstein J, Brett C, Milenic D, Dnistrian A, Shapiro L, Schlom J, **Larson SM**. Interferon-y and monoclonal antibody 131 I-labeled CC49: outcomes in patients with androgen-independent prostate cancer. Clin Can Res 1998; 4:643-651.

293. Loh A, Sgouros G, O'Donoghue JA, Deland D, Puri D, Capitelli P, Humm JL, **Larson SM,** Old LJ, Divgi CR. Pharmacokinetic model of iodine-131-G250 antibody in renal cell carcinoma patients. J Nucl Med 1998; 39(3):484-489.

294. Cheung N-K V, Kushner BH, Yeh SDJ, **Larson SM**. 3F8 monoclonal antibody treatment of patients with stage 4 neuroblastoma: a phase II study. Intl J of Oncol 1998; 12:1299-306.

295. Imbriaco M, **Larson SM,** Yeung HW, Mawlawi OR, Erdi Y, Venkatraman ES, Scher HI. A new parameter for measuring metastatic bone involvement by prostate cancer: the bone scan index. Clin Can Res 1998; 4:1765-1772.

296. Akhurst T, Boland P, Macapinlac HA, Finn RD, Yeung HW, Squire O, **Larson SM**. Excess muscle FDG uptake in a euglycaemic patient that is corrected by fasting. Clinical Positron Imaging 1998; 1(2)131-133.

297. Kramer K, Gerald WL, Kushner BH, **Larson SM,** Hameed M, Cheung N-KV. Disialoganglioside G-D2 loss following monoclonal antibody therapy is rare in neuroblastoma. Clin Can Res 1998; 4:2135-2139.

298. Cheung N-KV, Kushner BH, Cheung IY, Kramer K, Canete A, Gerald W, Bonilla MA, Finn R, Yeh SDJ, **Larson SM**. Anti-GD2 antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age. J Clin Oncol 1998; 16(9)3053-3060.

299. Tjuvajev JG, Avril N, Oku T, Sasajima T, Miyagawa T, Joshi R, Safer M, Beattie B, DiResta G, Daghighian F, Augensen F, Koutcher J, Zweit, Humm J, **Larson SM,** Finn RD, Blasberg R. Imaging herpes virus thymidine kinase gene transfer and expression by Positron Emission Tomography. Cancer Res 1998; 58:4333-4341.

300. McDevitt MR, Sgouros G, Finn RD, Humm JL, Jurcic JG, **Larson SM,** Scheinberg DA. Radioimmunotherapy with alpha-emitting nuclides. Eur J Nuc Med 1998; 25:1341-1351.

301. Mawlawi OR, Miodownik S, Leonard EF, DiResta G, **Larson SM**. A customized motion acquisition circuit for image deblurring in Positron Emission Tomography. IEEE Trans Instr and Meas 1998;47(2):566-571.

302. Sabbatini P, **Larson SM,** Kremer A, Zhang ZF, Sun M, Yeung HW, Imbriaco M, Horak I, Conolly M, Ding C, Quyang P, Kelly WK, Scher HI. Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. J Clin Onc 1998;17(3):948-957.

303. Divgi CR, Bander NH, Scott AM, O'Donaghue JA, Sgouros G, Welt S, Finn RD, Morrissey F, Capitelli P, Williams JM, Deland D, Nakhre A, Oosterwijk E, Gules S, Graham MC, **Larson SM,** Old LJ. Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma. Clin Cancer Res 1998 Nov;4(11): 2729-2739.

304. Foss FM, Raubitscheck A, Mulshine JL, Fleisher TA, Reynolds JC, Paik CH, Neumann RD, Boland C, Perentesis P, Brown MR, Frincke JM, Lollo CP, **Larson SM,** Carrasquillo JA. Phase I study of the pharmacokinetics of a radioimmunoconjugate, 90-Y T101, in patients with CD5 expressing leukemia and lymphoma. Clin Cancer Res 1998 Nov; 4(11): 2691-2700.

305. Imbriaco M, **Larson SM,** Yeung HW, Mawlawi OR, Erdi Y, Venkatraman ES, Scher HI. A new parameter for measuruing metastatic bone involvement by prostate cancer: the bone scan index. Clin Can Res 1998 Jul; 4(7): 1765-1772.

306. Fonti R, Levchenko A, Mehta BM, Zhang JJ, Tsuruo T, **Larson SM**. Measurement of P-glycoprotein expression in human neuroblastoma xenografts using in vitro quantitative autoradiography. Nucl Med & Biol. 1999; 26:35-41.

307. Furhang EE, **Larson SM,** Buranapong P, Humm JL. Thyroid cancer dosimetry using clearance fitting. J Nucl Med 1999; 40:131-138.

308. Graham MC, Scher HI, Liu GB, Yeh SDJ, Curley T, Daghighian F, Goldsmith SJ, **Larson SM**. Rhenium-186-labeled hydroxyethylidene disphosphonate dosimetry and dosing guidelines for palliation of skeletal metastases from androgen-independent prostate cancer. Clin Cancer Res 1999 Jun; 5(6): 1307-1318.

309. An T, Nguyen BA, Akhurst T, **Larson SM,** Coit DG, Brady MS. PET scanning with [18F]-2-Fluoro-2-deoxy-D-glucose (FDG) in patients with melanoma: benefits and limitations. Clin Pos Imaging 1999; 2(2):93-98.

310. Wang W, Macapinlac HA, **Larson SM,** Yeh SDJ, Akhurst T, Finn RD, Rosai J, Robbins RJ. [18F]-2-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography localizes residual thyroid cancer in patients with negative diagnostic 131I whole body scans and elevated serum thyroglobulin levels. J of Clin Endoc & Metabol 1999; (84)7: 2291-2302.

311. Erdi YE, Macapinlac H, **Larson SM,** Erdi AK, Yeung H, Furhang EE, Humm JL. Radiation dose assessment for I-131 therapy of thyroid cancer using I-124 PET imaging. Clin Pos Imaging 1999(2)1; 41-46.

312. **Larson SM,** Erdi Y, Akhurst T, Mazumdar M, Macapinlac H, Finn R, Casila C, Fazzari M, Srivastava N, Yeung H, Humm J, Guillem J, Downey R, Karpeh M, Cohen A, Ginsberg R. Tumor treatment response based on visual and quantitative changes in global tumor glycolysis using PET-FDG imaging: the visual response score and the change in the total lesion glycolysis. Clin Pos Imaging 1999; 3:159-171.

313. Macapinlac H, Humm J, Akhurst T, Osman I, Pentlow K, Cai S, Yeung H, Squire O, Finn R, Scher H, **Larson SM**. Differential metabolism and pharmacokinetics of L-[1-11C]-methionine and 2-[18F] fluoro-2-deoxy-D-glucose (FDG) in androgen independent prostate cancer. Clinical Pos Imaging 1999; 3:173-181.

314. Fonti R, Cheung N-K, Bridger GJ, Guo H-F, Abrams MJ, **Larson SM**. 99mTc-monoclonal antibody radiolabeled via hydrazino nicotinamide derivative for imaging disialoganglioside GD2-positive tumors. Nuclear Medicine & Biology 1999;26:681-686.

315. Fong Y, Saldinger PF, Akhurst T, Macapinlac H, Yeung H, Finn RD, Cohen A, Kemeny N, Blumgart LH, **Larson SM**. Utility of 18F-FDG PET-scanning on selection of patients for resection of hepatic colorectal metastases. Amer J of Surgery 1999 Oct;178(4):282-287.

316. Chaudry A, Carrasquillo JA, Avis IL, Shuke N, Reynolds JC, Bartholomew R, **Larson SM,** Johnson BE, and Mulshine JL. Phase I and imaging trial of monoclonal antibody directed against gastrin-releasing peptide in patients with lung cancer. Clinical Cancer Res 1999 Nov;5(11):3385-3393.

317. McDevitt MR, Finn RD, Ma D, **Larson SM,** Scheinberg DA. Preparation of α-emitting 213Bi-labeled antibody constructs for clinical use. The Journal of Nuc Med 1999; (40)10: 1722-1727.

318. Sgouros G, Ballangrud AM, Jurcic JG, McDevitt MR, Humm JL, Erdi YE, Mehta BM, Finn RD, **Larson SM,** Scheinberg DA. Pharmacokinetics and dosimetry of an α-particle emitter labeled antibody: 213Bi-HuM195 (Anti-CD33) in patients with leukemia. J of Nuc Med 1999;40(11):1935-1946.

319. Barendswaard EC, O'Donoghue JA, **Larson SM,** Tschmelitsch J, Welt S, Finn RD, Humm JL. 131I radioimmunotherapy and fractionated external beam radiotherapy: comparative effectiveness in a human tumor xenograft. J Nucl Med 1999; 40(10):1764-1768.

320. Humm JL, LeeJB, O'Donoghue JA, Squire O, Ling CC, Pentlow K, Mehta B, Erdi Y, Ruan S, **Larson SM**. Changes in FDG tumor uptake during and after fractionated radiation therapy in a rodent tumor xenograft. Clin Pos Imaging 1999;2(5):289-296.

321. Tjuvajev JG, Joshi A, Callegari J, Lindsley L, Joshi R, Balatoni J, Finn R, **Larson SM**, Sadelain M, Blasberg RG. A general approach to the non-invasive imaging of transgenes using cis-linked herpes simplex virus thymidine kinase. Neoplasia. 1999 Oct;1(4):315-20.

322. Sabbatini P, **Larson SM**, Kremer A, Zhang ZF, Sun M, Yeung H, Imbriaco M, Horak I, Conolly M, Ding C, Ouyang P, Kelly WK, Scher HI. Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. J Clin Oncol. 1999 Mar;17(3):948-57.

323. Macapinlac HA, Yeung HW, **Larson SM**. Defining the Role of FDG PET in Head and Neck Cancer. Clin Positron Imaging. 1999 Nov;2(6):311-316.

324. Rini JN, Yeung HW, Nunez RF, la Calle JP, **Larson S,** Macapinlac HA. FDG-PET Patterns of Abdominal Carcinomatosis. Clin Positron Imaging. 1999 Nov;2(6):333.

325. Srivastava NC, Erdi YE, Divgi CR, Scher H, **Larson SM**. A Coordinate System for Lesion Mapping and Distribution in Progressive Prostate Cancer Using Positron Emission Tomography (PET). Clin Positron Imaging. 1999 Nov;2(6):348.

326. Yeung HW, Macapinlac HA, Mazumdar M, Bains M, Finn RD, **Larson SM**. FDG-PET in Esophageal Cancer. Incremental Value over Computed Tomography. Clin Positron Imaging. 1999 Oct;2(5):255-260.

327. Guillem JG, Calle JP-L, Akurst T, Tickoo S, Ruo L, Minsky BD, Gollub MJ, Klimstra DS, Mazumdar M, Paty PB, Macapinlac HA, Yeung H, Saltz L, Finn RD, Erdi Y, Humm J, Cohen AM, **Larson SM**. Prospective assessment of primary rectal cancer response to preoperative radiation and chemotherapy using 18-Fluorodeoxyglucose Positron Emission Tomography. Dis Colon Rectum, 2000;43(1):18-24.

328. Levchenko A, Mehta BM, Lee J-B, Humm JL, Augensen F, Squire O, Kothari PJ, Finn RD, Leonard EF, **Larson SM**. Evaluation of 11C-Colchicine for PET imaging of multiple drug resistance. J Nucl Med 2000;41(3):493-501.

329. Sundin J, Tolmachev V, Koziorowski J, Carlsson J, Lundqvist H, Welt S, **Larson SM,** Sundin A. High yield direct 76Br-bromination of monoclonal antibodies using Chloramine-T. Nuclear Medicine and Biology 1999;26:923-929.

330. Wang W, **Larson SM,** Fazzari M, Tickoo SK, Kolbert K, Sgouros G, Yeung H, Macapinlac M, Rosai J, Robbins RJ. Prognostic Value of [18F] Fluorodeoxyglucose Positron Emission Tomographic Scanning in Patients with Thyroid Cancer. The J of Clin Endocrinology & Metabolism 1999; 85(3):1107-1113.

331. Robbins RJ, Hill RH, Wang W, Macapinlac HA, **Larson SM**. Inhibition of Metabolic Activity in Papillary Thyroid Carcinoma by a Somatostatin Analogue. Thryoid 2000;10 (2):177-183.

332. DiResta GR, Lee J, Healey JH, Levchenko A, **Larson SM,** Arbit E. The artificial lymphatic system: A new approach to reduce interstitial hypertension and increase blood flow, pH and pO2 in solid tumors. Annals of Biomedical Engineering 2000;28(5), 543-555.

333. DiResta GR, Lee J, Healey JH, **Larson SM,** Arbit E. Enhancing the uptake of chemotherapeutic Drugs into Tumors using an Artifical Lymphatic System. Annals of Biomedical Enginneering 2000; 28(5), 556-564.

334. Imbriaco M, Akhurst T, Hilton S, Yeung H, Macapinlac HA, Mazumdar M, Pace L, Kemeny N, Erdi Y, Cohen A, Fong Y, Guillem J, **Larson SM**. Whole-body FDG-PET in patients with recurrent colorectal carcinoma: a comparative study with CT. Clin Pos Imaging 2000; 3(3), 107-114.

335. Robbins RJ, Hill RH, Macapinlac HA, **Larson SM**. Inhibition of Metabolic Activity in Papillary Thyroid Carcinoma by a Spmatostatin Analogue. Thyroid 2000; 10(2), 177-183.

336. Kramer K, Cheung N-K, Humm JL, Dantis E, Finn R, Yeh SJ, Antunes NL, Dunkel IJ, Souwedaine M, **Larson SM**. Targeted radioimmunotherapy for leptomeningeal cancer using (131)I-3F8. Med Pediatr Oncol. 2000 Dec 1;35(6):716-718.

337. Tickoo SK, Pittas AG, Adler M, Fazzari M, **Larson SM,** Robbins RJ, Rosai J. Bone metastases from thyroid carcinoma. Arch Pathol Lab Med. 2000 Oct;124(10):1440-1447.

338. Gambhir SS, Herschman HR, Cherry SR, Barrio JR, Satyamurthy N, Toyokuni T, Phelps ME, **Larson SM,** Balatoni J, Finn R, Sadelain M, Tjuvajev J, Blasberg R. Imaging Transgene Expression with Radionuclide Imaging Technologies. Neoplasia, Jan-April 2000, 2(1-2):118-138.

339. DiResta GR, Lee J, Healey JH, Levchenko A, **Larson SM,** Arbit E. Artificial lymphatic system: a new approach to reduce interstitial hypertension and increase blood flow, pH and pO2 in solid tumors. Ann Biomed Eng. 2000 May;28(5):543-555.

340. Pittas AG, Adler M, Fazzari M, Tickoo S, Rosai J, **Larson SM,** Robbins RJ. Bone metastases from thyroid carcinoma: clinical characteristics and prognostic variables in one hundred forty-six patients. Thyroid. 2000 Mar;10(3)261-268.

341. Ruan S, O'Donaghue J, **Larson SM,** Finn RD, Jungbluth A, Welt S, Humm JL. Optimizing the sequence of combination therapy with radiolabeled antibodies and fractionated external beam. J of Nuc Med. 2000 November;41(11)1905-1912.

342. Erdi YE, Macapinlac H, Rosenzweig KE, Humm JL, **Larson SM**, Erdi AK, Yorke ED. Use of PET to monitor the response of lung cancer to radiation treatment. Eur J Nucl Med. 2000 Jul;27(7):861-6.

343. Kolbert KS, Hamacher KA, Jurcic JG, Scheinberg DA, **Larson SM,** Sgouros G: Parameteric Images of Antibody Pharamcokinetics in Bi213-HuM195 Therapy of Leukemia. J Nucl Med 2001 42:27-32.

344. Erdi YE, Srivastava NC, Humm JL, **Larson SM**. A Coordinate System for Tumor Identification in Positron Emission Tomography (PET) Imaging. Clin Pos Imag 2000 3(4):131-136.

345. Nuñez RF, Yeung HW, Macapinlac HA, Castro-Malaspina H, **Larson SM**. Ga-67 uptake in cutaneous lesions of graft-versus-host disease. Clin Nucl Med. 2000 Sep;25(9):676-8.

346. Srivastava NC, Erdi YE, Humm JL, **Larson SM**. 8. A Spherical Coordinate System for Tumor Identification in Positron Emission Tomography (PET) Imaging. Clin Positron Imaging. 2000 Jul;3(4):162.

347. Akhurst T, Ng V V, **Larson SM**, O'Donoghue JA, O'Neel J, Erdi Y, Divgi CR. Tumor Burden Assessment with Positron Emission Tomography with. Clin Positron Imaging. 2000 Mar;3(2):57-65.

348. Yeung HW, Humm JL, **Larson SM**. Radioiodine uptake in thyroid remnants during therapy after tracer dosimetry. J Nucl Med. 2000 Jun;41(6):1082-5.

349. Pentlow KS, Finn RD, **Larson SM,** Erdi YE, Beattie BJ, Humm JL. Quantitative Imaging of Yttrium-86 with PET. The Occurrence and Correction of Anomalous Apparent Activity in High Density Regions. Clin Positron Imaging. 2000 May;3(3):85-90.

350. **Larson SM**, Di Nardo AA, Davidson AR. Analysis of covariation in an SH3 domain sequence alignment: applications in tertiary contact prediction and the design of compensating hydrophobic core substitutions. J Mol Biol. 2000 Oct 27;303(3):433-46.

351. **Larson SM**. Molecular imaging in oncology: the diagnostic imaging "revolution". Clin Cancer Res. 2000 Jun;6(6):2125.

352. Ramos CD, Erdi YE, Gonen M, Reidel E, Yeung HWD, Macapinlac HA, Chisin R, **Larson SM.** FDG-PET Standardized uptake values in normal anatomical structures using iterative reconstruction segmented attenuation correction and filtered back-projection. Eur J Nucl Med 2001 28:155-164.

353. Kramer K, Cheung N-K, Humm JL, Dantis E, Finn R, Yeh S, Antunes NL, Dunkel IJ, Souwedaine M, **Larson SM.** Targeted Radioimmunotherapy for Leptomeningeal Cancer Using 131I-3F8. Medical and Pediatric Oncology. (2000) 35:716-718.

354. Kelly WK, Curley T, Slovin S, Heller G, McCaffrey J, Bajorin D, Ciolino A, Regan K, Schwartz M, Kantoff P, George D, Oh W, Smith M, Kaufman D, Small EJ, Schwartz L, **Larson SM,** Tong W, Scher H: Paclitaxel, Estramustine Phosphate, and Carboplatin in Patients with Advanced Prostate Cancer. Journal of Clinical Oncology, 19(1) 2001:44-53.

355. Robbins RJ, Tuttle RM, Sharaf RN, **Larson SM,** Robbins HK, Ghossein RA, Smith A, Drucker WD: Preparation by Recombinant Human Thyrotropin or Thyroid Hormone Withdrawal Are Comparable for the Detection of Residual Differentiated Thyroid Carcinoma. Journal of Clinical Endocrinology & Metabolism, 86(2) 2001:619-625.

356. Yeung HWD, Cody HS, Turlakow A, Riedel ER, Fey J, Gonen M, Nunez R, Yeh SD, **Larson SM.** Lymphoscintigraphy and Sentinel Node Localization in Breast Cancer Patients: A Comparison Between 1-Day and 2-Day Protocols. Journal of Nuclear Medicine, 42(3) 2001:420-423.

357. Ramos CD, Chisin R, Yeung HWD, **Larson SM,** Macapinlac HA: Incidental Focal Thyroid Uptake on FDG Positron Emission Tomographic Scans may represent a Second Primary Tumor. Clinical Nuclear Medicine, 26(3) 2001:193-197.

358. Jacobs A, Tjuvajev JG, Dubrovin M, Akhurst T, Balatoni J, Beattie B, Joshi R, Finn R, **Larson SM,** Herrlinger U, Pechan PA, Chiocca A, Breakefield XO, Blasberg RG2: Positron Emission

Tomography-based Imaging of Transgene Expression Mediated by Replication-conditional, Oncolytic Herpes Simplex Virus Type 1 Mutant Vectors in Vivo1. Cancer Research, 61(7) 2001:2983-2995.

359. Bennett JJ, Tjuvajev J, Johnson P, Doubrovin M, Akhurst T, Malholtra S, Hackman T, Balatoni J, Finn R, **Larson SM,** Federoff H, Blasberg R, Fong Y. Positron emission tomography imaging for herpes virus infection: Implications for oncolytic viral treatments of cancer. Nat Med 2001 Jul;7(7):859-863.

360. Turlakow A, Yeung HW, Pui J, Macapinlac H, Liebovitz E, Rusch V, Goy A, **Larson SM**. Fludeoxyglucose positron emission tomography in the diagnosis of giant cell arteritis. Arch Intern Med 2001 Apr 9;161(7):1003-1007.

361. Tanswell P, Garin-Chesa P, Rettig WJ, Welt S, Divgi CR, Casper ES, Finn RD, **Larson SM,** Old LJ, Scott AM. Population pharmacokinetics of antifibroblast activation protein monoclonal antibody F19 in cancer patients. Br J Clin Pharmacol 2001 Feb;51(2):177-180.

362. Robbins RJ, Voelker E, Wang W, Macapinlac HA, **Larson SM**: Compassionate use of recombinant human thyrotropin to facilitate radioiodine therapy: case report and review of literature. Endocr Pract 2000 Nov-Dec;6(6):460-464.

363. Turlakow A, **Larson SM,** Coakley F, Akhurst T, Gonen M, Macapinlac HA, Kelly W, Leibel S, Humm J, Scardino P, Scher H, Hricak H. Local detection of prostate cancer by positron emission tomography with 2-fluorodeoxyglucose: comparison of filtered back projection and iterative reconstruction with segmented attenuation correction. Q J Nucl Med. 2001 Sep;45(3):235-244.

364. Kushner BH, Yeung HWD, **Larson SM,** Kramer K, Cheung N-KV: Extending Positron Emission Tomography Scan Utility to High-Risk Neuroblastoma: Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography as Sole Imaging Modality in Follow-up of Patients. J. Clinical Oncology; 19(14) 2001 July: 3397-3405.

365. Robbins RJ, Tuttle RM, Sonenberg M, Shaha A, Sharaf R, Robbins H, Fleisher M, **Larson SM**: Radioiodine Ablation of Thyroid Remnants After Preparation with Recombinant Human Thyrotropin. Thyroid, 11(9) 2001.

366. Lovqvist A, Humm JL, Sheikh A, Finn RD, Koziorowski J, Ruan S, Pentlow KS, Jungbluth A, Welt S, Lee FT, Brechbiel MW, **Larson SM**: PET Imaging of 86Y-Labeled Anti-Lewis Y Monoclonal Antibodies in a Nude Mouse Model: Comparison Between 86Y and 111In Radiolabels. Journal of Nuclear Medicine, 42(8) 2001:1281-1287.

367. Gorlick R, Liao AC, Antonescu C, Huvos AG, Healey JH, Sowers R, Daras M, Calleja E, Wexler LH, Panicek D, Meyers PA, Yeh SD, **Larson SM**: Lack of Correlation of Functional Scintigraphy with 99mTechnetium-Methoxyisobutylisonitrile with Histological Necrosis following Induction Chemotherapy or Measures of P-Glycoprotein Expression in High-Grade Osteosarcoma1. Clinical Cancer Research, (7) 2001:3065-3070.

368. Gonen M, Panageas KS, **Larson SM.** Statistical issues in analysis of diagnostic imaging experiments with multiple observations per patient. Radiology. 2001 Dec;221(3):763-767.

369. Ponomarev V, Doubrovin M, Lyddane C, Beresten T, Balatoni J, Bornman W, Finn R, Akhurst T, **Larson S**, Blasberg R, Sadelain M, Tjuvajev JG. Imaging TCR-dependent NFAT-mediated T-cell activation with positron emission tomography in vivo. Neoplasia. 2001 Nov-Dec;3(6):480-8.

370. Doubrovin M, Ponomarev V, Beresten T, Balatoni J, Bornmann W, Finn R, Humm J, **Larson S**, Sadelain M, Blasberg R, Gelovani Tjuvajev J. Imaging transcriptional regulation of p53-dependent genes with positron emission tomography in vivo. Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):9300-5.

371. Burt BM, Humm JL, Kooby DA, Squire OD, Mastorides S, **Larson SM,** Fong Y. Using positron emission tomography with [(18)F]FDG to predict tumor behavior in experimental colorectal cancer. Neoplasia. 2001 May-Jun;3(3):189-95.

372. Cheung NK, Kushner BH, LaQuaglia M, Kramer K, Gollamudi S, Heller G, Gerald W, Yeh S, Finn R, **Larson SM**, Wuest D, Byrnes M, Dantis E, Mora J, Cheung IY, Rosenfield N, Abramson S, O'Reilly RJ. N7: a novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age. Med Pediatr Oncol. 2001 Jan;36(1):227-30.

373. Kolbert KS, Hamacher KA, Jurcic JG, Scheinberg DA, **Larson SM**, Sgouros G. Parametric images of antibody pharmacokinetics in Bi213-HuM195 therapy of leukemia. J Nucl Med. 2001 Jan;42(1):27-32.

374. Barendswaard EC, Humm JL, O'Donoghue JA, Sgouros G, Finn RD, Scott AM, **Larson SM**, Welt S. Relative therapeutic efficacy of (125)I- and (131)I-labeled monoclonal antibody A33 in a human colon cancer xenograft. J Nucl Med. 2001 Aug;42(8):1251-6.

375. Wang W, **Larson SM**, Tuttle RM, Kalaigian H, Kolbert K, Sonenberg M, Robbins RJ. Resistance of [18f]-fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine. Thyroid. 2001 Dec;11(12):1169-75.

376. Mayer-Kuckuk P, Banerjee D, Malhotra S, Doubrovin M, Iwamoto M, Akhurst T, Balatoni J, Bornmann W, Finn R, **Larson SM,** Fong Y, Gelovani Tjuvajev J, Blasberg R, Bertino JR. Cells exposed to antifolates show increased cellular levels of proteins fused to dihydrofolate reductase: a method to modulate gene expression. Proc Natl Acad Sci U S A, 2002. 99: 3400-3405.

377. Akhurst T, Downey RJ, Ginsberg MS, Gonen M, Bains M, Korst R, Ginsberg RJ, Rusch VW, **Larson SM**. An initial experience with FDG-PET in the imaging of residual disease after induction therapy for lung cancer. Ann Thorac Surg, 2002. 73:259-264; discussion 264-256.

378. Erdi YE, Rosenzweig K, Erdi AK, Macapinlac HA, Hu YC, Braban LE, Humm JL, Squire OD, Chui CS, **Larson SM,** Yorke ED. Radiotherapy treatment planning for patients with non-small cell lung cancer using positron emission tomography (PET). Radiother Oncol, 2002. 62:51-60.

379. Ugur O, Kothari PJ, Finn RD, Zanzonico P, Ruan S, Guenther I, Maecke HR, **Larson SM**. Ga-66 labeled somatostatin analogue DOTA-DPhe1-Tyr3-octreotide as a potential agent for positron emission tomography imaging and receptor mediated internal radiotherapy of somatostatin receptor positive tumors. Nucl Med Biol, 2002. 29:147-157.

380. Yeung HW, Sanches A, Squire OD, Macapinlac HA, **Larson SM,** Erdi YE. Standardized uptake value in pediatric patients: an investigation to determine the optimum measurement parameter. Eur J Nucl Med Mol Imaging, 2002. 29:61-66.

381. Nunez R, Macapinlac HA, Yeung HW, Akhurst T, Cai S, Osman I, Gonen M, Riedel E, Scher HI, **Larson SM**. Combined 18F-FDG and 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer. J Nucl Med, 2002. 43:46-55.

382. Nehmeh SA, Erdi YE, Ling CC, Rosenzweig KE, Squire OD, Braban LE, Ford E, Sidhu K, Mageras GS, **Larson SM,** Humm JL. Effect of respiratory gating on reducing lung motion artifacts in PET imaging of lung cancer. Med Phys, 2002. 29:366-371.

383. Nehmeh SA, Erdi YE, Ling CC, Rosenzweig KE, Yorke ED, Squire OD, Ford E, Sidhu K, Mageras G, Braban LE, **Larson SM,** Humm JL, Effect of respiratory gating on reducing lung motion artifacts in PET imaging of lung cancer, Med.Phys. 2002. 29:366-371.

384. Morris MJ, Akhurst T, Osman I, Nunez R, Macapinlac H, Siedlecki K, Verbel D, Schwartz L, **Larson SM,** Scher HI. Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer. Urology, 2002. 59:913-918.

385. Robbins RJ, Chon JT, Fleisher M, **Larson SM,** Tuttle RM. Is the serum thyroglobulin response to recombinant human thyrotropin sufficient, by itself, to monitor for residual thyroid carcinoma? J Clin Endocrinol Metab, 2002. 87:3242-3247.

386. Etchebehere EC, Macapinlac HA, Gonen M, Humm K, Yeung HW, Akhurst T, Scher HI, **Larson SM**. Qualitative and quantitative comparison between images obtained with filtered back projection and iterative reconstruction in prostate cancer lesions of (18)F-FDG PET. Q J Nucl Med, 2002. 46:122-130.

387. Ruo L, Tickoo S, Klimstra DS, Minsky BD, Saltz L, Mazumdar M, Paty PB, Wong WD, **Larson SM,** Cohen AM Guillem JG. Long-term prognostic significance of extent of rectal cancer response to preoperative radiation and chemotherapy. Ann Surg, 2002. 236:75-81.

388. Jurcic JG, **Larson SM,** Sgouros G, McDevitt MR, Finn RD, Divgi CR, Ballangrud AM, Hamacher KA, Ma D, Humm JL, Brechbiel MW, Molinet R, Scheinberg DA. Targeted alpha particle immunotherapy for myeloid leukemia. Blood, 2002. 100:1233-1239.

389. Wong RJ, Lin DT, Schoder H, Patel SG, Gonen M, Wolden S, Pfister DG, Shah JP, **Larson SM,** Kraus DH. Diagnostic and prognostic value of [(18)F]fluorodeoxyglucose positron emission tomography for recurrent head and neck squamous cell carcinoma. J Clin Oncol, 2002. 20:4199-4208.

390. Robbins RJ, **Larson SM,** Sinha N, Shaha A, Divgi C, Pentlow KS, Ghossein R, Tuttle RM. A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation. J Nucl Med, 2002. 43:1482-1488.

391. Wang W, **Larson SM,** Tuttle RM, Kalaigian H, Kolbert K, Sonenberg M, Robbins RJ. Resistance of [18f]-fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine. Thyroid, 2001. 11:1169-1175.

392. **Larson SM**, Ruczinski I, Davidson AR, Baker D, Plaxco KW. Residues participating in the protein folding nucleus do not exhibit preferential evolutionary conservation. J Mol Biol. 2002 Feb 15;316(2):225-33.

393. Brentjens RJ, Latouche JB, Santos E, Marti F, Gong MC, Lyddane C, King PD, **Larson SM,** Weiss M, Riviere I, Sadelain M. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med, 2003. 9:279-286.

394. Downey RJ, Akhurst T, Ilson D, Ginsberg R, Bains MS, Gonen M, Koong H, Gollub M, Minsky BD, Zakowski M, Turnbull A, **Larson SM,** Rusch, V. Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial. J Clin Oncol, 2003. 21:428-432.

395. Koehne G, Doubrovin M, Doubrovina E, Zanzonico P, Gallardo HF, Ivanova A, Balatoni J, Teruya-Feldstein J, Heller G, May C, Ponomarev V, Ruan S, Finn R, Blasberg RG, Bornmann W, Riviere I, Sadelain M, O'Reilly RJ, **Larson SM,** Tjuvajev JG. Serial in vivo imaging of the targeted migration of human HSV-TK-transduced antigen-specific lymphocytes. Nat Biotechnol, 2003. 21: 405-413.

396. Sgouros G, Squeri S, Ballangrud AM, Kolbert KS, Teitcher JB, Panageas KS, Finn RD, Divgi CR, **Larson SM,** Zelenetz AD. Patient-specific, 3-dimensional dosimetry in non-Hodgkin's lymphoma patients treated with 131I-anti-B1 antibody: assessment of tumor dose-response. J Nucl Med, 2003. 44:260-268.

397. Scott AM, Wiseman G, Welt S, Adjei A, Lee FT, Hopkins W, Divgi CR, Hanson LH, Mitchell P, Gansen DN, **Larson SM,** Ingle JN, Hoffman EW, Tanswell P, Ritter G, Cohen LS, Bette P, Arvay L,

Amelsberg A, Vlock D, Rettig WJ, Old LJ. A Phase I Dose-Escalation Study of Sibrotuzumab in Patients with Advanced or Metastatic Fibroblast Activation Protein-positive Cancer. Clin Cancer Res, 2003. 9:1639-1647.

398. Palm S, Enmon RM Jr., Matei C, Kolbert KS, Xu S, Zanzonico PB, Finn RL, Koutcher JA, **Larson SM,** , Sgouros G. Pharmacokinetics and Biodistribution of (86)Y-Trastuzumab for (90)Y dosimetry in an ovarian carcinoma model: correlative MicroPET and MRI. J Nucl Med, 2003. 44:1148-1155.

399. Kushner BH, Yeh SD, Kramer K, **Larson SM,** Cheung NK. Impact of metaiodobenzylguanidine scintigraphy on assessing response of high-risk neuroblastoma to dose-intensive induction chemotherapy. J Clin Oncol, 2003. 21:1082-1086.

400. Pandit N, Gonen M, Krug L, **Larson SM**. Prognostic value of [(18)F]FDG-PET imaging in small cell lung cancer. Eur J Nucl Med Mol Imaging. 2003; 30:78-84.

401. Kelly WK, Zhu AX, Scher H, Curley T, Fallon M, Slovin S, Schwartz L, **Larson SM,** Tong W, Hartley-Asp B, Pellizzoni C, Rocchetti M. Dose escalation study of intravenous estramustine phosphate in combination with Paclitaxel and Carboplatin in patients with advanced prostate cancer. Clin Cancer Res, 2003. 9:2098-2107.

402. Moore HG, Akhurst T, **Larson SM,** Minsky BD, Mazumdar M, Guillem JG. A case-controlled study of 18-fluorodeoxyglucose positron emission tomography in the detection of pelvic recurrence in previously irradiated rectal cancer patients. J Am Coll Surg, 197:22-28, 2003.

403. Flores RM, Akhurst T, Gonen M, **Larson SM,** Rusch VW. Positron emission tomography defines metastatic disease but not locoregional disease in patients with malignant pleural mesothelioma. J Thorac Cardiovasc Surg, 2003. 126:11-16.

404. Zager JS, Delman KA, Ebright MI, Malhotra S, **Larson SM,** Fong Y. Use of radiolabelled iododeoxyuridine as adjuvant treatment for experimental tumours of the liver. Br J Surg, 2003. 90:1225-1231.

405. Turlakow A, Yeung HW, Salmon AS, Macapinlac HA, **Larson SM**. Peritoneal carcinomatosis: role of (18)F-FDG PET. J Nucl Med, 2003. 44:1407-1412.

406. Burke JM, Caron PC, Papadopoulos EB, Divgi CR, Sgouros G, Panageas KS, Finn RD, **Larson SM,** O'Reilly RJ, Scheinberg DA. and Jurcic, J. G. Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias. Bone Marrow Transplant, 2003. 32: 549-556.

407. Nehmeh SA, Erdi YE, Rosenzweig KE, Schoder H, **Larson SM,** SM, Squire OD, Humm JL. Reduction of Respiratory Motion Artifacts in PET Imaging of Lung Cancer by Respiratory Correlated Dynamic PET: Methodology and Comparison with Respiratory Gated PET. J Nucl Med. 2003 Oct;44(10):1644-1648.

408. Nehmeh SA, Erdi YE, Kalaigian H, Kolbert KS, Pan T, Yeung H, Squire O, Sinha A, **Larson SM**, Humm JL. Correction for oral contrast artifacts in the CT attenuation corrected PET images of the Discovery LS PET/CT. J Nucl Med 2003. 44:1940-1944.

409. Solit DB, Morris M, Slovin S, Curley T, Schwartz L, **Larson SM,** Kattan MW, Hartley-Asp B, Scher HI, Kelly WK: Clinical Experience with intravenous estramustine phosphate, paclitaxel, and carboplatin in ptients with castrae, metastatic prostate adenocarcinoma. Cancer 2003; 98:1842-1848.

410. Sarikaya I, Yeung HW, Erdi Y, **Larson SM.** Respiratory artefact causing malpositioning of liver dome lesion in right lower lung. Clin Nucl Med. 2003 Nov;28(11):943-944.

411. Yeung HW, Grewal RK, Gonen M, Schoder H, **Larson SM**. Patterns of (18)F-FDG Uptake in Adipose Tissue and Muscle: A Potential Source of False-Positives for PET.J Nucl Med. 2003 Nov;44(11):1789-1796.

412. Pandit-Taskar N, Hamlin PA, Reyes S, **Larson SM**, Divgi CR. New strategies in radioimmunotherapy for lymphoma. Curr Oncol Rep. 2003 Sep;5(5):364-71.

413. Solit DB, Morris M, Slovin S, Curley T, Schwartz L, **Larson S**, Kattan MW, Hartley-Asp B, Scher HI, Kelly WK. Clinical experience with intravenous estramustine phosphate, paclitaxel, and carboplatin in patients with castrate, metastatic prostate adenocarcinoma. Cancer. 2003 Nov 1;98(9):1842-8.

414. Mayer-Kuckuk P, Doubrovin M, Gusani NJ, Gade T, Balatoni J, Akhurst T, Finn R, Fong Y, Koutcher JA, **Larson S**, Blasberg R, Tjuvajev JG, Bertino JR, Banerjee D. Imaging of dihydrofolate reductase fusion gene expression in xenografts of human liver metastases of colorectal cancer in living rats. Eur J Nucl Med Mol Imaging. 2003 Sep;30(9):1281-91. Epub 2003 Mar 27.

415. Di Nardo AA, **Larson SM**, Davidson AR. The relationship between conservation, thermodynamic stability, and function in the SH3 domain hydrophobic core. J Mol Biol. 2003 Oct 24;333(3):641-55.

416. **Larson SM**, Pande VS. Sequence optimization for native state stability determines the evolution and folding kinetics of a small protein. J Mol Biol. 2003 Sep 5;332(1):275-86

417. Alavi A, Blahd WH, DeNardo SJ, Graham MM, Holder LE, **Larson SM**, Maurer AH, Miller TR, Nusynowitz ML, Palestro CJ, Parker JA, Schelbert HR, Taylor AT Jr, Treves ST. Components of professional competence for nuclear medicine physicians. J Nucl Med. 2003 Jun;44(6):988-90.

418. **Larson SM**, Garg A, Desjarlais JR, Pande VS. Increased detection of structural templates using alignments of designed sequences. Proteins. 2003 May 15;51(3):390-6.

419. Pande VS, Baker I, Chapman J, Elmer SP, Khaliq S, **Larson SM,** Rhee YM, Shirts MR, Snow CD, Sorin EJ, Zagrovic B. Atomistic protein folding simulations on the submillisecond time scale using worldwide distributed computing. Biopolymers. 2003 Jan;68(1):91-109.

420. Chapman JD, Bradley JD, Eary JF, Haubner R, **Larson SM**, Michalski JM, Okunieff PG, Strauss HW, Ung YC, Welch MJ. Molecular (functional) imaging for radiotherapy applications: an RTOG symposium. Int J Radiat Oncol Biol Phys. 2003 Feb 1;55(2):294-301.

421. Zanzonico P, O'Donoghue J, Chapman JD, Schneider R, Cai S, **Larson SM,** Wen B, Chen Y, Finn R, Ruan S, Gerweck L, Humm J, Ling C. Iodine-124-labeled iodo-azomycin-galactoside imaging of tumor hypoxia in mice with serial microPET scanning Eur J Nucl Med Mol Imaging. 2004 Jan;31(1):117-128.

422. Gobalakrishnan Sundaresan, Paul J. Yazaki, John E. Shively, Ronald D. Finn, Steven M. **Larson SM,** Andrew A. Raubitschek, Lawrence E. Williams, Arion F. Chatziioannou, Sanjiv S. Gambhir, and Anna M. Wu 124I-Labeled Engineered Anti-CEA Minibodies and Diabodies Allow High-Contrast, Antigen-Specific Small-Animal PET Imaging of Xenografts in Athymic Mice J Nucl Med 2003 44:1952-1969.

423. Schoder H, Yeung HW, Gonen M, Kraus D, **Larson SM.** Head and Neck Cancer: Clinical Usefulness and Accuracy of PET/CT Image Fusion. Radiology. Radiology. 2004 Apr;231(1):65-72.

424. **Larson SM,** Morris M, Gunther I, Beattie B, Humm JL, Akhurst TA, Finn RD, Erdi Y, Pentlow K, Dyke J, Squire O, Bornmann W, McCarthy T, Welch M, Scher H.: Tumor localization of 16beta-18F-fluoro-5alpha-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer. J Nucl Med. 2004 Mar;45(3):366-373.

425. Schoder H, Erdi YE, Chao K, Gonen M, **Larson SM,** Yeung HW. Clinical Implications of Different Image Reconstruction Parameters for Interpretation of Whole-Body PET Studies in Cancer Patients. J Nucl Med. 2004 Apr;45(4):559-566.

426. Nai-Kong V. Cheung, Shakeel Modak, Yukang Lin, Hongfen Guo, Pat Zanzonico, John Chung, Yuting Zuo, James Sanderson, Sibylle Wilbert, Louis J. Theodore, Donald B. Axworthy, **Larson SM,** Single-Chain Fv-Streptavidin Substantially Improved Therapeutic Index in Multistep Targeting Directed at Disialoganglioside GD2 J Nucl Med 2004;45 867-877.

427. Smith-Jones PM, Solit DB, Akhurst T, Afroze F, Rosen N, **Larson SM**: Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat Biotechnol. 2004 Jun;22(6):701-706.

428. Guillem JG, Moore HG, Akhurst T, Klimstra DS, Ruo L, Mazumdar M, Minsky BD, Saltz L, Wong WD, **Larson SM**. Sequential preoperative fluorodeoxyglucose-positron emission tomography assessment of response to preoperative chemoradiation: a means for determining longterm outcomes of rectal cancer. J Am Coll Surg. 2004 Jul;199(1):1-7.

429. Downey RJ, Akhurst T, Gonen M, Vincent A, Bains MS, **Larson SM,** Rusch V.Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. J Clin Oncol. 2004 Aug 15;22(16):3255-3260.

430. Divgi CR, O'Donoghue JA, Welt S, O'Neel J, Finn R, Motzer RJ, Jungbluth A, Hoffman E, Ritter G, **Larson SM,** Old LJ. Phase I clinical trial with fractionated radioimmunotherapy using 131I-labeled chimeric G250 in metastatic renal cancer. J Nucl Med. 2004 Aug;45(8):1412-1421.

431. Erdi YE, Nehmeh SA, Pan T, Pevsner A, Rosenzweig KE, Mageras G, Yorke ED, Schoder H, Hsiao W, Squire OD, Vernon P, Ashman JB, Mostafavi H, **Larson SM,** Humm JL. The CT motion quantitation of lung lesions and its impact on PET-measured SUVs.JNuclMed.2004Aug;45(8):1287-1292.

432. Nehmeh SA, Erdi YE, Pan T, Yorke E, Mageras GS, Rosenzweig KE, Schoder H, Mostafavi H, Squire O, Pevsner A, **Larson SM,** Humm JL. Quantitation of respiratory motion during 4D-PET/CT acquisition. Med Phys. 2004 Jun;31(6):1333-1338.

433. Sgouros G, Kolbert KS, Sheikh A, Pentlow KS, Mun EF, Barth A, Robbins RJ, **Larson SM**. Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software. J Nucl Med. 2004 Aug;45(8):1366-1372.

434. Pandit-Taskar N, Schoder H, Gonen M, **Larson SM,** Yeung HW: Clinical Significance of Unexplained Abnormal Focal FDG Uptake in the Abdomen During Whole-Body PET.AJR Am J Roentgenol. 2004 Oct;183(4):1143-1147.

435. Zanzonico PB, Finn R, Pentlow KS, Erdi Y, Beattie B, Akhurst T, Squire O, Morris M, Scher H, McCarthy T, Welch M, **Larson SM,** Humm JL: PET-based radiation dosimetry in man of 18F-fluorodihydrotestosterone, a new radiotracer for imaging prostate cancer. J Nucl Med. 2004 Nov;45(11):1966-1971.

436. Robbins RJ, Srivastava S, Shaha A, Ghossein R, **Larson SM,** Fleisher M, Tuttle RM: Factors influencing the Basal and recombinant human thyrotropin-stimulated serum thyroglobulin in patients with metastatic thyroid carcinoma. J Clin Endocrinol Metab. 2004 Dec;89(12):6010-6016.

437. Mageras GS, Pevsner A, Yorke ED, Rosenzweig KE, Ford EC, Hertanto A, **Larson SM,** Lovelock DM, Erdi YE, Nehmeh SA, Humm JL, Ling CC. Measurement of lung tumor motion using respiration-correlated CT. Int J Radiat Oncol Biol Phys. 2004 Nov 1;60(3):933-941.

438. Tuttle M, Robbins R, **Larson SM,** Strauss HW. Challenging cases in thyroid cancer: a multidisciplinary approach. Eur J Nucl Med Mol Imaging. 2004 Apr;31(4):605-12. Epub 2003 Dec 10.

439. Zanzonico P, O'Donoghue J, Chapman JD, Schneider R, Cai S, **Larson S,** Wen B, Chen Y, Finn R, Ruan S, Gerweck L, Humm J, Ling C. Iodine-124-labeled iodo-azomycin-galactoside imaging of tumor hypoxia in mice with serial microPET scanning. Eur J Nucl Med Mol Imaging. 2004 Jan;31(1):117-28. Epub 2003 Oct 2.

440. Nehmeh SA, Erdi YE, Pan T, Pevsner A, Rosenzweig KE, Yorke E, Mageras GS, Schoder H, Vernon P, Squire O, Mostafavi H, **Larson SM**, Humm JL. Four-dimensional (4D) PET/CT imaging of the thorax. Med Phys. 2004 Dec;31(12):3179-86.

441. **Larson SM**. Positron emission tomography-based molecular imaging in human cancer: exploring the link between hypoxia and accelerated glucose metabolism. Clin Cancer Res. 2004 Apr 1;10(7):2203-4.

442. Salaun PY, Grewal RK, Dodamane I, Yeung HW, **Larson SM,** Strauss HW: An Analysis of the 18F-FDG Uptake Pattern in the Stomach. J Nucl Med. 2005 Jan;46(1):48-51.

443. Schoder H, Noy A, Gonen M, Weng L, Green D, Erdi YE, **Larson SM,** Yeung HW. Intensity of 18Fluorodeoxyglucose Uptake in Positron Emission Tomography Distinguishes Between Indolent and Aggressive Non-Hodgkin's Lymphoma. J Clin Oncol, 2005. Jul 20;23(21):4643-4651.

444. Levchenko A, Mehta BM, Niu X, Kang G, Villafania L, Way D, Polycarpe D, Sadelain M, **Larson SM**. Intercellular transfer of P-glycoprotein mediates acquired multidrug resistance in tumor cells. Proc Natl Acad Sci U S A, 2005. 102(6): p. 1933-1938.

445. **Larson SM,** Krenning EP. A pragmatic perspective on molecular targeted radionuclide therapy. J Nucl Med. 2005 Jan;46(1 Suppl):1S-3S.

446. Brady MS, Akhurst T, Spanknebel K, Hilton S, Gonen M, Patel A, **Larson S**. Utility of preoperative [(18)]f fluorodeoxyglucose-positron emission tomography scanning in high-risk melanoma patients. Ann Surg Oncol. Apr 2006;13(4):525-532.

447. Morris MJ, Akhurst T, **Larson SM**, Ditullio M, Chu E, Siedlecki K, Verbel D, Heller G, Kelly WK, Slovin S, Schwartz L, Scher HI. Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy. Clin Cancer Res. 2005 May 1;11(9):3210-6.

448. Modak S, Guo HF, Humm JL, Smith-Jones PM, **Larson SM**, Cheung NK. Radioimmunotargeting of human rhabdomyosarcoma using monoclonal antibody 8H9. Cancer Biother Radiopharm. 2005 Oct;20(5):534-46.

449. Morris MJ, Divgi CR, Pandit-Taskar N, Batraki M, Warren N, Nacca A, Smith-Jones P, Schwartz L, Kelly WK, Slovin S, Solit D, Halpern J, Delacruz A, Curley T, Finn R, O'donoghue JA, Livingston P, **Larson S**, Scher HI. Pilot trial of unlabeled and indium-111-labeled anti-prostate-specific membrane antigen antibody J591 for castrate metastatic prostate cancer. Clin Cancer Res. 2005 Oct 15;11(20):7454-61.

450. Akhurst T, Kates TJ, Mazumdar M, Yeung H, Riedel ER, Burt BM, Blumgart L, Jarnagin W, **Larson SM,** Fong Y. Recent chemotherapy reduces the sensitivity of [18F]fluorodeoxyglucose positron emission tomography in the detection of colorectal metastases. J Clin Oncol. 2005 Dec 1;23(34):8713-6.

451. Gade TP, Hassen W, Santos E, Gunset G, Saudemont A, Gong MC, Brentjens R, Zhong XS, Stephan M, Stefanski J, Lyddane C, Osborne JR, Buchanan IM, Hall SJ, Heston WD, Rivière I, **Larson SM**,

Koutcher JA, Sadelain M. Targeted elimination of prostate cancer by genetically directed human T lymphocytes. Cancer Res. 2005 Oct 1;65(19):9080-8.

452. Yeung HW, Schöder H, Smith A, Gonen M, **Larson SM**. Clinical value of combined positron emission tomography/computed tomography imaging in the interpretation of 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography studies in cancer patients. Mol Imaging Biol. 2005 May-Jun;7(3):229-35.

453. **Larson SM**, Nehmeh SA, Erdi YE, Humm JL. PET/CT in non-small-cell lung cancer: value of respiratory-gated PET. Chang Gung Med J. 2005 May;28(5):306-14.

454. Schöder H, Herrmann K, Gönen M, Hricak H, Eberhard S, Scardino P, Scher HI, **Larson SM**. 2-[18F]fluoro-2-deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy. Clin Cancer Res. 2005 Jul 1;11(13):4761-9.

455. Schöder H, Yeung HW, **Larson SM**. CT in PET/CT: essential features of interpretation. J Nucl Med. 2005 Aug;46(8):1249-51.

456. Pugachev A, Ruan S, Carlin S, **Larson SM**, Campa J, Ling CC, Humm JL. Dependence of FDG uptake on tumor microenvironment. Int J Radiat Oncol Biol Phys. 2005 Jun 1;62(2):545-53.

457. Veach DR, Namavari M, Beresten T, Balatoni J, Minchenko M, Djaballah H, Finn RD, Clarkson B, Gelovani JG, Bornmann WG, **Larson SM**. Synthesis and in vitro examination of [124I]-, [125I]- and [131I]-2-(4-iodophenylamino) pyrido[2,3-d]pyrimidin-7-one radiolabeled Abl kinase inhibitors. Nucl Med Biol. 2005 May;32(4):313-21.

458. Dunphy MP, Freiman A, **Larson SM**, Strauss HW. Association of vascular 18F-FDG uptake with vascular calcification. J Nucl Med. 2005 Aug;46(8):1278-84.

459. Wong CO, Pandit-Taskar N, **Larson SM**. JNM supplement on molecular radiotherapy. J Nucl Med. 2005 Oct;46(10):1765-6; author reply 1766.

460. Kelloff GJ, Krohn KA, **Larson SM**, Weissleder R, Mankoff DA, Hoffman JM, Link JM, Guyton KZ, Eckelman WC, Scher HI, O'Shaughnessy J, Cheson BD, Sigman CC, Tatum JL, Mills GQ, Sullivan DC, Woodcock J. The progress and promise of molecular imaging probes in oncologic drug development. Clin Cancer Res. 2005 Nov 15;11(22):7967-85.

461. Forster GJ, Santos EB, Smith-Jones PM, Zanzonico P, **Larson SM**. Pretargeted Radioimmunotherapy with a Single-Chain Antibody/Streptavidin Construct and Radiolabeled DOTA-Biotin: Strategies for Reduction of the Renal Dose. J Nucl Med. Jan 2006;47(1):140-149.

462. **Larson SM,** Schwartz LH. 18F-FDG PET as a candidate for "qualified biomarker": functional assessment of treatment response in oncology. J Nucl Med. Jun 2006;47(6):901-903.

463. Pevsner A, Davis B, Joshi S, Hertanto A, Mechalakos J, Yorke E, Rosenzweig K, Nehmeh S, Erdi YE, Humm JL, **Larson S**, Ling CC, Mageras GS. Evaluation of an automated deformable image matching method for quantifying lung motion in respiration-correlated CT images. Med Phys. 2006 Feb;33(2):369-736.

464. Port ER, Yeung H, Gonen M, Liberman L, Caravelli J, Borgen P, **Larson S**. 18F-2-fluoro-2-deoxy-D-glucose positron emission tomography scanning affects surgical management in selected patients with high-risk, operable breast carcinoma. Ann Surg Oncol. 2006 May;13(5):677-684.

465. Pryma DA, Schoder H, Gonen M, Robbins RJ, **Larson SM,** Yeung HW. Diagnostic accuracy and prognostic value of 18F-FDG PET in Hurthle cell thyroid cancer patients. J Nucl Med. Aug 2006;47(8):1260-1266.

466. Rizk N, Downey RJ, Akhurst T, Gonen M, Bains MS, **Larson S,** Rusch V. Preoperative 18[F]-fluorodeoxyglucose positron emission tomography standardized uptake values predict survival after esophageal adenocarcinoma resection. Ann Thorac Surg. 2006 Mar;81(3):1076-1081.

467. Robbins RJ, Wan Q, Grewal RK, Reibke R, Gonen M, Strauss HW, Tuttle RM, Drucker W, **Larson SM.** Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab. 2006 Feb;91(2):498-505.

468. Schöder H, Carlson DL, Kraus DH, Stambuk HE, Gönen M, Erdi YE, Yeung HW, Huvos AG, Shah JP, **Larson SM**, Wong RJ. 18F-FDG PET/CT for detecting nodal metastases in patients with oral cancer staged N0 by clinical examination and CT/MRI. J Nucl Med. 2006 May;47(5):755-762.

469.

470. Smith-Jones PM, Solit D, Afroze F, Rosen N, **Larson SM**. Early tumor response to Hsp90 therapy using HER2 PET: comparison with 18F-FDG PET. J Nucl Med. May 2006;47(5):793-796.

471. Zanzonico P, Campa J, Polycarpe-Holman D, Forster G, Finn R, **Larson SM**, Humm J, Ling C. Animal-specific positioning molds for registration of repeat imaging studies: comparative microPET imaging of F18-labeled fluoro-deoxyglucose and fluoro-misonidazole in rodent tumors. Nucl Med Biol. Jan 2006;33(1):65-70.

472. Zanzonico P, Koehne G, Gallardo HF, Doubrovin M, Doubrovina E, Finn R, Blasberg RG, Riviere I, O'Reilly RJ, Sadelain M, **Larson SM**. [(131)I]FIAU labeling of genetically transduced, tumor-reactive lymphocytes: cell-level dosimetry and dose-dependent toxicity. Eur J Nucl Med Mol Imaging. Sep 2006;33(9):988-997.

473. Pal A, Glekas A, Doubrovin M, Balatoni J, Namavari M, Beresten T, Maxwell D, Soghomonyan S, Shavrin A, Ageyeva L, Finn R, **Larson SM**, Bornmann W, Gelovani JG. Molecular imaging of EGFR kinase activity in tumors with 124I-labeled small molecular tracer and positron emission tomography. Molecular imaging and biology. 2006;8(5):262-277.

474. Tuttle RM, Leboeuf R, Robbins RJ, Qualey R, Pentlow K, **Larson SM**, Chan CY. Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer. The Journal of nuclear medicine. 2006;47(10):1587-1591.

475. Gollub MJ, Akhurst T, Markowitz AJ, Weiser MR, Guillem JG, Smith LM, **Larson SM**, Margulis AR.Combined CT colonography and 18F-FDG PET of colon polyps: potential technique for selective detection of cancer and precancerous lesions. AJR, American journal of roentgenology. 2007;188(1):130-138.

476. GJ, Sullivan DM, Wilson W, Cheson B, Juweid M, Mills GQ, Zelenetz AD, Horning SJ, Weber W, Sargent DJ, Dodd L, Korn E, Armitage J, Schilsky R, Christian M, O'connor OA, Wang SJ, Farrell AT, Pazdur R, Graham M, Wahl RL, **Larson SM**, et al. FDG-PET Lymphoma Demonstration Project Invitational Workshop. Academic radiology. 2007;14(3):330-339.

477. Kolbert KS, Pentlow KS, Pearson JR, Sheikh A, Finn RD, Humm JL, **Larson SM**. Prediction of absorbed dose to normal organs in thyroid cancer patients treated with 131I by use of 124I PET and 3-dimensional internal dosimetry software. The Journal of nuclear medicine. 2007;48(1):143-149.

478. Nehmeh SA, Erdi YE, Meirelles GS, Squire O, **Larson SM**, Humm JL, Schöder H. Deep-inspiration breath-hold PET/CT of the thorax. The Journal of nuclear medicine. 2007;48(1):22-26.

479. C. R. Divgi, N. Pandit-Taskar, A. A. Jungbluth, V. E. Reuter, M. Gonen, S. Ruan, C. Pierre, A. Nagel, D. A. Pryma, J. Humm,**Larson SM**, L. J. Old, and P. Russo, "Preoperative Characterisation of Clear-Cell Renal Carcinoma Using Iodine-124-Labelled Antibody Chimeric G250 (124i-Cg250) and Pet in Patients with Renal Masses: A Phase I Trial," Lancet Oncol, 2007 8: 304-310.

480. W. R. Hendee, F. Banovac, P. L. Carson, R. A. DeFronzo, W. C. Eckelman, G. D. Fullerton, **Larson SM**, G. McLennan, and M. J. Welch, "Biomedical Imaging Research Opportunities Workshop Iv: A White Paper," Med Phys, 2007 34: 673-679.

481. G. J. Kelloff, D. M. Sullivan, W. Wilson, B. Cheson, M. Juweid, G. Q. Mills, A. D. Zelenetz, S. J. Horning, W. Weber, D. J. Sargent, L. Dodd, E. Korn, J. Armitage, R. Schilsky, M. Christian, A. O'Connor O, S. J. Wang, A. T. Farrell, R. Pazdur, M. Graham, R. L. Wahl, **Larson SM**, L. Kostakoglu, M. Daube-Witherspoon, C. Gastonis, B. A. Siegel, L. K. Shankar, D. B. Lee, H. R. Higley, C. C. Sigman, D. Carucci, D. Timko, L. J. Degennaro, E. Sigal, A. Barker, and J. Woodcock, "Fdg-Pet Lymphoma Demonstration Project Invitational Workshop," Acad Radiol, 2007 14: 330-339.

482. K. S. Kolbert, K. S. Pentlow, J. R. Pearson, A. Sheikh, R. D. Finn, J. L. Humm, and **Larson SM,** "Prediction of Absorbed Dose to Normal Organs in Thyroid Cancer Patients Treated with 131i by Use of 124i Pet and 3-Dimensional Internal Dosimetry Software," J Nucl Med, 2007 48: 143-149.

483. G. S. Meirelles, Y. E. Erdi, S. A. Nehmeh, O. D. Squire, **Larson SM**, J. L. Humm, and H. Schoder, "Deep-Inspiration Breath-Hold Pet/Ct: Clinical Findings with a New Technique for Detection and Characterization of Thoracic Lesions," J Nucl Med*,* 2007 48: 712-719.

484. S. C. Ong, H. Schoder, S. G. Patel, I. M. Tabangay-Lim, I. Doddamane, M. Gonen, A. R. Shaha, R. M. Tuttle, J. P. Shah, and **Larson SM**, "Diagnostic Accuracy of 18f-Fdg Pet in Restaging Patients with Medullary Thyroid Carcinoma and Elevated Calcitonin Levels," J Nucl Med, 2007 48: 501-507.

485. Podoloff DA, Advani RH, Allred C, Benson AB 3rd, Brown E, Burstein HJ, Carlson RW, Coleman RE, Czuczman MS, Delbeke D, Edge SB, Ettinger DS, Grannis FW Jr, Hillner BE, Hoffman JM, Kiel K, Komaki R, **Larson SM**, Mankoff DA, Rosenzweig KE, Skibber JM, Yahalom J, Yu JM, Zelenetz AD. NCCN task force report: positron emission tomography (PET)/computed tomography (CT) scanning in cancer. J Natl Compr Canc Netw. 2007 May;5 Suppl 1:S1-S22; quiz S23-2.

486. Abdelnour AF, Nehmeh SA, Pan T, Humm JL, Vernon P, Schoder H, Rosenzweig KE, Mageras GS, Yorke E, **Larson SM**, Erdi YE. Phase and amplitude binning for 4D-CT imaging. Phys Med Biol. 2007;52:3515-3529.

487. Brentjens RJ, Santos E, Nikhamin Y, Yeh R, Matsushita M, La Perle K, Quintas-Cardama A, **Larson SM**, Sadelain M. Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin Cancer Res. 2007;13:5426-5435.

488. Jaggi JS, Carrasquillo JA, Seshan SV, Zanzonico P, Henke E, Nagel A, Schwartz J, Beattie B, Kappel BJ, Chattopadhyay D, Xiao J, Sgouros G, **Larson SM**, Scheinberg DA. Improved tumor imaging and therapy via i.v. IgG-mediated time-sequential modulation of neonatal Fc receptor. J Clin Invest. 2007;117:2422-2430.

489. M. M. Doubrovin, E. S. Doubrovina, P. Zanzonico, M. Sadelain, **Larson SM**, and R. J. O'Reilly, "In Vivo Imaging and Quantitation of Adoptively Transferred Human Antigen-Specific T Cells Transduced to Express a Human Norepinephrine Transporter Gene," Cancer Res*,* 2007 67: 11959-11969.

490. K. Kramer, J. L. Humm, M. M. Souweidane, P. B. Zanzonico, I. J. Dunkel, W. L. Gerald, Y. Khakoo, S. D. Yeh, H. W. Yeung, R. D. Finn, S. L. Wolden,**Larson SM**, and N. K. Cheung, "Phase I Study of Targeted Radioimmunotherapy for Leptomeningeal Cancers Using Intra-Ommaya 131-I-3f8," J Clin Oncol*,* 2007 25: 5465-5470.

491. D. L. Roter, **Larson SM**, M. C. Beach, and L. A. Cooper, "Interactive and Evaluative Correlates of Dialogue Sequence: A Simulation Study Applying the Rias to Turn Taking Structures," Patient Educ Couns*,* 2007.

492. V. E. Strong, J. Humm, P. Russo, A. Jungbluth, W. D. Wong, F. Daghighian, L. Old, Y. Fong, and **Larson SM**, "A Novel Method to Localize Antibody-Targeted Cancer Deposits Intraoperatively Using Handheld Pet Beta and Gamma Probes," Surg Endosc, 2008 22: 386-391.

493. R. M. Tuttle, R. K. Grewal, and **Larson SM**, "Radioactive Iodine Therapy in Poorly Differentiated Thyroid Cancer," Nat Clin Pract Oncol, 2007 4: 665-668.

494. D. R. Veach, M. Namavari, N. Pillarsetty, E. B. Santos, T. Beresten-Kochetkov, C. Lambek, B. J. Punzalan, C. Antczak, P. M. Smith-Jones, H. Djaballah, B. Clarkson, and **Larson SM**, "Synthesis and Biological Evaluation of a Fluorine-18 Derivative of Dasatinib," J Med Chem, 2007 50: 5853-5857.

495. **Larson SM**, and H. Schoder, "Advances in Positron Emission Tomography Applications for Urologic Cancers," Curr Opin Urol, 2008 18: 65-70.

496. S. A. Nehmeh, N. Y. Lee, H. Schroder, O. Squire, P. B. Zanzonico, Y. E. Erdi, C. Greco, G. Mageras, H. S. Pham, **Larson SM**, C. C. Ling, and J. L. Humm, "Reproducibility of Intratumor Distribution of (18)F-Fluoromisonidazole in Head and Neck Cancer," Int J Radiat Oncol Biol Phys, 2008 70: 235-42.

497. M. S. Bradbury, D. Hambardzumyan, P. B. Zanzonico, J. Schwartz, S. Cai, E. M. Burnazi, V. Longo, **Larson SM**, and E. C. Holland, "Dynamic Small-Animal Pet Imaging of Tumor Proliferation with 3'-Deoxy-3'-18f-Fluorothymidine in a Genetically Engineered Mouse Model of High-Grade Gliomas," J Nucl Med, 2008 49: 422-429.

498. **Larson SM**, "Practice-Based Evidence of the Beneficial Impact of Positron Emission Tomography in Clinical Oncology," J Clin Oncol, 2008 26: 2083-2084.

499. S. C. Ong, H. Schoder, N. Y. Lee, S. G. Patel, D. Carlson, M. Fury, D. G. Pfister, J. P. Shah, **Larson SM**, and D. H. Kraus, "Clinical Utility of 18f-Fdg Pet/Ct in Assessing the Neck after ConcurrentChemoradiotherapy for Locoregional Advanced Head and Neck Cancer," J Nucl Med, 2008 49: 532-540.

500. N. Pandit-Taskar, J. A. O'Donoghue, M. J. Morris, E. A. Wills, L. H. Schwartz, M. Gonen, H. I. Scher, **Larson SM**, and C. R. Divgi, "Antibody Mass Escalation Study in Patients with Castration-Resistant Prostate Cancer Using 111in-J591: Lesion Detectability and Dosimetric Projections for 90y Radioimmunotherapy," J Nucl Med, 2008.

501. M. Rivera, R. A. Ghossein, H. Schoder, D. Gomez, **Larson SM**, and R. M. Tuttle, "Histopathologic Characterization of Radioactive Iodine-Refractory Fluorodeoxyglucose-Positron Emission Tomography-Positive Thyroid Carcinoma," Cancer, 2008 113: 48-56.

502. D. L. Roter, **Larson SM**, M. C. Beach, and L. A. Cooper, "Interactive and Evaluative Correlates of Dialogue Sequence: A Simulation Study Applying the Rias to Turn Taking Structures," Patient Educ Couns, 2008 71: 26-33.

503. P. M. Smith-Jones, N. Pandit-Taskar, W. Cao, J. O'Donoghue, M. D. Philips, J. Carrasquillo, J. A. Konner, L. J. Old, and **Larson SM**, "Preclinical Radioimmunotargeting of Folate Receptor Alpha Using the Monoclonal Antibody Conjugate Dota-Morab-003," Nucl Med Biol, 2008 35: 343-351.

504. R. M. Tuttle, M. Brokhin, G. Omry, A. J. Martorella, **Larson SM**, R. K. Grewal, M. Fleisher, and R. J. Robbins, "Recombinant Human Tsh-Assisted Radioactive Iodine Remnant Ablation Achieves Short-Term Clinical Recurrence Rates Similar to Those of Traditional Thyroid Hormone Withdrawal," J Nucl Med, 2008 49: 764-770.

505. C. Greco, S. A. Nehmeh, H. Schoder, M. Gonen, B. Raphael, H. E. Stambuk, J. L. Humm, **Larson SM**, and N. Y. Lee, "Evaluation of Different Methods of 18f-Fdg-PET Target Volume Delineation in the Radiotherapy of Head and Neck Cancer," Am J Clin Oncol, 2008 31: 439-445.

506. N. Ratanawongsa, D. Roter, M. C. Beach, S. L. Laird,**Larson SM**, K. A. Carson, and L. A. Cooper, "Physician Burnout and Patient-Physician Communication During Primary Care Encounters," J Gen Intern Med, 2008 23: 1581-1588.

507. R. J. Robbins, and **Larson SM**, "The Value of Positron Emission Tomography (PET) in the Management of Patients with Thyroid Cancer," Best Pract Res Clin Endocrinol Metab, 2008 22: 1047-1059.

508. L. A. Cooper, D. L. Roter, L. R. Bone, **Larson SM**, E. R. Miller, 3rd, M. S. Barr, K. A. Carson, and D. M. Levine, "A Randomized Controlled Trial of Interventions to Enhance Patient-Physician Partnership, Patient Adherence and High Blood Pressure Control among Ethnic Minorities and Poor Persons: Study Protocol Nct00123045," Implement Sci, 2009 4: 7.

509. A. A. Burns, J. Vider, H. Ow, E. Herz, O. Penate-Medina, M. Baumgart, **Larson SM**, U. Wiesner, and M. Bradbury, "Fluorescent Silica Nanoparticles with Efficient Urinary Excretion for Nanomedicine," Nano Lett, 2009 9: 442-448.

510. **Larson SM**, "Cancer Drug Development with the Help of Radiopharmaceuticals: Academic Experience," Curr Pharm Des, 2009 15: 950-956.

511. **Larson SM**, and M. Salvatore, "Foreword," Q J Nucl Med Mol Imaging, 2009 53: 157.

512. **Larson SM**, and H. Schoder, "New PET Tracers for Evaluation of Solid Tumor Response to Therapy," Q J Nucl Med Mol Imaging, 2009 53: 158-166.

513. E. B. Santos, R. Yeh, J. Lee, Y. Nikhamin, B. Punzalan, K. La Perle, **Larson SM**, M. Sadelain, and R. J. Brentjens, "Sensitive in Vivo Imaging of T Cells Using a Membrane-Bound Gaussia Princeps Luciferase," Nat Med, 2009 15: 338-344.

514. V. E. Strong, C. J. Galanis, C. C. Riedl, V. A. Longo, F. Daghighian, J. L. Humm, **Larson SM**, and Y. Fong, "Portable PET Probes Are a Novel Tool for Intraoperative Localization of Tumor Deposits," Ann Surg Innov Res, 2009 3: 2.

515. B. Zhao, L. H. Schwartz, and **Larson SM**, "Imaging Surrogates of Tumor Response to Therapy: Anatomic and Functional Biomarkers," J Nucl Med, 2009 50: 239-249.

516. Morris MJ, Pandit-Taskar N, Carrasquillo J, Divgi CR, Slovin S, Kelly WK, Rathkopf D, Gignac GA, Solit D, Schwartz L, Stephenson RD, Hong C, Delacruz A, Curley T, Heller G, Jia X, O'Donoghue J, **Larson S**, Scher HI. "Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer". J Clin Oncol. 2009 May20;27(15):2436-2442.

517. Dauer LT, Boylan DC, Williamson MJ, St Germaine J, **Larson SM**. "Clearance kinetics nd external dosimetry of 1311-labeled murine and humanized monoclonal antibody A33 in patients with colon cancer: radiation safety implications". Health Phys. 2009 May;96(5):550-557.

518. Dunphy MP, Entenberg D, Toledo-Crow R, **Larson SM**. "In vivo microcartography and subcellular imaging of tumor angiogenesis: a novel platform for translational angiogenesis research". Microvasc Res.2009Jun;78(1):51-56.

519. Tuttle RM, Robbins RJ, Brokhin M, **Larson SM**. "A New Age for Recombinant Human Thyroid-Stimulating Hormone? J Nucl Med.2009 Apr 16.[Epub ahead of print]

520. Gollub MJ, Akhurst TJ, Williamson MJ, Shia J, Humm JL, Wong WD, Paty PB, Guillem JG, Weiser MR, Temple LK, Dauer LT, Jhanwar SC, Kronman RE, Montalvo CV, Miller AR, **Larson SM**, Margulis AR. "Feasibility of ex vivo FDG PET of the colon". Radiology.2009 Jul;252(1)232-239.

521. Langstrom B, Grahnen A, Honore PH, Borlak J, Bergstrom M, Nielsen B, Vanderheyden J, Watanabe Y, Josephsson R, Hoilund-Carlsen PF, Schwaiger M, **Larson SM**, Goldenberg DM, Melzer A, Engler

H, Hicks R, Sundin A, Seppanen M, Hedenstierna G, Nordberg A, Brooks D. "The risk of exaggerated risk aversion-a life and death struggle for molecular imaging". Eur J Nucl Med Mol Imaging 2009 Oct;36(10):1693-1694.

522. Shaw WS, Pransky G, winters T, Tveito TH, **Larson SM**, Roter DL. "Does the Presence of Psychosocial "Yellow Flags" Alter Patient-Provider Communication for Work-Related, Acute Low Back Pain? J Occup Environ Med.2009 Aug 14.

523. Grewal RK, **Larson SM**, Pentlow CE, Pentlow KS, Gonen M. Qualey r, Natbony L, Tuttle RM. "Salivary gland side effects commonly develop several weeks after initial radioactive iodine ablation". J Nucl Med. 2009 Oct;50(10):1605-1610.

524. Pilarsetty N, Punzalan B, **Larson SM.** "2-18F-Fluoropropionic acid as a PET imaging agent for prostate cancer". J Nucl Med.2009 Oct;50(10):1709-1714.

525. Nehmeh SA, El-Zeftawy H, Greco C, Schwartz J, Erdi YE, Kirov A, Schmidtlein CR, Gyau AB, **Larson SM,** Humm JL. "An interative technigue to segment PET lesions using a Monte Carlo based mathematical model". Med Phys. 2009 Oct;36(10):4803-4809.

526. Doubrovin M, Kochetkovova T, Santos E, Veach DR, Smith-Jones P, Pillarsetty N, Balatoni J, Bornmann W, Gelovani J, **Larson SM. "**(124)I-iodopyridopyrimidinone for PET of Abl kinase-expressing tumors in vivo". J Nucl Med. 2010 Jan;51(1):121-129.

527. Beattie BJ, Smith-Jones PM, Jhanwar YS, Schöder H, Schmidtlein CR, Morris MJ, Zanzonico P, Squire O, Meirelles GS, Finn R, Namavari M, Cai S, Scher HI, **Larson SM**, Humm JL**.** "Pharmacokinetic assessment of the uptake of 16beta-18F-fluoro-5alpha-dihydrotestosterone (FDHT) in prostate tumors as measured by PET". J Nucl Med. 2010 Feb;51(2):183-192.

528. Morris PG, Poznak CV, Modi S, Mak AF, Patil S, **Larson SM**, Hudis CA, Divgi C, Grewal RK. "Intravenous bisphosphonate therapy does not acutely alter nuclear bone scan results". Clin Breast Cancer. 2010 Feb;10(1):33-39.

529. Wu ZL, Ethen CM, **Larson SM**, Prather B, Jiang W**. "**A versatile polyacrylamide gel electrophoresis based sulfotransferase assay". BMC Biotechnol. 2010 Feb 10;10:11.

530. Danila DC, Morris MJ, de Bono JS, Ryan CJ, Denmeade SR, Smith MR, Taplin ME, Bubley GJ, Kheoh T, Haqq C, Molina A, Anand A, Koscuiszka M, **Larson SM**, Schwartz LH, Fleisher M, Scher HI. **"**Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer". (124)I-iodopyridopyrimidinone for PET of Abl kinase-expressing tumors in vivo". J Clin Oncol. 2010 Mar 20;28(9):1496-1501.

531. Tuttle RM, Lopez N, Leboeuf R, Minkowitz SM, Grewal R, Brokhin M, Omry G, **Larson SM**. **"**Radioactive iodine administered for thyroid remnant ablation following recombinant human thyroid stimulating hormone preparation also has an important adjuvant therapy function". Thyroid. 2010 Mar;20(3):257-263.

532. Osborne JR, Port E, Gonen M, Doane A, Yeung H, Gerald W, Cook JB, **Larson SM**. **"**18F-FDG PET of locally invasive breast cancer and association of estrogen receptor status with standardized uptake value: microarray and immunohistochemical analysis". J Nucl Med. 2010 Apr;51(4):543-550.

533. Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, Rathkopf D, Shelkey J, Yu EY, Alumkal J, Hung D, Hirmand M, Seely L, Morris MJ, Danila DC, Humm J, **Larson SM**, Fleisher M, Sawyers CL; Prostate Cancer Foundation/Department of Defense Prostate Cancer Clinical Trials Consortium. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet. 2010 Apr 24;375(9724):1437-1446.

534. Pandit-Taskar N, Gemignani ML, Lyall A, **Larson SM**, Barakat RR, Abu Rustum NR. "Single photon emission computed tomography SPECT-CT improves sentinel node detection and localization in cervical and uterine malignancy". Gynecol Oncol. 2010 Apr;117(1):59-64.

535. Kramer K, Kushner BH, Modak S, Pandit-Taskar N, Smith-Jones P, Zanzonico P, Humm JL, Xu H, Wolden SL, Souweidane MM, **Larson SM,** Cheung NK. "Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma". J Neurooncol. May;2010 97(3):409-418.

536. Lucignani G, **Larson SM**. "Doctor, what does my future hold? The prognostic value of FDG-PET in solid tumours". Eur J Nucl Med Mol Imaging. 2010 May;37(5):1032-1038.

537. Carlin S, Khan N, Ku T, Longo VA, **Larson SM**, Smith-Jones PM. "Molecular targeting of carbonic anhydrase IX in mice with hypoxic HT29 colorectal tumor xenografts". PLoS One. 2010 May 27;5(5):e10857.

538. Bhandari S, Cheung NK, Kushner BH, Kramer K, Modak S, **Larson SM**, Yeh S, Heller G, Sklar CA "Hypothyroidism after 131I-monoclonal antibody treatment of neuroblastoma". Pediatr Blood Cancer. 2010 Jul 15;55(1):76-80.

539. Morris PG, Lynch C, Feeney JN, Patil S, Howard J, **Larson SM**, Dickler M, Hudis CA, Jochelson M, McArthur HL. "Integrated positron emission tomography/computed tomography may render bone scintigraphy unnecessary to investigate suspected metastatic breast cancer".J Clin Oncol. 2010 Jul 1;28(19):3154-3159.

540. Holland JP, Divilov V, Bander NH, Smith-Jones PM, **Larson SM**, Lewis JS. "89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo".J Nucl Med. 2010 Aug;51(8):1293-1300.

541. Hricak H, Choi BI, Scott AM, Sugimura K, Muellner A, von Schulthess GK, Reiser MF, Graham MM, Dunnick NR, **Larson SM**. "Global Trends in Hybrid Imaging". Radiology. 2010 Sep 9. [Epub ahead of print]

542. **Larson SM**. Oncology. J Nucl Med. 2010 Sep;51(9):19N-25N.

543. Grewal RK, Tuttle RM, Fox J, Borkar S, Chou JF, Gonen M, Strauss HW, **Larson SM**, Schöder H "The effect of posttherapy 131I SPECT/CT on risk classification and management of patients with differentiated thyroid cancer".J Nucl Med. 2010 Sep;51(9):1361-1367.

544. **Larson SM**, Lee HJ, Hung PH, Matthews LM, Robinson DN, Evans JP "Cortical mechanics and meiosis II completion in mammalian oocytes are mediated by myosin-II and Ezrin-Radixin-Moesin (ERM) proteins".Mol Biol Cell. 2010 Sep 15;21(18):3182-3192.

545. Rosenblat TL, McDevitt MR, Mulford DA, Pandit-Taskar N, Divgi CR, Panageas KS, Heaney ML, Chanel S, Morgenstern A, Sgouros G, **Larson SM**, Scheinberg DA, Jurcic JG. "Sequential Cytarabine and {alpha}-Particle Immunotherapy with Bismuth-213-Lintuzumab (HuM195) for Acute Myeloid Leukemia". Clin Cancer Res. 2010 Nov 1;16(21):5303-5311.

546. Konner J, Bell-McGuinn K, Sabbatini PJ, Hensley ML, Tew W, Pandit-Taskar N, Vander Els N, Phillips MD, Schweizer C, Weil SC, **Larson SM**, Old LJ. "Farletuzumab, a Humanized Monoclonal Antibody against Folate Receptor Alpha, in Epithelial Ovarian Cancer: A Phase I Study". Clin Cancer Res. 2010 Nov 1;16(21):5288-5295.

547. Meirelles GS, Schöder H, Ravizzini GC, Gönen M, Fox JJ, Humm J, Morris MJ, Scher HI, **Larson SM**. "Prognostic value of baseline [18F] fluorodeoxyglucose positron emission tomography and 99mTc-MDP bone scan in progressing metastatic prostate cancer." Clin Cancer Res. 2010 Dec 15;16(24):6093-6099.

548. Dunphy MP, Zanzonico P, Veach D., Somwar R, Pillarsetty N, Lewis J, **Larson SM** "Dosimetry of (18) F-Labeled Tyrosine Kinase Inhibitor SKI-249380, a Dasatinib-Tracer for PET Imaging." Mol Imaging Biol. 2010 Dec 16.

549. **Larson SM**, Godley LA. "Getting to the root of the stem cell in mutated chronic myeloid leukemia." Leuk Lymphoma. 2010 Dec;51(12):2147-2148.

550. Singnurkar A, Solomon SB, Gönen M, **Larson SM**, Schöder H. "18F-FDG PET/CT for the prediction and detection of local recurrence after radiofrequency ablation of malignant lung lesions." J Nucl Med. 2010 Dec;51(12):1833-1840.

551. Meirelles GS, Schöder H, Ravizzini GC, Gönen M, Fox JJ, Humm J, Morris MJ, Scher HI, **Larson SM**. "Prognostic value of baseline [18F] fluorodeoxyglucose positron emission tomography and 99mTc-MDP bone scan in progressing metastatic prostate cancer." Clin Cancer Res. 2010 Dec 15;16(24):6093-6099.

552. Shaw WS, Pransky G, Roter DL, Winters T, Tveito TH, **Larson SM**. "The effects of patient-provider communication on 3-month recovery from acute low back pain". J Am Board Fam Med. 2011 Jan-Feb;24(1):16-25.

553. **Larson SM**. "SNM CMIIT Hosts Prostate Cancer Summit". J Nucl Med. 2011 Jan;52(1):16N.

554. Zhang H, Moroz MA, Serganova I, Ku T, Huang R, Vider J, Maecke HR, **Larson SM**, Blasberg R, Smith-Jones PM "Imaging Expression of the Human Somatostatin Receptor Subtype-2 Reporter Gene with 68Ga-DOTATOC."J Nucl Med. 2011 Jan;52(1):123-131.

555. He P, Kramer K, Smith-Jones P, Zanzonico P, Humm J, **Larson SM**, Cheung NK. Two-compartment model of radioimmunotherapy delivered through cerebrospinal fluid. Eur J Nucl Med Mol Imaging. 2011 Feb;38(2):334-42. Erratum in: Eur J Nucl Med Mol Imaging. 2011 Feb;38(2):410.

556. Macapinlac HA, Czernin J, **Larson SM.** Practice based evidence of the beneficial impact of PET in patients with brain tumors. Mol Imaging Biol. 2011 Feb;13(1):1-2.

557. Medina OP, Pillarsetty N, Glekas A, Punzalan B, Longo V, Gönen M, Zanzonico P, Smith-Jones P, **Larson SM**. "Optimizing tumor targeting of the lipophilic EGFR-binding radiotracer SKI 243 using a liposomal nanoparticle delivery system." J Control Release. 2011 Feb 10;149(3):292-298.

558. Smith-Jones P, Zanzonico P, Humm J, **Larson SM**, Cheung NK. "Erratum to: Two-compartment model of radioimmunotherapy delivered through cerebrospinal fluid."Eur J Nucl Med Mol Imaging. 2011 Feb;38(2):334-342.

559. Schoellnast H, **Larson SM**, Nehmeh SA, Carrasquillo JA, Thornton RH, Solomon SB. **"**Radiofrequency Ablation of Non-Small-Cell Carcinoma of the Lung Under Real-Time FDG PET CT Guidance". Cardiovasc Intervent Radiol. 2011 Feb;34 Suppl 2:S182-5.

560. Pryma DA, O'Donoghue JA, Humm JL, Jungbluth AA, Old LJ, **Larson SM**, Divgi CR. "Correlation of In Vivo and In Vitro Measures of Carbonic Anhydrase IX Antigen Expression in Renal Masses Using Antibody 124I-cG250". J Nucl Med. 2011 Apr;52(4):535-540.

561. Leibold T, Akhurst TJ, Chessin DB, Yeung HW, Macapinlac H, Shia J, Minsky BD, Saltz LB, Riedel E, Mazumdar M, Paty PB, Weiser MR, Wong WD, **Larson SM**, Guillem JG. Ann "Evaluation of (18)F-FDG-PET for Early Detection of Suboptimal Response of Rectal Cancer to Preoperative Chemoradiotherapy: A Prospective Analysis". Surg Oncol. 2011 Apr 8.

562. Schöder H, Ong SC, Reuter VE, Cai S, Burnazi E, Dalbagni G, **Larson SM**, Bochner BH. "Initial Results with (11)C-Acetate Positron Emission Tomography/Computed Tomography (PET/CT) in the Staging of Urinary Bladder Cancer". Mol Imaging Biol. 2011 Apr 14.

563. Tala H, Robbins R, Fagin JA, **Larson SM**, Tuttle RM. "Five-Year Survival Is Similar in Thyroid Cancer Patients with Distant Metastases Prepared for Radioactive Iodine Therapy with either Thyroid Hormone Withdrawal or Recombinant Human TSH". J Clin Endocrinol Metab. 2011 May 11.

564. Ehlers SJ, **Larson SM**, Rasmussen HE, Park YK, Lee JY. "High-density lipoprotein metabolism in human apolipoprotein B(100) transgenic/brown adipose tissue deficient mice: a model of obesity-induced hyperinsulinemia". Appl Physiol Nutr Metab. 2011 Jun;36(3):313-22. Epub 2011 May 16.

565. Evans MJ, Smith-Jones PM, Wongvipat J, Navarro V, Kim S, Bander NH, **Larson SM**, Sawyers CL. "Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen". Proc Natl Acad Sci U S A. 2011 Jun 7;108(23):9578-82. Epub 2011 May 23.

566. Fox JJ, Morris MJ, **Larson SM**, Schöder H, Scher HI.Acta Oncol. "Developing imaging strategies for castration resistant prostate cancer". 2011 Jun;50 Suppl 1:39-48.

567. Palaskas NJ, **Larson SM**, Schultz N, Komisopoulou E, Wong J, Rohle D, Campos C, Yannuzzi N, Osborne JR, Linkov I, Kastenhuber E, Taschereau R, Plaisier SB, Tran C, Heguy A, Wu H, Sander C, Phelps ME, Brennan CW, Port E, Huse JT, Graeber TG, Mellinghoff I. "18F-fluorodeoxy-glucose positron emission tomography (18FDG-PET) marks MYC-overexpressing human basal-like breast cancers". Cancer Res. 2011 Jun 6.

568. Benezra M, Penate-Medina O, Zanzonico PB, Schaer D, Ow H, Burns A, Destanchina E, Longo V, Herz E, Iyer S, Wolchok J, **Larson SM**, Wiesner U, Bradbury MS. "Multimodal silica nanoparticles are effective cancer-targeted probes in a model of human melanoma".J Clin Invest. 2011 Jun 13.

569. O'Donoghue JA, Smith-Jones PM, Humm JL, Ruan S, Pryma DA, Jungbluth AA, Divgi CR, Carrasquillo JA, Pandit-Taskar N, Fong Y, Strong VE, Kemeny NE, Old LJ, **Larson SM**. "124I-huA33 Antibody Uptake Is Driven by A33 Antigen Concentration in Tissues from Colorectal Cancer Patients Imaged by Immuno-PET". J Nucl Med. 2011 Nov 8.

570. **Larson SM**. Oncology. J Nucl Med. 2011 Nov;52(11):13N-20N. No abstract available.

571. Fox JJ, Autran-Blanc E, Morris MJ, Gavane S, Nehmeh S, Van Nuffel A, Gönen M, Schöder H, Humm JL, Scher HI, **Larson SM**. "Practical Approach for Comparative Analysis of Multilesion Molecular Imaging Using a Semiautomated Program for PET/CT". J Nucl Med. 2011 Nov;52(11):1727-32.

572. Moulick K, Ahn JH, Zong H, Rodina A, Cerchietti L, Gomes Dagama EM, Caldas-Lopes E, Beebe K, Perna F, Hatzi K, Vu LP, Zhao X, Zatorska D, Taldone T, Smith-Jones P, Alpaugh M, Gross SS, Pillarsetty N, Ku T, Lewis JS, **Larson SM**, Levine R, Erdjument-Bromage H, Guzman ML, Nimer SD, Melnick A, Neckers L, Chiosis G. "Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90".Nat Chem Biol. 2011 Sep 25;7(11):818-26.

573. **Larson SM**, Campbell NP, Huo D, Artz A, Zhang Y, Gajria D, Green M, Weiner H, Daugherty C, Odenike O, Godley LA, Hyjek E, Gurbuxani S, Thirman M, Sipkins D, Van Besien K, Larson RA, Stock W. "High Dose Cytarabine and Mitoxantrone: An Effective Induction Regimen for High-Risk Acute Myeloid Leukemia (AML)". Leuk Lymphoma. 2011 Sep 13.

574. Schwartz J, Humm JL, Gonen M, Kalaigian H, Schoder H, **Larson SM**, Nehmeh SA. "Repeatability of SUV measurements in serial PET". Med Phys. 2011 May;38(5):2629-38.

575. Carrasquillo JA, Pandit-Taskar N, O'Donoghue JA, Humm JL, Zanzonico P, Smith-Jones PM, Divgi CR, Pryma DA, Ruan S, Kemeny NE, Fong Y, Wong D, Jaggi JS, Scheinberg DA, Gonen M, Panageas KS, Ritter G, Jungbluth AA, Old LJ, **Larson SM**. "(124)I-huA33 antibody PET of colorectal cancer". J Nucl Med. 2011 Aug;52(8):1173-80. Epub 2011 Jul 15.

576. Glekas AP, Pillarsetty NK, Punzalan B, Khan N, Smith-Jones P, **Larson SM**. "In vivo imaging of Bcr-Abl overexpressing tumors with a radiolabeled imatinib analog as an imaging surrogate for imatinib". J Nucl Med. 2011 Aug;52(8):1301-7. Epub 2011 Jul 15.

577. Cooper LA, Roter DL, Carson KA, Bone LR, **Larson SM**, Miller ER 3rd, Barr MS, Levine DM. "A randomized trial to improve patient-centered care and hypertension control in underserved primary care patients". J Gen Intern Med. 2011 Nov;26(11):1297-304. Epub 2011 Jul 6.

578. Iyer G, Morris MJ, Rathkopf D, Slovin SF, Steers M, **Larson SM,** Schwartz LH, Curley T, Delacruz A, Ye Q, Heller G, Egorin MJ, Ivy SP, Rosen N, Scher HI, Solit DB. A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors. Cancer Chemother Pharmacol. 2011 Nov 29.

579. **Larson SM.** The Janus project: the remaking of nuclear medicine and radiology. J Nucl Med. 2011 Dec;52 Suppl 2:3S-9S. No abstract available

580. Stelter L, Evans MJ, Jungbluth AA, Zanzonico P, Ritter G, Ku T, Rosenfeld E, Bomalaski JS, Old L, **Larson SM.** Novel mechanistic insights into arginine deiminase pharmacology suggest 18F-FDG is not suitable to evaluate clinical response in melanoma J Nucl Med. 2012 Feb;53(2):281-6. Epub 2012 Jan 6.

581. Dennis ER, Jia X, Mezheritskiy IS, Stephenson RD, Schoder H, Fox JJ, Heller G, Scher HI, **Larson SM,** Morris MJ. Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer. J Clin Oncol. 2012 Feb 10;30(5):519-24. Epub 2012 Jan 9.

582. Ulmert D, Kaboteh R, Fox JJ, Savage C, Evans MJ, Lilja H, Abrahamsson PA, Björk T, Gerdtsson A, Bjartell A, Gjertsson P, Höglund P, Lomsky M, Ohlsson M, Richter J, Sadik M, Morris MJ, Scher HI, Sjöstrand K, Yu A, Suurküla M, Edenbrandt L, **Larson SM**. A Novel Automated Platform for Quantifying the Extent of Skeletal Tumour Involvement in Prostate Cancer Patients Using the Bone Scan Index. Eur Urol. 2012 Jan 27.

583. Brown MS, Chu GH, Kim HJ, Allen-Auerbach M, Poon C, Bridges J, Vidovic A, Ramakrishna B, Ho J, Morris MJ, **Larson SM,** Scher HI, Goldin JG. Computer-aided quantitative bone scan assessment of prostate cancer treatment response. Nucl Med Commun. 2012 Apr;33(4):384-394.

584. Schwartz J, Humm JL, Divgi CR, **Larson SM,** O'Donoghue JA. Bone Marrow Dosimetry Using 124I-PET. J Nucl Med. 2012 Apr;53(4):615-21 Epub 2012 Mar 13.

585. Ruby JA, Leibold T, Akhurst TJ, Shia J, Saltz LB, Mazumdar M, Riedel ER, **Larson SM**, Guillem JG. FDG-PET Assessment of Rectal Cancer Response to Neoadjuvant Chemoradiotherapy Is Not Associated With Long-Term Prognosis: A Prospective Evaluation. Dis Colon Rectum. 2012 Apr;55(4):378-86.

586. Kircher MF, Hricak H, **Larson SM.** Molecular imaging for personalized cancer care. Mol Oncol. 2012 Apr;6(2):182-95. Epub 2012 March 10

587. Morris PG, Ulaner GA, Eaton A, Fazio M, Jhaveri K, Patil S, Evangelista L, Park JY, Serna-Tamayo C, Howard J, **Larson S**, Hudis CA, McArthur HL, Jochelson MS. Standardized uptake value by positron emission tomography/computed tomography as a prognostic variable in metastatic breast cancer. Cancer. 2012 Apr 19. doi: 10.1002/cncr.27579. [Epub ahead of print]

588. Ulmert D, Evans MJ, Holland JP, Rice SL, Wongvipat J, Pettersson K, Abrahamsson PA, Scardino PT, **Larson SM,** Lilja H, Lewis JS, Sawyers CL. Imaging androgen receptor signaling with a radiotracer tartgeting free prostate-specific antigen. Cancer Discov. 2012 Apr;2(4):320-7. Epub 2012 March 31.

589. Fox JJ, Schöder H, **Larson SM.** Molecular imaging of prostate. Curr Opin Urol. 2012 Jul;22(4):320-7.

590. Stelter L, Tseng JC, Torosjan A, Levin B, Longo VA, Pillarsetty N, Zanzonico P, Meruelo D, **Larson SM.** Tumor-Specific Targeting With Modified Sindbis Viral Vectors: Evaluation with Optical Imaging and Positron Emission Tomography In Vivo. Mol Imaging Biol. 2012 Jul 31. [Epub ahead of print]

591. Nguyen V, Conyers JM, Zhu D, Gibo DM, Hantgan RR, **Larson SM**, Debinski W, Mintz. A. A novel ligand delivery system to non-invasively visualize and therapeutically exploit the IL13Rα2 tumor-restricted biomarker. Neuro Oncol. 2012 Oct;14(10):1239-53. Epub 2012 Sep 5.

592. Guillem JG, Ruby JA, Leibold T, Akhurst TJ, Yeung HW, Gollub MJ, Ginsberg MS, Shia J, Suriawinata AA, Riedel ER, Mazumdar M, Saltz LB, Minsky BD, Nash GM, Paty PB, Temple LK, Weiser MR, **Larson SM**. Neither FDG-PET Nor CT Is Able to Distinguish Between a Pathological Complete Response and an Incomplete Response After Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer: A Prospective Study. Ann Surg. 2012 Nov 26. [Epub ahead of print]

593. Benezra M, Hambardzumyan D, Penate-Medina O, Veach DR, Pillarsetty N, Smith-Jones P, Phillips E, Ozawa T, Zanzonico PB, Longo V, Holland EC, **Larson SM**, Bradbury MS. Fluorine-labeled Dasatinib Nanoformulations as Targeted Molecular Imaging Probes in a PDGFB-driven Murine Glioblastoma Model. Neoplasia. 2012 Dec;14(12):1132-43.

594. Gemignani ML, Patil S, Seshan VE, Sampson M, Humm JL, Lewis JS, Brogi E, **Larson SM**, Morrow M, Pandit-Taskar N. Feasibility and predictability of perioperative PET and estrogen receptor ligand in patients with invasive breast cancer. J Nucl Med. 2013 Oct;54(10):1697-702. doi: 10.2967/jnumed.112.113373. Epub 2013 Aug 22.

595. Yoo B, Cheal SM, Torchon G, Dilhas A, Yang G, Pu J, Punzalan B, **Larson SM**, Ouerfelli O. N-acetylgalactosamino dendrons as clearing agents to enhance liver targeting of model antibody-fusion protein. Bioconjug Chem. 2013 Dec 18;24(12):2088-103. doi: 10.1021/bc400333m. Epub 2013 Nov 18.

596. Rathkopf DE, Morris MJ, Fox JJ, Danila DC, Slovin SF, Hager JH, Rix PJ, Chow Maneval E, Chen I, Gönen M, Fleisher M, **Larson SM**, Sawyers CL, Scher HI. Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer. J Clin Oncol. 2013 Oct 1;31(28):3525-30. doi: 10.1200/JCO.2013.50.1684. Epub 2013 Sep 3.

597. Beylergil V, Morris PG, Smith-Jones PM, Modi S, Solit D, Hudis CA, Lu Y, O'Donoghue J, Lyashchenko SK, Carrasquillo JA, **Larson SM**, Akhurst TJ. Pilot study of 68Ga-DOTA-F(ab')2-trastuzumab in patients with breast cancer. Nucl Med Commun. 2013 Dec;34(12):1157-65. doi: 10.1097/MNM.0b013e328365d99b.

598. Ulaner GA, Eaton A, Morris PG, Lilienstein J, Jhaveri K, Patil S, Fazio M, **Larson S**, Hudis CA, Jochelson MS. Prognostic value of quantitative fluorodeoxyglucose measurements in newly diagnosed metastatic breast cancer. Cancer Med. 2013 Oct;2(5):725-33. doi: 10.1002/cam4.119. Epub 2013 Sep 12.

599. Stelter L, Evans MJ, Jungbluth AA, Longo VA, Zanzonico P, Ritter G, Bomalaski JS, Old L, **Larson SM**. Imaging of tumor vascularization using fluorescence molecular tomography to monitor arginine deiminase treatment in melanoma. Mol Imaging. 2013 Feb 1;12(1):67-73.

600. Ho AL, Grewal RK, Leboeuf R, Sherman EJ, Pfister DG, Deandreis D, Pentlow KS, Zanzonico PB, Haque S, Gavane S, Ghossein RA, Ricarte-Filho JC, Domínguez JM, Shen R, Tuttle RM, **Larson SM**, Fagin JA. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N Engl J Med. 2013 Feb 14;368(7):623-32. doi: 10.1056/NEJMoa1209288. PubMed PMID: 23406027.

601. Sabra MM, Dominguez JM, Grewal RK, **Larson SM**, Ghossein RA, Tuttle RM, Fagin JA. Clinical outcomes and molecular profile of differentiated thyroid cancers with radioiodine-avid distant metastases. J Clin Endocrinol Metab. 2013 May;98(5): E829-36. doi: 10.1210/jc.2012-3933. Epub 2013 Mar 26.

602. Ryan ER, Sofocleous CT, Schöder H, Carrasquillo JA, Nehmeh S, **Larson SM**, Thornton R, Siegelbaum RH, Erinjeri JP, Solomon SB. Split-dose technique for FDG PET/CT-guided percutaneous ablation: a method to facilitate lesion targeting and to provide immediate assessment of treatment effectiveness. Radiology. 2013 Jul;268(1):288-95. doi: 10.1148/radiol.13121462. Epub 2013 Apr 5.

603. Carrasquillo JA, O'Donoghue JA, Pandit-Taskar N, Humm JL, Rathkopf DE, Slovin SF, Williamson MJ, Lacuna K, Aksnes AK, **Larson SM**, Scher HI, Morris MJ. Phase I pharmacokinetic and biodistribution study with escalating doses of (223) Ra-dichloride in men with castration-resistant metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2013 Sep;40(9):1384-93. doi: 10.1007/s00259-013-2427-6. Epub 2013 May 8.

604. Buchegger F, Mach JP, Press OW, Bischof Delaloye A, **Larson SM**, Prior JO, Ketterer N. Improving the chance of cure of follicular lymphoma by combining immunotherapy and radioimmunotherapy based on anti-CD20 antibodies? Ann Oncol. 2013 Jul;24(7):1948-9. doi: 10.1093/annonc/mdt198. Epub 2013 May 23.

605. Tagawa ST, Milowsky MI, Morris MJ, Vallabhajosula S, Christos PJ, Akhtar NH, Goldsmith SJ, Osborne J, **Larson SM**, Pandit-Taskar N, Scher HI, Bander NH, Nanus DM. Phase II study of lutetium-177 labeled anti-prostate-specific membraneantigen (PSMA) monoclonal antibody J591 for metastatic castration-resistantprostate cancer. Clin Cancer Res. 2013 May 28. [Epub ahead of print]

606. Stelter L, Fuchs S, Jungbluth AA, Ritter G, Longo VA, Zanzonico P, Raschzok N, Sauer IM, Bomalaski JS, **Larson SM**. Evaluation of Arginine Deiminase Treatment in Melanoma Xenografts Using (18)F-FLT PET. Mol Imaging Biol. 2013 May 31. [Epub ahead of print]

607. Nixon IJ, Ganly I, Patel SG, Palmer FL, Di Lorenzo MM, Grewal RK, **Larson SM**, Tuttle RM, Shaha A, Shah JP. The results of selective use of radioactive iodine on survival and on recurrence in the management of papillary thyroid cancer, based on Memorial Sloan-Kettering Cancer Center risk group stratification. Thyroid. 2013 Jun;23(6):683-94. doi: 10.1089/thy.2012.0307.

608. Autio KA, Pandit-Taskar N, Carrasquillo JA, Stephenson RD, Slovin SF, Rathkopf DE, Hong C, Heller G, Scher HI, **Larson SM**, Morris MJ. Repetitively dosed docetaxel and (153) samarium-EDTMP as an antitumor strategy for metastatic castration-resistant prostate cancer. Cancer. 2013 Jun 13. doi:10.1002/cncr.28103. [Epub ahead of print]

609. Buchegger F, **Larson SM**, Mach JP, Chalandon Y, Dietrich PY, Cairoli A, Prior JO, Romero P, Daniel E. Radioimmunotherapy Combined with Maintenance Anti-CD20 Antibody May Trigger Long-Term Protective T Cell Immunity in Follicular Lymphoma Patients,.Speiser Clinical and Developmental Immunology Volume 2013 (2013), Article ID 875343

610. Cheal SM, Punzalan B, Doran MG, Evans MJ, Osborne JR, Lewis JS, Zanzonico P, **Larson SM.** Pairwise comparison of 89Zr- and 124I-labeled cG250 based on positron emission tomography imaging and nonlinear immunokinetic modeling: in vivo carbonic anhydrase IX receptor binding and internalization in mouse xenografts of clear-cell renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2014 May;41(5):985-94. doi: 10.1007/s00259-013-2679-1. Epub 2014 Mar 7.

611. Phillips E, Penate-Medina O, Zanzonico PB, Carvajal RD, Mohan P, Ye Y, Humm J, Gönen M, Kalaigian H, Schöder H, Strauss HW, **Larson SM**, Wiesner U, Bradbury MS. Clinical translation of an ultrasmall inorganic optical-PET imaging nanoparticle probe. Sci Transl Med. 2014 Oct 29;6(260):260ra149. doi: 10.1126/scitranslmed.3009524. Epub 2014 Oct 29.

612. Osborne JR, Green DA, Spratt DE, Lyashchenko S, Fareedy SB, Robinson BD, Beattie BJ, Jain M, Lewis JS, Christos P, **Larson SM**, Bander NH, Scherr DS. A prospective pilot study of (89) Zr-J591/prostate specific membrane antigen positron emission tomography in men with localized prostate cancer undergoing radical prostatectomy. J Urol. 2014 May;191(5):1439-45. doi: 10.1016/j.juro.2013.10.041. Epub 2013 Oct 14.

613. Thorek DL, Ulmert D, Diop NF, Lupu ME, Doran MG, Huang R, Abou DS, **Larson SM**, Grimm J. Non-invasive mapping of deep-tissue lymph nodes in live animals using a multimodal PET/MRI nanoparticle. Nat Commun. 2014; 5:3097. doi: 10.1038/ncomms4097.

614. Vargas HA, Wassberg C, Fox JJ, Wibmer A, Goldman DA, Kuk D, Gonen M, Larson SM, Morris MJ, Scher HI, Hricak H. Bone metastases in castration-resistant prostate cancer: associations between morphologic CT patterns, glycolytic activity, and androgen receptor expression on PET and overall survival. Radiology. 2014 Apr;271(1):220-9. doi: 10.1148/radiol.13130625. Epub 2013 Nov 18. [PubMed - indexed for MEDLINE]

615. Burger IA, Vargas HA, Apte A, Beattie BJ, Humm JL, Gonen M, **Larson SM**, Ross Schmidtlein C. PET quantification with a histogram derived total activity metric: superior quantitative consistency compared to total lesion glycolysis with absolute or relative SUV thresholds in phantoms and lung cancer patients. Nucl Med Biol. 2014 May-Jun;41(5):410-8. doi: 10.1016/j.nucmedbio.2014.02.006. Epub 2014 Feb 28.

616. Cheal SM, Xu H, Guo HF, Zanzonico PB, **Larson SM**, Cheung NK. Preclinical evaluation of multistep targeting of diasialoganglioside GD2 using an IgG-scFv bispecific antibody with high affinity for GD2 and DOTA metal complex. Mol Cancer Ther. 2014 Jul;13(7):1803-12. doi: 10.1158/1535-7163.MCT-13-0933. Epub 2014 Jun 18.

617. Pandit-Taskar N, O'Donoghue JA, Beylergil V, Lyashchenko S, Ruan S, Solomon SB, Durack JC, Carrasquillo JA, Lefkowitz RA, Gonen M, Lewis JS, Holland JP, Cheal SM, Reuter VE, Osborne JR, Loda MF, Smith-Jones PM, Weber WA, Bander NH, Scher HI, Morris MJ, **Larson SM**. ^{89}Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2014 Nov;41(11):2093-105. doi: 10.1007/s00259-014-2830-7. Epub 2014 Aug 21.

618. Phillips E, Penate-Medina O, Zanzonico PB, Carvajal RD, Mohan P, Ye Y, Humm J, Gönen M, Kalaigian H, Schöder H, Strauss HW, **Larson SM**, Wiesner U, Bradbury MS. Clinical translation of an ultrasmall inorganic optical-PET imaging nanoparticle probe.

619. **Larson SM**. Prostate cancer: Better use of bone scans in prostate cancer. Nat Rev Urol. 2014 Nov 11. doi: 10.1038/nrurol.2014.305. [Epub ahead of print] No abstract available.

620. Vilhelmsson-Timmermand O, Santos E, Thorek DL, Evans-Axelsson S, Bjartell A, Lilja H, **Larson SM**, Strand SE, Tran TA, Ulmert D. Radiolabeled antibodies in prostate cancer: A case study showing the effect of host immunity on antibody bio-distribution. Nucl Med Biol. 2014 Dec 23. pii: S0969-8051(14)00577-0. doi: 10.1016/j.nucmedbio.2014.12.012.

621. Morris MJ, Molina A, Small EJ, de Bono JS, Logothetis CJ, Fizazi K, de Souza P, Kantoff PW, Higano CS, Li J, Kheoh T, **Larson SM**, Matheny SL, Naini V, Burzykowski T, Griffin TW, Scher HI, Ryan CJ. Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results. J Clin Oncol. 2015 Apr 20;33(12):1356-63. doi: 10.1200/JCO.2014.55.3875. Epub 2015 Jan 26.

622. Autio KA, Pandit-Taskar N, Carrasquillo JA, Stephenson RD, Slovin SF, Rathkopf DE, Hong C, Heller G, Scher HI, **Larson SM**, Morris MJ. Repetitively dosed docetaxel and ^{153}samarium-EDTMP as an antitumor strategy for metastatic castration-resistant prostate cancer. Cancer. 2013 Sep 1; 119(17):3186-94. Doi: 10.1002/cncr.28103. Epub 2013 Jun 13.

623. **Larson SM**, Carrasquillo JA, Cheung NK, Press OW. Radioimmunotherapy of human tumours. Nat Rev Cancer. 2015 May 22;15(6):347-60. doi: 10.1038/nrc3925.

624. Zanzonico P, Carrasquillo JA, Pandit-Taskar N, O'Donoghue JA, Humm JL, Smith-Jones P, Ruan S, Divgi C, Scott AM, Kemeny NE, Fong Y, Wong D, Scheinberg D, Ritter G, Jungbluth A, Old LJ, **Larson SM**. PET-based compartmental modeling of (124)I-A33 antibody: quantitative characterization of patient-specific tumor targeting in colorectal cancer. Eur J Nucl Med Mol Imaging. 2015 Oct;42(11):1700-6. doi: 10.1007/s00259-015-3061-2. Epub 2015 Jul 21.

625. **Larson SM**. EXINI Quantitative Bone Scan Index: Expanded utility for the planar radionuclide bone scan. Journal of Nuclear Medicine. 2015 October 8; 57(1); 5-6. Doi: 10.2967/jnumed.115.164137. Epub 2016 January 1.

626. Cheal SM, Xu H, Guo HF, Lee SG, Punzalan B, Chalasani S, Fung EK, Jungbluth A, Zanzonico PB, Carrasquillo JA, O'Donoghue J, Smith-Jones PM, Wittrup KD, Cheung NV, **Larson SM**. Theranostic pretargeted radioimmunotherapy of colorectal cancer xenografts in mice using picomolar affinity ⁸⁶Y- or ¹⁷⁷Lu-DOTA-Bn binding scFv C825/GPA33 IgG bispecific immunoconjugates. Eur J Nucl Med Mol Imaging. 2015 Nov 24. [Epub ahead of print].

627. Fung Edward K, Cheal SM, Fareedy Shoaib, Punzalan Blesida, **Larson SM,** et al. Targeting of radiolabeled J591 antibody to PSMA-expressing tumors: optimization of imaging and therapy based on non-linear compartmental modeling. Eur J Nucl Med Mol Imaging. 2016 Dec; 6(1):2191-219X. doi: 10.1186/s13550-016-0164-0. Epub 2016 Jan 22.

628. Taldone T, Zatorska D, Ochiana SO, Smith-Jones P, Koziorowski J, Dunphy MP, Zanzonico P, Bolaender A, Lewis JS, **Larson SM**, Chiosis G, Pillarsetty NV. Radiosynthesis of the iodine-124 labeled Hsp90 inhibitor PU-H71. J Labelled Comp Radiopharm. 2016 Jan 25. doi: 10.1002/jlcr.3369. [Epub ahead of print].

629. Pandit-Taskar N, Veach DR, Fox JJ, Scher HI, Morris MJ, **Larson SM**. Evaluation of Castration-Resistant Prostate Cancer with Androgen Receptor-Axis Imaging. J Nucl Med. 2016 Oct; 57(Suppl 3):73S-78S.

630. Sood A, Miller AM, Brogi E, Sui Y, Armenia J, McDonough E, Santamaria-Pang A, Carlin S, Stamper A, Campos C, Pang Z, Li Q, Port E, Graeber TG, Schultz N, Ginty F, **Larson SM,** Mellinghoff IK. Multiplexed immunofluorescence delineates proteomic cancer cell states associated with metabolism. JCI Insight. 2016 May 5;1(6). pii: e87030.

631. Anand A, Morris MJ, **Larson SM**, Minarik D, Josefsson A, Helgstrand JT, Oturai PS, Edenbrandt L, Røder MA, Bjartell A. Automated Bone Scan Index as a quantitative imaging biomarker in metastatic castration-resistant prostate cancer patients being treated with enzalutamide. EJNMMI Res. 2016 Dec;6(1):23. doi: 10.1186/s13550-016-0173-z. Epub 2016 Mar 9.

632. Deandreis D, Rubino C, Tala H, Leboulleux S, Terroir M, Baudin E, **Larson S**, Fagin JA, Schlumberger M, Tuttle RM. Comparison of Empiric Versus Whole-Body/-Blood Clearance Dosimetry-Based Approach to Radioactive Iodine Treatment in Patients with Metastases from Differentiated Thyroid Cancer. J Nucl Med. 2017 May;58(5):717-722. doi: 10.2967/jnumed.116.179606. Epub 2016 Oct 13. PMID: 27738010.

633. Lee SG, Gangangari K, Kalidindi TM, Punzalan B, **Larson SM**, Pillarsetty NV. Copper-64 labeled liposomes for imaging bone marrow. Nucl Med Biol. 2016 Dec;43(12):781-787. doi: 10.1016/j.nucmedbio.2016.08.011. Epub 2016 Aug 27.

634. Rodina A, Wang T, Yan P, Gomes ED, Dunphy MP, Pillarsetty N, Koren J, Gerecitano JF, Taldone T, Zong H, Caldas-Lopes E, Alpaugh M, Corben A, Riolo M, Beattie B, Pressl C, Peter RI, Xu C, Trondl R, Patel HJ, Shimizu F, Bolaender A, Yang C, Panchal P, Farooq MF, Kishinevsky S, Modi S, Lin O, Chu F, Patil S, Erdjument-Bromage H, Zanzonico P, Hudis C, Studer L, Roboz GJ, Cesarman E, Cerchietti L, Levine R, Melnick A, **Larson SM**, Lewis JS, Guzman ML, Chiosis G. The epichaperome is an integrated chaperome network that facilitates tumour survival. Nature. 2016 Oct 20;538(7625):397-401. doi: 10.1038/nature19807.

635. Nagarajah J, Le M, Knauf JA, Ferrandino G, Montero-Conde C, Pillarsetty N, Bolaender A, Irwin C, Krishnamoorthy GP, Saqcena M, **Larson SM**, Ho AL, Seshan V, Ishii N, Carrasco N, Rosen N, Weber WA, Fagin JA. Sustained ERK inhibition maximizes responses of BrafV600E thyroid cancers to radioiodine. J Clin Invest. 2016 Nov 1;126(11):4119-4124. doi: 10.1172/JCI89067. Epub 2016 Sep 26. PMID: 27669459; PMCID: PMC5096947.

636. Fox JJ, Gavane SC, Blanc-Autran E, Nehmeh S, Gönen M, Beattie B, Vargas HA, Schöder H, Humm JL, Fine SW, Lewis JS, Solomon SB, Osborne JR, Veach D, SawyersCL, Weber WA, Scher HI, Morris MJ, **Larson SM**. Positron Emission Tomography/Computed Tomography-Based Assessments of Androgen Receptor Expression and Glycolytic Activity as a Prognostic Biomarker for Metastatic Castration-Resistant Prostate Cancer. JAMA Oncol. 2017 Nov 9: e173588. doi:10.1001/jamaoncol.2017.3588. [Epub ahead of print] PubMed PMID: 29121144.

637. Pankov D, Sjöström L, Kalidindi T, Lee SG, Sjöström K, Gardner R, McDevitt MR, O'Reilly R, Thorek DLJ, **Larson SM**, Veach D, Ulmert D. In vivo immuno-targeting ofan extracellular epitope of membrane bound preferentially expressed antigen in melanoma (PRAME). Oncotarget. 2017 Jul 26;8(39):65917-65931. doi:10.18632/oncotarget.19579. eCollection 2017 Sep 12. PubMed PMID: 29029482; PubMed Central PMCID: PMC5630382.

638. Kramer K, Pandit-Taskar N, Humm JL, Zanzonico PB, Haque S, Dunkel IJ, Wolden SL, Donzelli M, Goldman DA, Lewis JS, Lyashchenko SK, Khakoo Y, Carrasquillo JA, Souweidane MM, Greenfield JP, Lyden D, De Braganca KD, Gilheeney SW, **Larson SM**, Cheung NV. A phase II study of radioimmunotherapy with intraventricular (131) I-3F8 for medulloblastoma. Pediatr Blood Cancer. 2018 Jan;65(1). doi:10.1002/pbc.26754. Epub 2017 Sep 22. PubMed PMID: 28940863.

639. Herrmann K, **Larson SM**, Weber WA. Theranostic Concepts: More Than Just a Fashion Trend-Introduction and Overview. J Nucl Med. 2017 Sep;58(Suppl 2):1S-2S. doi: 10.2967/jnumed.117.199570. PubMed PMID: 28864608.

640. Cheal SM, Fung EK, Patel M, Xu H, Guo HF, Zanzonico PB, Monette S, Wittrup KD, Cheung NV, **Larson SM**. Curative Multicycle Radioimmunotherapy Monitored by Quantitative SPECT/CT-Based Theranostics, Using Bispecific Antibody Pretargeting Strategy in Colorectal Cancer. J Nucl Med. 2017 Nov;58(11):1735-1742. doi:10.2967/jnumed.117.193250. Epub 2017 Jul 13. PubMed PMID: 28705917; PubMed Central PMCID: PMC5666642.

641. Pandit-Taskar N, Zanzonico P, Staton KD, Carrasquillo JA, Reidy-Lagunes D, Lyashchenko S, Burnazi E, Zhang H, Lewis JS, Blasberg R, **Larson SM**, Weber WA, Modak S. Biodistribution and Dosimetry of (18)F-Meta-Fluorobenzylguanidine: A First-in-Human PET/CT Imaging Study of Patients with Neuroendocrine Malignancies. J Nucl Med. 2018 Jan;59(1):147-153. doi: 10.2967/jnumed.117.193169. Epub 2017 Jul 13. PubMed PMID: 28705916; PubMed Central PMCID: PMC5750519.

642. Osborne JR, Kalidindi TM, Punzalan BJ, Gangangari K, Spratt DE, Weber WA, **Larson SM**, Pillarsetty NVK. Erratum to: Repeatability of [(68) Ga] DKFZ11-PSMA PET Scans for Detecting Prostate-specific Membrane Antigen-positive Prostate Cancer. Mol Imaging Biol. 2017 Dec;19(6):952. doi: 10.1007/s11307-017-1104-8. PubMed PMID: 28695370.

643. Harmon SA, Perk T, Lin C, Eickhoff J, Choyke PL, Dahut WL, Apolo AB, Humm JL, **Larson SM,** Morris MJ, Liu G, Jeraj R. Quantitative Assessment of Early [(18)F] Sodium Fluoride Positron Emission Tomography/Computed Tomography Response to Treatment in Men with Metastatic Prostate Cancer to Bone. J Clin Oncol. 2017 Aug 20;35(24):2829-2837. doi: 10.1200/JCO.2017.72.2348. Epub 2017 Jun 27. PubMed PMID: 28654366; PubMed Central PMCID: PMC5562173.

644. O'Donoghue JA, Lewis JS, Pandit-Taskar N, Fleming SE, Schöder H, **Larson SM**, Beylergil V, Ruan S, Lyashchenko SK, Zanzonico PB, Weber WA, Carrasquillo JA, Janjigian YY. Pharmacokinetics, Biodistribution, and Radiation Dosimetry for (89) Zr-Trastuzumab in Patients with Esophagogastric Cancer. J Nucl Med. 2018 Jan;59(1):161-166. doi: 10.2967/jnumed.117.194555. Epub 2017 Jun 21. PubMed PMID:28637800; PubMed Central PMCID: PMC5750520.

645. Osborne JR, Kalidindi TM, Punzalan BJ, Gangangari K, Spratt DE, Weber WA, **Larson SM**, Pillarsetty NVK. Repeatability of [(68) Ga] DKFZ11-PSMA PET Scans for Detecting Prostate-specific Membrane Antigen-positive Prostate Cancer. Mol Imaging Biol. 2017 Dec;19(6):944-951. doi: 10.1007/s11307-017-1091-9. Erratum in: Mol Imaging Biol. 2017 Jul 10. PubMed PMID: 28534214; PubMed Central PMCID: PMC5664162.

646. Abou-Alfa GK, Yen CJ, Hsu CH, O'Donoghue J, Beylergil V, Ruan S, Pandit-Taskar N, Gansukh B, Lyashchenko SK, Ma J, Wan P, Shao YY, Lin ZZ, Frenette C, O'Neil B, Schwartz L, Smith-Jones PM, Ohtomo T, Tanaka T, Morikawa H, Maki Y, Ohishi N, Chen YC, Agajanov T, Boisserie F, Di Laurenzio L, Lee R, **Larson SM**, Cheng AL, Carrasquilo JA. Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC). Cancer Chemother Pharmacol. 2017 Feb;79(2):421-429. doi:10.1007/s00280-017-3241-9. Epub 2017 Jan 24. PubMed PMID: 28120036; PubMed Central PMCID: PMC5548107.

647. Graham NA, Minasyan A, Lomova A, Cass A, Balanis NG, Friedman M, Chan S, Zhao S, Delgado A, Go J, Beck L, Hurtz C, Ng C, Qiao R, Ten Hoeve J, Palaskas N, Wu H, Müschen M, Multani AS, Port E, **Larson SM**, Schultz N, Braas D, Christofk HR, Mellinghoff IK, Graeber TG. Recurrent patterns of DNA copy number alterations in tumors reflect metabolic selection pressures. Mol Syst Biol. 2017 Feb 15;13(2):914. doi: 10.15252/msb.20167159. PubMed PMID: 28202506; PubMed Central PMCID: PMC5327725

648. Kramer K, Kushner B, Modak S, Pandit-Taskar N, Tomlinson U, Donzelli M, Wolden S, Zanzonico P, Humm J, Haque S, Souweidane M, Greenfield J, Basu E, Roberts S, Carrasquillo J, Lewis J, Lyashchenko S, **Larson S**, Cheung NK. PDCT-04. SAFETY AND EFFICACY OF INTRAVENTRICULAR 131I-LABELED MONOCLONAL ANTIBODY 8H9 TARGETING THE SURFACE GLYCOPROTEIN B7-H3 IN PATIENTS WITH CNS/LM DISEASE. Neuro Oncol. 2017 Nov;19(Suppl 6):vi184. doi: 10.1093/neuonc/nox168.748. Epub 2017 Nov 6. PMCID: PMC5693087.

649. Vargas HA, Kramer GM, Scott AM, Weickhardt A, Meier AA, Parada N, Beattie BJ, Humm JL, Staton KD, Zanzonico PB, Lyashchenko SK, Lewis JS, Yaqub M, Sosa RE, van den Eertwegh AJ, Davis ID, Ackermann U, Pathmaraj K, Schuit RC, Windhorst AD, Chua S, Weber WA, **Larson SM**, Scher HI, Lammertsma AA, Hoekstra OS, Morris MJ. Reproducibility and Repeatability of Semiquantitative (18)F-Fluorodihydrotestosterone Uptake Metrics in Castration-Resistant Prostate Cancer Metastases: A Prospective Multicenter Study. J Nucl Med. 2018 Oct;59(10):1516-1523. doi: 10.2967/jnumed.117.206490. Epub 2018 Apr 6. PubMed PMID: 29626121; PubMed Central PMCID: PMC6167532.

650. Thorek DL, Ku AT, Mitsiades N, Veach D, Watson PA, Mehta D, Strand SE, Sharma SK, Lewis JS, Abou DS, Lilja HG, **Larson SM**, McDevitt MR, Ulmert D. Harnessing Androgen-Receptor Pathway Activation for Targeted Alpha Particle Radioimmunotherapy of Breast Cancer. Clin Cancer Res. 2018 Sep 25. pii: clincanres.1521.2018. doi: 10.1158/1078-0432.CCR-18-1521. [Epub ahead of print] PubMed PMID: 30254080.

651. Dunn LA, Sherman EJ, Baxi SS, Tchekmedyian V, Grewal RK, **Larson SM**, Pentlow KS, Haque S, Tuttle RM, Sabra MM, Fish S, Boucai L, Walters J, Ghossein RA, Seshan VE, Ni A, Li D, Knauf JA, Pfister DG, Fagin JA, Ho AL. Vemurafenib Redifferentiation of BRAF Mutant, RAI-Refractory Thyroid Cancers. J Clin Endocrinol Metab. 2018 Sep 25. doi: 10.1210/jc.2018-01478. [Epub ahead of print] PubMed PMID: 30256977.

652. Souweidane MM, Kramer K, Pandit-Taskar N, Zhou Z, Haque S, Zanzonico P, Carrasquillo JA, Lyashchenko SK, Thakur SB, Donzelli M, Turner RS, Lewis JS, Cheung NV, **Larson SM**, Dunkel IJ. Convection-enhanced delivery for diffuse intrinsic pontine glioma: a single-centre, dose-escalation, phase 1 trial. Lancet Oncol. 2018 Aug;19(8):1040-1050. doi: 10.1016/S1470-2045(18)30322-X. Epub 2018 Jun 18. Erratum in: Lancet Oncol. 2018 Aug;19(8): e382. PubMed PMID: 29914796.

653. Krebs S, Ahad A, Carter L, Eyquem J, Brand C, Bell M, Ponomarev V, Reiner T, Meares CF, Gottschalk S, Sadelain M, **Larson SM**, Weber WA. Antibody with infinite affinity for in vivo tracking of genetically engineered lymphocytes. J Nucl Med. 2018 Jun 14. pii: jnumed.118.208041. doi: 10.2967/jnumed.118.208041. [Epub ahead of print] PubMed PMID: 29903928.

654. Cheal SM, Ruan S, Veach DR, Longo VA, Punzalan BJ, Wu J, Fung EK, Kelly MP, Kirshner JR, Giurleo JT, Ehrlich G, Han AQ, Thurston G, Olson WC, Zanzonico PB, **Larson SM**, Carrasquillo JA. ImmunoPET Imaging of Endogenous and Transfected Prolactin Receptor Tumor Xenografts. Mol Pharm. 2018 Jun 4;15(6):2133-2141. doi: 10.1021/acs.molpharmaceut.7b01133. Epub 2018 Apr 30. PubMed PMID: 29684277.

655. Gangangari KK, Humm JL, **Larson SM**, Pillarsetty NVK. TMSOTf assisted synthesis of 2'deoxy-2'-[18F] fluoro-β-D-arabinofuranosylcytosine ([18F] FAC). PLoS One. 2018 May 1;13(5): e0196784. doi: 10.1371/journal.pone.0196784. eCollection 2018. PubMed PMID: 29715301; PubMed Central PMCID: PMC5929562.

656. McDevitt MR, Thorek DLJ, Hashimoto T, Gondo T, Veach DR, Sharma SK, Kalidindi TM, Abou DS, Watson PA, Beattie BJ, Timmermand OV, Strand SE, Lewis JS, Scardino PT, Scher HI, Lilja H, **Larson SM**, Ulmert D. Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancer. Nat Commun. 2018 Apr 24;9(1):1629. doi: 10.1038/s41467-018-04107-w. PubMed PMID: 29691406; PubMed Central PMCID: PMC5915579.

657. Carrasquillo JA, O'Donoghue JA, Beylergil V, Ruan S, Pandit-Taskar N, **Larson SM**, Smith-Jones PM, Lyashchenko SK, Ohishi N, Ohtomo T, Abou-Alfa GK. I-124 codrituzumab imaging and biodistribution in patients with hepatocellular carcinoma. EJNMMI Res. 2018 Mar 5;8(1):20. doi: 10.1186/s13550-018-0374-8. PubMed PMID: 29508107; PubMed Central PMCID: PMC5838028.
658. **Larson SM**, Ruiz-Lambides A, Platt ML, Brent LJN. Social network dynamics precede a mass eviction in group-living rhesus macaques. Anim Behav. 2018 Feb; 136:185-193. doi: 10.1016/j.anbehav.2017.08.019. Epub 2017 Sep 28. PubMed PMID: 29887618; PubMed Central PMCID: PMC5990275.
659. Fox JJ, Gavane SC, Blanc-Autran E, Nehmeh S, Gönen M, Beattie B, Vargas HA,Schöder H, Humm JL, Fine SW, Lewis JS, Solomon SB, Osborne JR, Veach D, Sawyers CL, Weber WA, Scher HI, Morris MJ, **Larson SM**. Positron Emission Tomography/Computed Tomography Based Assessments of Androgen Receptor Expression and Glycolytic Activity as a Prognostic Biomarker for Metastatic Castration-Resistant Prostate Cancer. JAMA Oncol. 2018 Feb 1;4(2):217-224. doi:10.1001/jamaoncol.2017.3588. PubMed PMID: 29121144.
660. Pandit-Taskar N, Zanzonico P, Staton KD, Carrasquillo JA, Reidy-Lagunes D, Lyashchenko S, Burnazi E, Zhang H, Lewis JS, Blasberg R, **Larson SM**, Weber WA, Modak S. Biodistribution and Dosimetry of (18)F-Meta-Fluorobenzylguanidine: A First-in-Human PET/CT Imaging Study of Patients with Neuroendocrine Malignancies. J Nucl Med. 2018 Jan;59(1):147-153. doi: 10.2967/jnumed.117.193169. Epub 2017 Jul 13. PubMed PMID: 28705916; PubMed Central PMCID: PMC5750519.
661. O'Donoghue JA, Lewis JS, Pandit-Taskar N, Fleming SE, Schöder H, **Larson SM,** Beylergil V, Ruan S, Lyashchenko SK, Zanzonico PB, Weber WA, Carrasquillo JA, Janjigian YY. Pharmacokinetics, Biodistribution, and Radiation Dosimetry for (89) Zr-Trastuzumab in Patients with Esophagogastric Cancer. J Nucl Med. 2018 Jan;59(1):161-166. doi: 10.2967/jnumed.117.194555. Epub 2017 Jun 21. PubMed PMID:28637800; PubMed Central PMCID: PMC5750520.
662. Kramer K, Pandit-Taskar N, Humm JL, Zanzonico PB, Haque S, Dunkel IJ, Wolden SL, Donzelli M, Goldman DA, Lewis JS, Lyashchenko SK, Khakoo Y, Carrasquillo JA, Souweidane MM, Greenfield JP, Lyden D, De Braganca KD, Gilheeney SW, **Larson SM**, Cheung NV. A phase II study of radioimmunotherapy with intraventricular (131) I-3F8 for medulloblastoma. Pediatr Blood Cancer. 2018 Jan;65(1). doi:10.1002/pbc.26754. Epub 2017 Sep 22. PubMed PMID: 28940863.
663. Fox JJ, Gavane SC, Blanc-Autran E, Nehmeh S, Gonen M, Beattie B, Vargas HA, Schoder H, Humm JL, Fine SW, Lewis JS, Solomon SB, Osborne JR, Veach D, Sawyers CL, Weber W, Scher H, Morris MJ, **Larson SM.** Positron Emission Tomography/ Computed Tomography-Based Assessments of Androgen Receptor Expression and Glycolytic Activity as a prognostic Biomarker for Metastatic Castration-Resistant Prostate Cancer. JAMA Oncol. 2018 Feb 1; 4(2):271-224. Doi: 10.1001/jamaoncolo.20173588. PubmMed PMID:29121144; PubMed Central PMCID: PMC6231549.
664. **Larson SM**, Cheal SM. New Insights in Theragnostics: Pre-targeted Radioimmunotherapy for Cure of Solid Human Tumors. World Journal of Nuclear Medicine / Volume 18 / Issue 2 / April-June 2019, pages 206-207.
665. Thorek DLJ., Ku AT., Mitsiades N., Veach D., Watson PA., Metha D., Strand SE., Sharma SK., Lewis JS., Abou DS., Lilja HG., **Larson, S. M.**, McDevitt MR., Ulmert D. Harnessing androgen receptor pathway activation for targeted alpha particle radioimmunotherapy of breast cancer. *Clinical Cancer Research.* 2019 January 15*;*25(2):881-891. Doi: 10.1158/1078-0432.Ccr-18-1521. PubMed PMID: 30254080. PubMed Central: PMC6524527.

666. Sanchez-Vega F., Hechtman JF., Castel P., Ku GY., Tuvy Y., Won H., Fong CJ., Bouvier N., Nanjangud GJ., Soong J., Vakiani E., Schattner M., Kelsen DP., Lefkowitz RA., Brown K., Lacouture ME., Capanu M., Mattar M., Qeriqi B., Cecchi F., Tian Y., Hembrough T., Nagy RJ., Lanman RB., **Larson SM.**, Pandit-Taskar N., Schöder H., Iacobuzio-Donahue CA., Ilson DH., Weber WA., Berger MF., de Stanchina E., Taylor BS., Lewis JS., Solit DB., Carrasquillo JA., Scaltriti M., Schultz N., Janjigian YY. EGFR and MET amplifications determine response to HER2 inhibition in ERBB2-amplified esophagogastric cancer. *Cancer Discovery.* 2019 February 1; 199(10). Volume 9, Issue 2. Doi.org/10.1158/2159-8290.Cd-18-0598. PubMed PMID: 30463996. PubMed Central PMCID: PMC6368868.

667. **Larson SM**; Czernin J. Discussions with leaders: A conversation between Steven Larson and Johannes Czernin. *Journal of Nuclear Medicine.* 2019 February 1; 60(2): 151-155. Doi.org/https://www.scopus.com/inward/record.uri?eid=2-s2.0-85060950719&partnerID=40&md5=ceb21dc2210da4cabd456e7cfba588f9.

668. Osborne JR, Kondraciuk JD, Rice SL, Zhou X, Knezevic A, Spratt DE, Sabra M, **Larson SM**, Grewal RK. Thyroid Cancer Brain Metastasis: Survival and Genomic Characteristics of a Large Tertiary Care Cohort. Clin Nucl Med. 2019 May 3; doi: 10.1097/RLU.0000000000002618. [Epub ahead of print] PubMed PMID: 31107749; NIHMSID: NIHMS1526159.

669. Carrasquillo JA, Fine BM, Pandit-Taskar N, **Larson SM**, Fleming SE, Fox JJ, *et al.* Imaging Patients with Metastatic Castration-Resistant Prostate Cancer Using 89Zr-DFO-MSTP2109A Anti-STEAP1 Antibody. *Journal of Nuclear Medicine* n.d.;60::1517–23. https://doi.org/10.2967/jnumed.118.222844. 2019 Nov 1. PubMed PMID: 31053681; Pubed Central PMCID: PMC6836860.

670. Pandit-Taskar, Neeta, Zanzonico, Pat B, Kramer, Kim, Grkovski, Milan, Fung, Edward K, Shi, Weiji, et al. Biodistribution and Dosimetry of Intraventricularly Administered 124 I-Omburtamab in Patients with Metastatic Leptomeningeal Tumors. Journal of Nuclear Medicine 2019;60::1794–801. https://doi.org/10.2967/jnumed.118.219576. 2019 Dec 1. PubMed PMID:31405921.

671. Dunn LA, Sherman EJ, Baxi SS, Tchekmedyian V, Grewal RK, **Larson SM**, Pentlow KS, Haque S, Tuttle RM, Sabra MM, Fish S, Boucai L, Walters J, Ghossein RA, Seshan VE, Ni A, Li D, Knauf JA, Pfister DG, Fagin JA, Ho AL. Vemurafenib Redifferentiation of BRAF Mutant, RAI-Refractory Thyroid Cancers. J Clin Endoccrinol Metab. 2019 May 1; 104(5): 1417-1428. Doi 10.1210/jc.2018-01478. PubMed PMID:30256977; PubMed Central PMCID: PMC6435099.

672. Weisman AJ., Harmon SA., Perk TG., Eickhoff J., Choyke PL., Kurdziel KA., Dahut WL., Humm JL., Apolo AB., **Larson SM.**, Morris MJ., Perlman SB., Liu G., Jeraj R. Quantification of bone flare on (18)F-NaF PET/CT in metastatic castration-resistant prostate cancer. Prostate Cancer and Prostatic Diseases. Volume 22, Issue 2. 2019 May 1; 324: 1365-7852. Doi.org/10.1038/s41391-018-0110-5. Pubmed PMID: 30413807.

673. Souweidane M M., Kramer K., Pandit-Taskar N., Zhou Z., Zanzonico P., Donzelli M., Lyashchenko S. K., Haque, S.; Thakur, S. B.; Cheung, N. K. V.; **Larson, S.** M.; Dunkel, I. J. A phase I study of convection-enhanced delivery of (124)I-8H9 radio-labeled monoclonal antibody in children with diffuse intrinsic pontine glioma: An update with dose-response assessment. Journal of Clinical Oncology. 2019 May 20; Volume 37, Issue 15 Suppl. p89s. Doi.org/10.1200/JCO.2019.37.15_suppl.2008.

674. Carrasquillo J. A., Morris P. G., Humm J. L., Smith-Jones P. M., Beylergil V., Akhurst T., O'Donoghue J. A., Ruan S., Modi S., Hudis C. A., **Larson S. M**. Copper-64 trastuzumab PET imaging: A reproducibility study. Quarterly Journal of Nuclear Medicine and Molecular Imaging. 2019 June 1. Volume 63, Issue 2, Doi.org/10.23736/s1824-4785.16.02867-3. PubMed PMID: 27171605.

675. O'Donoghue J. A., Danila D. C., Pandit-Taskar N., Beylergil V., Cheal S. M., Fleming S. E., Fox J. J., Ruan S., Zanzonico P. B., Ragupathi G., Lyashchenko S. K., Williams S. P., Scher, H. I., Fine B. M., Humm J. L., **Larson, S. M**., Morris M. J., Carrasquillo J. A.. Pharmacokinetics and biodistribution of a [(86)Zr]Zr-DFO-MSTP2109A anti-STEAP1 antibody in metastatic castration-resistant prostate cancer patients. Molecular Pharmaceutics. 2019 July 1; Volume 16, Issue 7. Doi.org/10.1021/acs.molpharmaceut.9b00326. PubMed PMID: 31117485.

676. Osborne JR., Kondraciuk JD., Rice SL., Zhou X., Knezevic A., Spratt DE., Sabra M., **Larson S. M.**, Grewal RK. Thyroid cancer brain metastasis: Survival and genomic characteristics of a large tertiary care cohort. Clinical Nuclear Medicine. 2019 July 1. Volume 44, Issue 7. Doi.org/10.1097/rlu.0000000000002618. PubMed PIMD: 31107749. PubMed Central PMCID: PMC6546545.

677. Kondraciuk J. D., Rice S. L., Zhou X., Gharzeddine K., Knezevic A., Spratt D. E., Sabra M., **Larson, S. M.**, Grewal R. K., Osborne J. R. Thyroid cancer bone metastasis: Survival and genomic characteristics of a large tertiary care cohort. Clinical Nuclear Medicine. 2019 August 1. Volume 44, Issue 8. Doi.org/10.1097/rlu.0000000000002626. PubMed PIMD: 31274625. PubMed Central PMCID: PMC6621602.

678. **Steven M. Larson.** Do you want an inspirational career? Choose nuclear medicine. Journal of Nuclear Medicine. 2019 September 1. Volume 60; Issue Suppl. 2. Doi.org/10.2967/jnumed.118.220574. PubMed PMID: 31481586.

679. Kramer K., Kushner B., Modak S., Pandit-Taskar N., Mauguen A., Tomlinson U., Wolden S., Zanzonico P., Humm J., Haque S., Souweidane M., Greenfield J., Basu E., Roberts S., Carrasquillo J., Lewis J., Lyashchenko S., **Larson S**., Cheung N. K. A curative approach to central nervous system metastases of neuroblastoma. Pediatric Blood and Cancer. 2019 December 1; Volume 66, Issue Suppl.4. Doi.org/10.1002/pbc.27989. PubMed PMID: 31568621.

680. Nagavarakishore Pillarsetty, Komal Jhaveri, Tony Taldone, Eloisi Caldas-Lopes, Blesida Punzalan, Suhasini Joshi, Alexander Bolaender, Mohammad M. Uddin, Anna Rodina, Pengrong Yan, Anson Ku, Thomas Ku, Smit K. Shah, Serge Lyashchenko, Eva Burnazi, Tai Wang, Nicolas Lecomte, Yelena Janjigian, Anas Younes, Connie W. Batlevi, Monica L. Guzman, Gail J. Roboz, Jacek Koziorowski, Pat Zanzonico, Mary L. Alpaugh, Adriana Corben, Shanu Modi, Larry Norton, **Steven M. Larson**, Jason S. Lewis, Gabriela Chiosis, John F. Gerecitano, Mark P.S. Dunphy. Paradigms for Precision Medicine in Epichaperome Cancer Therapy, Cancer Cell. Volume 36, Issue 5. Doi.org/10.1016/j.ccell.2019.09.007. 11 November 2019, p. 559-573. e7. PubMed PMID: 31668946.

681. Gangangari KK, Váradi A, Majumdar S, **Larson SM**, Pasternak GW, Pillarsetty NK. Imaging Sigma-1 Receptor (S1R) Expression Using Iodine-124-Labeled 1-(4-Iodophenyl)-3-(2-adamantyl)guanidine ([124I]IPAG). Mol Imaging Biol. 2020 Apr;22(2):358-366. doi: 10.1007/s11307-019-01369-8. PMID: 31165385; PMCID: PMC6893110.

682. **Larson SM**. Wil Borchers Nelp, MD (1930-2020). J Nucl Med. 2020 Jun;61(6):19N-20N. PMID: 32499286.

683. Bicak M, Lückerath K, Kalidindi T, Phelps ME, Strand SE, Morris MJ, Radu CG, Damoiseaux R, Peltola MT, Peekhaus N, Ho A, Veach D, Malmborg Hager AC, **Larson SM**, Lilja H, McDevitt MR, Klein RJ, Ulmert D. Genetic signature of prostate cancer mouse models resistant to optimized hK2 targeted α-particle therapy. Proc Natl Acad Sci U S A. 2020 Jun 30;117(26):15172-15181. doi: 10.1073/pnas.1918744117. Epub 2020 Jun 12. PMID: 32532924; PMCID: PMC7334567.

684. Lee SG, Muralidhar Kalidindi T, Lou H, Gangangari K, Punzalan B, Bitton A, Lee C, Park S, Bodei L, Kharas M, Singh VK, Pillarsetty N, **Larson SM**. Gamma-Tocotrienol loaded liposomes as radioprotection from hematopoietic side effects caused by radiotherapeutic drugs. J Nucl Med. 2020 Aug 21:jnumed.120.244681. doi: 10.2967/jnumed.120.244681. Epub ahead of print. PMID: 32826318.

685. Wise DR, Schneider JA, Armenia J, Febles VA, McLaughlin B, Brennan R, Thoren KL, Abida W, Sfanos KS, De Marzo AM, Yegnasubramanian S, Fox JJ, Haas M, Heath H, Kagey MH, Newman W, Sirard CA, Fleisher M, Morris MJ, Chen Y, **Larson SM**, Haffner MC, Nelson PS, Schultz N, Garabedian MJ, Scher HI, Logan SK, Sawyers CL; International SU2C/PCF Prostate Cancer Dream Team. Dickkopf-1 Can Lead to Immune Evasion in Metastatic Castration-Resistant Prostate Cancer. JCO Precis Oncol. 29 September 2020;4:PO.20.00097. doi: 10.1200/PO.20.00097. PMID: 33015525; PMCID: PMC7529521.

686. Cheal SM, McDevitt MR, Santich BH, Patel M, Yang G, Fung EK, Veach DR, Bell M, Ahad A, Vargas DB, Punzalan B, Pillarsetty NVK, Xu H, Guo HF, Monette S, Michel AO, Piersigilli A, Scheinberg DA, Ouerfelli O, Cheung NV, **Larson SM**. Alpha radioimmunotherapy using 225Ac-proteus-DOTA for solid tumors - safety at curative doses. Theranostics. 14 September 2020;10(25):11359-11375. doi: 10.7150/thno.48810. PMID: 33052220; PMCID: PMC7546012.

687. Roncali E, Capala J, Benedict SH, Akabani G, Bednarz B, Bhadrasain V, Bolch WE, Buchsbaum JC, Coleman NC, Dewaraja YK, Frey E, Ghaly M, Grudzinski J, Hobbs RF, Howell RW, Humm JL, Kunos CA, **Larson S**, Lin FI, Madsen M, Mirzadeh S, Morse D, Pryma D, Sgouros G, St James S, Wahl RL, Xiao Y, Zanzonico P, Zukotynski K. Overview of the First NRG Oncology-National Cancer Institute Workshop on Dosimetry of Systemic Radiopharmaceutical Therapy. J Nucl Med. 2021 Aug 1;62(8):1133-1139. doi: 10.2967/jnumed.120.255547. Epub Dec 4 2020. PMID: 33277396; PMCID: PMC8833877.

688. Santich BH, Cheal SM, Ahmed M, McDevitt MR, Ouerfelli O, Yang G, Veach DR, Fung EK, Patel M, Burnes Vargas D, Malik AA, Guo HF, Zanzonico PB, Monette S, Michel AO, Rudin CM, **Larson SM**, Cheung NK. A Self-Assembling and Disassembling (SADA) Bispecific Antibody (BsAb) Platform for Curative Two-step Pretargeted Radioimmunotherapy. Clin Cancer Res. 2021 Jan 15;27(2):532-541. doi: 10.1158/1078-0432.CCR-20-2150. Epub 2020 Sep 21. PMID: 32958698; PMCID: PMC7855367.

689. Dunphy MPS, Pressl C, Pillarsetty N, Grkovski M, Modi S, Jhaveri K, Norton L, Beattie BJ, Zanzonico PB, Zatorska D, Taldone T, Ochiana SO, Uddin MM, Burnazi EM, Lyashchenko SK, Hudis CA, Bromberg J, Schöder HM, Fox JJ, Zhang H, Chiosis G, Lewis JS, **Larson SM**. First-in-Human Trial of Epichaperome-Targeted PET in Patients with Cancer. Clin Cancer Res. 2020 Oct 1;26(19):5178-5187. doi: 10.1158/1078-0432.CCR-19-3704. Epub 2020 May 4. PMID: 32366671; PMCID: PMC7541604.

690. Yerrabelli RS, He P, Fung EK, Kramer K, Zanzonico PB, Humm JL, Guo H, Pandit-Taskar N, **Larson SM**, Cheung NV. IntraOmmaya compartmental radioimmunotherapy using 131I-omburtamab-pharmacokinetic modeling to optimize therapeutic index. Eur J Nucl Med Mol Imaging. 13 October 2020. doi: 10.1007/s00259-020-05050-z. PMID: 33047248.

691. Krebs S, Veach DR, Carter LM, Grkovski M, Fornier M, Mauro MJ, Voss MH, Danila DC, Burnazi E, Null M, Staton K, Pressl C, Beattie BJ, Zanzonico P, Weber WA, Lyashchenko SK, Lewis JS, **Larson SM**, Dunphy MPS. First-in-Humans Trial of Dasatinib-Derivative Tracer for Tumor Kinase-Targeted PET. J Nucl Med. 2020 Nov;61(11):1580-1587. doi: 10.2967/jnumed.119.234864. Epub 2020 Mar 13. PMID: 32169913.

692. Roncali E, Capala J, Benedict SH, Akabani G, Bednarz B, Bhadrasain V, Bolch WE, Buchsbaum J, Clarke BN, Coleman N, Dewaraja YK, Frey EC, Ghaly M, Grudzinski J, Hobbs RF, Howell RW, Humm JL, Kunos C, **Larson SM**, Lin FI, Madsen MT, Mirzadeh S, Morse DL, Pryma DA, Sgouros G, St James S, Wahl RL, Xiao Y, Zanzonico PB, Zukotynski KB. Overview of the First NRG-NCI Workshop on Dosimetry of Systemic Radiopharmaceutical Therapy (RPT). J Nucl Med. 4 December 2020 :jnumed.120.255547. doi: 10.2967/jnumed.120.255547. Epub ahead of print. PMID: 33277396.

693. Wibmer AG, Morris MJ, Gonen M, Zheng J, Hricak H, **Larson SM**, Scher HI, Vargas HA. QUANTIFICATION OF METASTATIC PROSTATE CANCER WHOLE-BODY TUMOR BURDEN WITH FDG PET PARAMETERS AND ASSOCIATIONS WITH OVERALL SURVIVAL AFTER FIRST LINE ABIRATERONE OR ENZALUTAMIDE: A SINGLE-CENTER RETROSPECTIVE COHORT STUDY. J Nucl Med. 8 January 2021:jnumed.120.256602. doi: 10.2967/jnumed.120.256602. Epub ahead of print. PMID: 33419944.

694. Cheal SM, Patel M, Yang G, Veach DR, Xu H, Guo HF, Zanzonico PB, Axworthy DB, Cheung NV, Ouerfelli O, **Larson SM**. Correction to An N-Acetylgalactosamino Dendron-Clearing Agent for High-Therapeutic-Index DOTA-Hapten Pretargeted Radioimmunotherapy. Bioconjug Chem. 2021 Jan 24. doi: 10.1021/acs.bioconjchem.0c00686. Epub ahead of print. Erratum for: Bioconjug Chem. 2020 Mar 18;31(3):501-506. PMID: 33486949.

695. Krebs S, Dacek MM, Carter LM, Scheinberg DA, **Larson SM**. CAR Chase: Where Do Engineered Cells Go in Humans? Front Oncol. 2020 Sep 11;10:577773. doi: 10.3389/fonc.2020.577773. 11 September 2020 PMID: 33042849; PMCID: PMC7518311.

696. **Larson SM**. Gallagher's Principle of Metabolic Trapping. J Nucl Med. December 2020;61(Suppl 2):74S-76S. doi: 10.2967/jnumed.120.251942. PMID: 33293453.

697. Veach D, Storey CM, Lueckerath K, Braun K, von Bodman C, Lamminmäki U, Kalidindi TM, Strand SE, Strand J, Altai M, Damoiseaux R, Zanzonico PB, Benabdallah N, Pankov D, Scher HI, Scardino P, **Larson SM**, Lilja HG, McDevitt MR, Thorek DL, Ulmert D. PSA-targeted Alpha-, Beta- and Positron Emitting Immuno-Theranostics in Murine Prostate Cancer Models and Non-Human Primates. Clin Cancer Res. 2021 Jan 13:clincanres.3614.2020. doi: 10.1158/1078-0432.CCR-20-3614. Epub ahead of print. PMID: 33441295.

698. Kalidindi TM, Lee SG, Jou K, Chakraborty G, Skafida M, Tagawa ST, Bander NH, Schoder H, Bodei L, Pandit-Taskar N, Lewis JS, **Larson SM**, Osborne JR, Pillarsetty NVK. A simple strategy to reduce the salivary gland and kidney uptake of PSMA-targeting small molecule radiopharmaceuticals. Eur J Nucl Med Mol Imaging. 25 January 2021. doi: 10.1007/s00259-020-05150-w. Epub ahead of print. PMID: 33495926.

699. Dacek MM, Veach DR, Cheal SM, Carter LM, McDevitt MR, Punzalan B, Burnes Vargas D, Kubik TZ, Monette S, Santich BH, Yang G, Ouerfelli O, Kesner AL, Cheung NV, Scheinberg DA, **Larson SM**, Krebs S. Engineered Cells as a Test Platform for Radiohaptens in Pretargeted Imaging and Radioimmunotherapy Applications. Bioconjug Chem. 2021 Apr 21;32(4):649-654. doi: 10.1021/acs.bioconjchem.0c00595. Epub 2021 Apr 5. PMID: 33819023; PMCID: PMC8284561.

700. Heneweer C, Peñate Medina T, Tower R, Kalthoff H, Kolesnick R, **Larson S**, Peñate Medina O. Acid-Sphingomyelinase Triggered Fluorescently Labeled Sphingomyelin Containing Liposomes in Tumor Diagnosis after Radiation-Induced Stress. Int J Mol Sci. 2021 Apr 8;22(8):3864. doi: 10.3390/ijms22083864. PMID: 33917976; PMCID: PMC8068344.

701. Fanchon LM, Beattie BJ, Pentlow K, **Larson SM**, Humm JL. Optimizing reconstruction parameters for quantitative 124I-PET in the presence of therapeutic doses of 131I. EJNMMI Phys. 2021 Jul 12;8(1):50. doi: 10.1186/s40658-021-00398-z. PMID: 34250566; PMCID: PMC8273044.

702. Bolaender A, Zatorska D, He H, Joshi S, Sharma S, Digwal CS, Patel HJ, Sun W, Imber BS, Ochiana SO, Patel MR, Shrestha L, Shah SK, Wang S, Karimov R, Tao H, Patel PD, Martin AR, Yan P, Panchal P, Almodovar J, Corben A, Rimner A, Ginsberg SD, Lyashchenko S, Burnazi E, Ku A, Kalidindi T, Lee SG, Grkovski M, Beattie BJ, Zanzonico P, Lewis JS, **Larson S**, Rodina A, Pillarsetty N, Tabar V, Dunphy MP, Taldone T, Shimizu F, Chiosis G. Chemical tools for epichaperome-mediated interactome dysfunctions of the central nervous system. Nat Commun. 3 August 2021;12(1):4669. doi: 10.1038/s41467-021-24821-2. PMID: 34344873; PMCID: PMC8333062.

703. Chandler CS, Bell MM, Chung SK, Veach DR, Fung EK, Punzalan B, Burnes Vargas D, Patel M, Xu H, Guo HF, Santich BH, Zanzonico PB, Monette S, Nash GM, Cercek A, Jungbluth A, Pandit-Taskar N, Cheung NKV, **Larson SM**, Cheal SM. Intraperitoneal Pretargeted Radioimmunotherapy for Colorectal Peritoneal Carcinomatosis. Mol Cancer Ther. 2022 Jan;21(1):125-137. doi: 10.1158/1535-7163.MCT-21-0353. Epub 2021 Oct 19. PMID: 34667111; PMCID: PMC9157533.

704. Anand A, Heller G, Fox J, Danila DC, Bjartell A, Edenbrandt L, **Larson SM**, Scher HI, Morris MJ. Automated Bone Scan Index to Optimize Prostate Cancer Working Group Radiographic Progression Criteria for Men With Metastatic Castration-Resistant Prostate Cancer. Clin Genitourin Cancer. 2022 Jun;20(3):270-277. doi: 10.1016/j.clgc.2022.02.002. Epub 2022 Feb 9. PMID: 35279418; PMCID: PMC10039455.

705. Mauguen A, Grewal RK, Augensen F, Abusamra M, Mahajan S, Jayaprakasam VS, Osborne J, Haque S, Wong BZY, Ghossein RA, Fagin J, Schöder H, Tuttle RM, Ho A, Humm JL, **Larson SM**. The use of single-timepoint images to link administered radioiodine activity (MBq) to a prescribed lesion radiation-absorbed dose (cGy): a regression-based prediction interval tool for the management of well-differentiated thyroid cancer patients. Eur J Nucl Med Mol Imaging. 2023 Aug;50(10):2971-2983. doi: 10.1007/s00259-023-06240-1. Epub 2023 May 12. PMID: 37171634; PMCID: PMC10382352.

706. Chung SK, Vargas DB, Chandler CS, Katugampola S, Veach DR, McDevitt MR, Seo SH, Vaughn BA, Rinne SS, Punzalan B, Patel M, Xu H, Guo HF, Zanzonico PB, Monette S, Yang G, Ouerfelli O, Nash GM, Cercek A, Fung EK, Howell RW, **Larson SM**, Cheal SM, Cheung NV. Efficacy of HER2-Targeted Intraperitoneal ^{225}Ac α-Pretargeted Radioimmunotherapy for Small-Volume Ovarian Peritoneal Carcinomatosis. J Nucl Med. 2023 Sep;64(9):1439-1445. doi: 10.2967/jnumed.122.265095. Epub 2023 Jun 22. PMID: 37348919; PMCID: PMC10478816.

707. Bodei L, Michael Tuttle R, Grewal RK, Mauguen A, Augensen F, Abusamra M, Mahajan S, Jayaprakasam VS, Osborne JR, Haque S, Wong BZY, Ghossein RA, Fagin J, Schöder H, Ho A, Humm JL, **Larson SM**. Toward individualized dosimetry for radiopharmaceutical therapy in day-to-day clinical practice of nuclear oncology: overcoming heterogeneity of radiation-absorbed dose to tumor and critical organs. Eur J Nucl Med Mol Imaging. 2023 Sep 15. doi: 10.1007/s00259-023-06420-z. Epub ahead of print. PMID: 37712994

708. Engineered CAR-T cells for radiohapten capture in imaging and radioimmunotherapy applications. Keifer Kurtz1,2#, Laura Eibler3#, Megan M. Dacek1,2, Lukas M. Carter4, Darren R. Veach5,6, Samantha Lovibond3, Emma Reynaud3, Sarah Qureshy1, Michael R. McDevitt5,6, Christopher Bourne1,7, Sebastien Monette8, Blesida Punzalan1, Shireen Khayat1,2, Svena Verma2, Adam L. Kesner4, Nai-Kong V. Cheung9, Heiko Schöder3,6, Leah Gajecki3, Sarah M. Cheal1,6, **Steven M. Larson**1,3,6##, David A. Scheinberg1,2##, Simone Krebs3,5,6##,□□Theranostics 2023; 13(15): 5469-5482. doi: 10.7150/thno.87489

Books, book chapters and reviews

Books

1. Strauss HW, Dibos P, North WA, **Larson SM,** and Wagner HN Jr. Liver slide set. W.B. Saunders Company Publishers, Philadelphia, 1975.
2. Thorell JI, **Larson SM.** Radioimmunoassay and Related Methods: Methodology and Clinical Applications. CV Mosby Co., St. Louis, 1978, p. 298.
3. Hustinx R, Paulus P, Rigo P, Yeung HW, Macapinlac HA, **Larson SM.** Clinical PET in Oncology. GE Medical Systems-Europe, Paris, France, 1996.
4. **Larson SM,** and Krenning EP: Clinical Practice of Molecular Radiotherapy" Supplement J. Nucl. Med. January 2005. 204 pp.
5. Strauss HW, Mariani G, Volterrani D, and **Larson SM.** Nuclear Oncology. Pathopysiology and Clinical Applications. Springer, New York, December 2012.

Book chapters

1. Nelp WB, and **Larson SM.** Photoscanning of the placenta with Tc-99m labeled albumin. In Scintillation Scanning, Johnson and Freeman (Eds), Harper and Row, New York, 1969.
2. **Larson SM,** Schall GL, and DiChiro G. The unsuccessful injection in cisternography: incidence, cause, and appearance. In Proceedings of the Symposium on Cisternography and Hydrocephalus. Edited by J. Harbert, Charles C. Thomas Publishers, Springfield, 1972; p. 153.
3. **Larson SM,** Millar RC, Chalmers TC, Gelrud LG, Kramer RJ, Bailey JJ, Johnston GS. Quantitation of hepatic blood flow by xenon-133 clearance: a primate model. In The Liver: Quantitative Aspects of Structure and Function, Edited by G. Paumgartner and R. Prisieg: Proceedings of the First International Gstaad Symposium, Sept. 12-14, 1972, S. Karger Publishers, Arnold-Bocklin-Strasse 25, CH-4011 Basel, Switzerland, 1973; p. 96.
4. Chalmers TC, **Larson SM,** Milder MS, Green MV, Henson JH, Gelrud LG, Johnston GS. Clinical estimation of liver and spleen size: percussion versus photoscan. In The Liver: Quantitative Aspects of Structure and Function, Edited by G. Paumgartner and R. Prisieg; Proceedings of the First International Gstaad Symposium, Sept. 12-14, 1972, S. Karger Publishers, Arnold-Bocklin-Strasse 25, CH-40ll Basel, Switzerland, 1973; p. 76.
5. Thorell JI, and **Larson SM.** Fundamentals of radioreceptor assays. In Cardiovascular Nuclear Medicine, CV Mosby Publishers, St. Louis, 1974; p. 335.
6. **Larson SM,** and Nelp WB. The Placenta. In Clinical Scintillation Scanning, P.M. Johnson and L.M. Freeman, Eds, Harper and Row Publishers, New York (2nd Edition), 1975; p. 623.
7. **Larson SM,** Milder M, Johnston GS. Tumor seeking radiopharmaceuticals. In Radiopharmaceuticals, Edited by G. Subramanian, B.A. Rhodes, J.F. Cooper, and V. Sodd, Society of Nuclear Medicine Publishers, New York, 1975; p. 413.
8. Rothfeld B, and **Larson SM,** Tumor Antigens. In Nuclear Medicine In Vitro, B. Rothfeld, Ed., JP Lippincott Publishers, Philadelphia, 1975; p. 315.
9. **Larson SM,** Hegge FN. The placenta. In CRC Handbook series in Clinical Laboratory Science, sec. A, Nuclear Medicine, vol. I, Edited by R.P. Spencer, Chemical Rubber Co. Publishers, 1977; p. 147.

10. Jansen AA, **Larson SM.** Data presentation for nuclear medicine. In Quality Control in Nuclear Medicine, Edited by BA Rhodes, CV Mosby Co., St. Louis, 1977; p. 42.

11. Jansen AA, **Larson SM.** Sample selection for in vivo nuclear medicine. In Quality Control in Nuclear Medicine, Edited by BA Rhodes, CV Mosby Co., St. Louis, 1977; p. 34.

12. Kramer RJ, **Larson SM,** Milder MS, Herdt JR, Johnson RE, DeVita VT, Johnston GS. Localization of 67 Gallium citrate in unsuspected sites of neoplastic disease. In Proceedings of the International Atomic Energy Agency Symposium on Medical Radioisotope Scintigraphy, Monte Carlo, Oct. 23-28, 1972, UNIPUB, New York, 1973, vol. II, p. 641.

13. **Larson SM,** Hoffer PB. Normal patterns of localization. In Gallium-67 Imaging, Edited by Hoffer, Bekerman, and Henkin, John Wiley & Sons, Inc., New York, 1978; pp. 24-38.

14. Chesnut CC, **Larson SM.** Nuclear medicine techniques in metabolic bone disease. In Nuclear Medicine: Endocrinology, Edited by Rothfeld B, JB Lippincott Publishers, Philadelphia, 1978; pp. 252-269.

15. Camargo EE, **Larson SM,** Wagner HN Jr. Radiomicrobiology. In Textbook of Nuclear Medicine: Basic Science, Edited by Rocha AFG and Harbert JC, Lea and Febiger, Philadelphia, 1978; pp. 364-381.

16. Camargo EE, Johnston GS, **Larson SM,** Wagner HN. Tumors. In Textbook of Nuclear Medicine: Clinical Applications, Rocha AFG and Harbert JC, eds., Lea & Febiger, Philadelphia, 179, pp. 441-455.

17. Srivastava S, Richards P, Meinken GE, Som P, Atkins HL, **Larson SM,** Grunbaum Z, Rasey JS: Evaluation of radiolabeled ruthenium compounds as tumor-localizing agents. In Proceedings of the 2nd International Symposium on Radiopharmaceuticals, Seattle, WA, March 1-22, 179, Publ Society of Nuclear Medicine, Inc., NY, NY, pp. 265-274.

18. Thorell JI, **Larson SM.** Fundamentals of radioimmunoassay and other radioligand assays. In Cardiovascular Nuclear Medicine, Edited by Pitt and Strauss, the CV Mosby Co., St. Louis, 1979, pp. 377-384.

19. **Larson SM,** Rasey JS, Nelson NJ, Grunbaum Z, Allen DR, Harp GD, Williams DL. The kinetics of uptake and macromolecular binding of Ga-7 and Fe-9 by the EMT- sarcoma-like tumor of BALB/c mice. In Proceedings of the 2nd International Symposium on Radiopharmaceuticals, Seattle, WA, March 19-22, 1979, Publ Society of Nuclear Medicine, Inc., NY, NY, pp. 297-308.

20. **Larson SM,** Rasey JS, Allen DR. The transferrin-receptor hypothesis: mechanism of tumor uptake of carrier-free Gallium-67. In Frontiers in Nuclear Medicine, Edited by Horst W, Wagner Jr, HN, and Buchanan JW, Springer-Verlag, Berlin Heidelberg, New York, 1980, pp. 134-153.

21. Srivastava SC, Richards P, Meinken GE, **Larson SM,** Grunbaum Z. Tumor uptake of radioruthenium compounds. In Radiopharmaceuticals: Structure-activity Relationships, Spencer RP, ed., Grune & Stratton, Inc., New York, NY, 1981; pp. 207-223.

22. **Larson SM,** Factors determining tumor affinity for gallium-67 citrate. In Radiopharmaceuticals: Structure-Activity Relationships, Spencer RP, ed., Grune & Stratton, Inc., New York, NY, 1981; pp. 167-181.

23. **Larson SM,** Rasey JS, Huebers H, Nelson NJ, Grunbaum Z. Transferrin receptor regulated iron transport into nonhematopoietic tumor cells. In: The Biochemistry and Physiology of Iron. Proc 5th Int Conf on Proteins of Iron Storage and Transport, San Diego, CA, August, 1981. Saltman P and Hegenauer J, eds, Elsevier, New York, 1982, pp. 219-223.

24. Rasey JS, **Larson SM,** Huebers H. Transferrin-mediated uptake of iron and gallium in three nonhematopoietic tumor cell lines. In: The Biochemistry and Physiology of Iron. Proc 5th Int Conf on Proteins of Iron Storage and Transport, San Diego, CA, August, 1981. Saltman P and Hegenauer J, eds, Elsevier, New York, 1982, pp. 225-227.

25. **Larson SM,** Carrasquillo JA, Krohn KA. Radiotherapy with "anti-p97" iodinated monoclonal antibodies in melanoma. In: Proc 3rd World Congress of Nuclear Medicine and Biology, August-September, 1982, Paris, France. Raynaud C, Ed., Pergamon Press, New York, 1982, vol. IV, pp. 3666-3669.

26. **Larson SM,** Carrasquillo JA. Nuclear Oncology: Current Perspectives. In: Nuclear Medicine Annual, Freeman LM and Weissman HS, eds. Raven Press, New York, 1983, pp. 167-198.

27. **Larson SM,** Carrasquillo JA. Antibody-radioisotope conjugates for tumor localization and treatment. Proceedings, Conference on Immunity to Cancer, Williamsburg, VA, Sept. 10-12, 1984, Academic Press, New York, 1985; pp. 587-603.

28. Hellstrom KE, Hellstrom I, Brown JP, **Larson SM,** Nepom GT, and Carrasquillo JA. Three human melanoma-associated antigens and their possible clinical application in "Genes and antigens in cancer cells: The monoclonal antibody approach." Book series of Karger Publishing, Basel: Contributions of Oncology 1984; vol. 19, pp 121-131.

29. Carrasquillo JA, **Larson SM,** Hellstrom KE, Hellstrom I. Radioimmunodetection of human melanoma with monoclonal antibodies and Fab fragments. In: Radioimmunoimaging, Burchiel SW and Rhodes BA, eds. Elsevier North Holland, Inc, 1983; pp 357-368.

30. Weinstein JN, Black CDV, Barbet J, Eger RR, Parker RJ, Holton OD, Mulshine JL, Keenan AM, **Larson SM,** Carrasquillo JA, Sieber SM, Covell DG. Selected issues in the pharmacology of monoclonal antibodies, Edited by E. Tomlinson and S.S. Davis, 1986, John Wiley & Sons Ltd.Chapter 5 in Site-Specific Drug Delivery, pp. 81-92.

31. Keenan AM, **Larson SM.** Therapeutic implications of radiolabeled monoclonal antibodies, radionuclides in therapy. Spencer et al, eds., CRC Press, 1987; chap. 17, pp 183-191.

32. **Larson SM,** Carrasquillo JA: Current status of radioimmunoimaging and therapy, immune responses to metastases, Vol. II, Herberman et al, eds., CRC Press, 1987; chap. 13, pp 117-126.

33. Bunn PA, Foon KA, Ihde DC, Longo D, Schroff RW, Minna JD, Carrasquillo JA, Keenan AM, **Larson SM,** Glatstein E. "Treatment of cutaneous T-cell lymphomas with biologic response modifiers: recombinant leukocyte A interferon and T101 monoclonal antibody." Proceedings of the Second International Conference on Malignant Lymphomas. F Cavailli (ed), Martinus Nijhoff Co. Boston, 1985, pp 579-590.

34. Weinstein JN, Black CDV, Keenan AM, Holton OD, **Larson SM,** Sieber SM, Covell DG, Carrasquillo JA, Barbet J, Parker RJ. Use of monoclonal antibodies for detection of lymph node metastases. ICN-UCLA Symposium. 1984. Published in Monoclonal Antibodies in Cancer Therapy, RA Reisfeld and S Sell (Eds), 1986; pp 473-488.

35. Weinstein JN, Black CDV, Holton OD, Covell DG, Parker RJ, Mulshine JL, Lotze MT, Carrasquillo JA, Eger RR, Lewis A, **Larson SM,** Keenan AM: "Delivery of monoclonal antibodies to lymph nodes via the lymphatics, for The pharmacology and toxicology of proteins", JL Winkelhake and JS Holcenberg (Eds.) Alan R. Liss, NY, 1987; pp 75-89.

36. Abrams PG, Carrasquillo JA, Schroff RW, Eary JF, Fritzberg AR, Morgan AC, Wilbur DS, Beaumier PL, **Larson SM,** Nelp WB: Imaging and therapy of metastatic carcinoma with radiolabelled

monoclonal antibodies. In RK Oldham (Ed) Principles of Cancer Biotherapy. Raven Press, New York,1987; pp 337-354.

37. Yarchoan R, Thomas RV, Fischl MA, Grafman J, Wichman A, Lalakas M, Jacobsen FK, McAtee N, Perno CF, Safai B, Klecker RW, Collins JM, Berg G, Brunetti A, Schmidt PJ, Brouwers P, Spitzer AR, **Larson SM,** Myers CE, Broder S. Treatment of human immunodeficiency virus-associated neurological disease with 3'-AZIDO-2',3'-DIDEOXYTHYMIDINE. In: Bolognesi D. ed. Human Retroviruses, Cancer and AIDS. New York: Alan R. Liss Inc., 1988; pp. 393-406.

38. Carrasquillo JA, **Larson SM.** Radioimmunoscintigraphy of lymphoma with monoclonal antibodies. In: McGuire WL, ed. Lymphoma III. Immunologic approaches to the classification and management of lymphomas and leukemias. Martinus Nijhoff Publishers, The Hague, 1988 In Press.

39. Weinstein JN, Egert RR, Covell DG, Black CDV, Mulshine J, Carrasquillo JA, **Larson SM,** Keenan AM. The Pharmacology of monoclonal antibodies. In: Juliano RL, ed., Biological Approaches to the Controlled Delivery of Drugs. Ann of NY Acad of Sciences 1988; 507:199-210.

40. Schlom J, Johnston WW, Szpak CA, Sugarbaker P, Colcher D, Siler K, Thor A, Bryant G, Carrasquillo JA, Reynolds JC, Keenan AM, **Larson SM.** Tumor targeting with monoclonal antibody B72.3: Experimental and clinical results. In: Goldenberg DM, ed. Cancer Imaging with Radiolabeled Antibodies. Norwel, Mass: Martin Nijhoff Publishing, 1988 (in Press).

41. **Larson SM,** Carrasquillo JA, Reynolds JC, Keenan A, Sugarbaker P, Colcher D, Schlom J, Neumann R, Hellstrom I, Hellstrom KE, Mulshine J, Lotz M, and Strudler PK. The National Institutes of Health experience with radiolabeled monoclonal antibodies: lymphoma, melanoma, and colon cancer. In: Srivastava SC, ed. Radiolabelled Monoclonal Antibodies for Imaging and Therapy. New York: Plenum Publishing Corporation, 1988; pp. 393-407.

42. Baum RP, Hertel A, Madry N, Chatenoud L, Reynolds JC, Saccavinni JC, Auerbach B, **Larson SM,** Hor G. Human anti-mouse (HAMA) response: short and long term follow-up in 76 patients after diagnostic and therapeutic application of radiolabelled monoclonal antibodies. Schmidt HAE, Csernay L, eds. Nuklearmedizin Schattauer Stuttgart-New York, 1988; pp. 608-610.

43. Reynolds JC, Maloney P, Rotman M, Fejka R, Farkas RA, Yokoyama K, **Larson SM.** Radiohalogenation of monoclonal antibodies: Experiences with radioiodination of monoclonal antibodies for radioimmunotherapy. In: Srivastava SC, ed., Radiolabeled Monoclonal Antibodies for Imaging and Therapy. Plenum Publishing Corp 1988; pp. 215-227.

44. Schlom J, Colcher D, Szpak CA, Johnston WW, Sugarbaker P, Carrasquillo JA, Reynolds JC, **Larson SM.** A monoclonal antibody (B72.3) to adenocarcinoma of the colon and related tumors. In Cancer Detection. Mitchell M, ed. Immunity to Cancer II: Alan R. Liss Inc. Pub., New York, 1989; pp. 63-72.

45. **Larson SM.** Positron Emission Tomography in Oncology and Allied Diseases. In: DeVita VT, Hellman S, Rosenberg SA, eds. CANCER, Principles and practice of oncology. 2nd ed. Philadelphia, JB Lippincott Publishing 1989; 3(2):1-12.

46. Carrasquillo JA, Reynolds JC, Bunn PA, Foon KA, Schroff RW, Mulshine JL, Perentesis P, Horowitz M, **Larson SM.** Pharmacokinetics of In-111 T101 (Anti-CD5) monoclonal antibody in patients with cutaneous T-cell lymphoma. In: Goldenberg DM, ed. Cancer Imaging with Radiolabeled Antibodies. Norwell, MA. Martin Nijhoff Publishing, 1988 In Press.

47. Keenan AM, **Larson SM.** Therapeutic implications of radiolabeled monoclonal antibodies. In: Spencer RP, Seevers, Jr RH, Friedman AM, eds. Radionuclides in Therapy, (chap 17). Boca Raton, Florida: CRC Press 1988; pp.183-191.

48. Newman A, Channing M, Finn R, Dunn B, Simpson N, Carson R, Strowski N, Cohen R, Burke T, **Larson SM,** Rice K. Ligands for imaging opioid receptors in conscious humans by Positron Emission Tomography (PET). In: Problems of Drug Dependence, l988, L.S. Harris (Ed.) NIDA Research Monograph 90, U.S. Government Printing Office, Washington, DC 1989; pp 117-121.

49. Woolfenden JM, **Larson SM.** Tumor imaging using radiolabeled monoclonal antibodies. In: Gottschalk A, Hoffer PB, Potchen EJ, eds. Golden's Diagnostic Radiology, 1989; vol. 2, Diagnostic Nuclear Medicine. Baltimore: Williams & Wilkins pp. 1090-1096.

50. **Larson SM,** Britton KE, Porta E, Salvatore M. Introduction: Monoclonal Antibodies: Technical issues of selection, their role in diagnosis, and therapy of malignant neoplasms--Part II. Naples Italy. Nucl Med Biol, 1989, Int J Radiat Appl Instrum Part B, vol. 16, no. 6: ppv-vi.

51. Kramer EL, **Larson SM.** Tumor targeting with radiolabeled antibody for diagnosis and therapy. Editor: Oettgen H: Immunology & Allergy Clinics of North America, Human Cancer Immunology, W.B. Saunders, Publisher. May 1991; no. 2, 11:301-339.

52. **Larson SM,** Bading J, Kramer EL, Mulshine J, Carrasquillo JA. Kinetics of the accumulation of radiolabeled T101 in cutaneous T-cell lymphoma: Implications for biology and dosimetry. In: DeNardo GL, ed. Biology of Radionuclide Therapy, (American College of Nuclear Physicians) 1989; 173-182.

53. **Larson SM,** Cheung NKV, Leibel, SA. Antibodies in Cancer Treatment: Radioisotope Conjugates. In: DeVita VT, Hellman S, Rosenberg SA, eds. Biologic therapy of cancer: Principles and practice. Philadelphia: JP Lippincott 1991; pp. 496-511.

54. Abrams PG, Carrasquillo JA, Schroff RW, Eary JF, Fritzberg AR, Morgan, Jr. AC, Wilbur S, Beaumier PL, **Larson SM,** Nelp WB. Imaging and therapy of metastatic carcinoma with radiolabeled monoclonal antibodies. In: Oldham RK, ed. Principles of Cancer Biotherapy, 2nd Edition, New York: Marcel Dekker, Inc. 1991; pp. 471-492.

55. **Larson, SM**. PET in non-CNS malignancy with special reference to extremity sarcoma. In: Hubner KF, Collmann J, Buonocore E, Kabalka GW, eds. Clinical Positron Emission Tomography._ St. Louis:Mosby Year Book 1991; pp. 61-65.

56. Cheung NKV, Yeh SDJ, Gulati S, LaQuaglia M, Burch L, Kushner BH, **Larson SM.** I-131-3F8: clinical validation of imaging studies and therapeutic applications. In: Evans AE, D'Angio GJ, Knudson AG, Seeger RC (ed).: Advances in neuroblastoma research 3, Phi Philadelphia, Wiley-Liss, 1991; pp. 409-415.

57. Cheung N-KV, Pentlow KS, Graham MC, Yeh SJ, Finn RD, **Larson SM.** Radiation absorbed dose and tumor response during therapy with 3F8 Iodine-131 conjugated monoclonal antibody. In: Watson EE, Schlafke-Stelson AT, eds. Fifth International Radiopharmaceutical Dosimetry Symposium (CONF-910529). Proceedings of a conference held at Oak Ridge, Tennessee; Oak Ridge Associated Universities, 1992; pp. 95-112.

58. Daghighian F, Pentlow KS, **Larson SM,** Graham MC, DiResta GR, Yeh SDJ, Macapinlac HA, Finn RD, Arbit E, Cheung N-K V. Application of PET and compartmental modeling in estimation of cellular level microdosimetry: PET studies of I-124 labeled 3F8 MAb in human glioma. In: Watson EE, Schlafke-Stelson AT, eds: Fifth International Radiopharmaceutical Dosimetry Symposium (CONF-910529). Proceedings of a conference held at Oak Ridge, Tennessee: Oak Ridge Associated Universities, 1992; pp. 396-413.

59. **Larson SM.** Current status of radioimmunodetection of human tumors. In: M.K. Haseman Ed: Frontiers in Nuclear Medicine, Diagnostic Uses of Radiolabeled Monoclonal Antibodies, Proceedings of Symposium 9/26-27/91, Washington DC, ACNP, May 1992; pp. 1-14.

60. Scher HI, Maxon HR, Thomas SR, Schroder L, Curley T, Graham M, Yeh SDJ, **Larson SM.** Rhenium-186 hydroxyethylidene diphosphonate [186-Re-HEDP] for treatment of bone metastases from prostatic cancer. In: Murphy GP, Khoury S (eds): Recent Advances in Urological Cancers Diagnosis and Treatment. Atlanta, American Cancer Society 1991; pp. 96-99.

61. Castellino RA, DeLaPaz RL, **Larson SM.** Imaging techniques in cancer. In: DeVita VT,Jr., Hellman S, Rosenberg SA (eds): CANCER Principles & Practice of Oncology. 4th ed Philadelphia: JB Lippincott, 1993; pp. 507-531.

62. Abdel-Dayem KHM, Scott AM, Macapinlac HA, El-Gazzar,AH, **Larson SM.** Role of ^{201} Tl chloride and ^{99m} Tc sestamibi in tumor imaging. In: Freeman LM. (ed.) Nuclear Medicine Annual 1994; Raven Press, Ltd., NY, pp. 181-234.

63. Abdel-Dayem H, **Larson SM,** Macapinlac HA, Scott AM. Tumor diagnosis and therapy. "Thalium-201 Chloride: A tumor imaging agent". In: Murray IPC, Ell P, eds. Nuclear Medicine in Clinical Diagnosis and Treatment, Volume II. Churchill Livingstone Publishers, London, 1994; 727-736.

64. **Larson SM,** Sgouros G, Cheung N-K V. Radioisotope Conjugates. In: DeVita VT Jr., Hellman S, Rosenberg SA, eds. Biologic Therapy of Cancer: Principles and Practice. 2nd edition. Philadelphia: JP Lippincott 1995; pp. 534-552.

65. Finn RD, Divgi C, Goldsmith S, **Larson SM,** Macapinlac HA, Scott A, Yeh SDJ. Radionuclides and their application in oncology research. In: Emran A, [editor], Chemists' views of imaging centers. New York: Plenum Press 1995; pp. 277-284.

66. Divgi CR, Sgouros G, Daghighian F, **Larson SM.** Radiolabeled antibody imaging: applications and methodology. (Chapter: American college of nuclear physicans handbook on quality control in nuclear medicine, 1995).

67. Heelan RT, **Larson SM.** Imaging of thoracic neoplasms. In: Aisner J, ArriagadaR, Green MR, Martini N, Perry MC, Eds. Comprehensive Textbook of Thoracic Oncology. Baltimore: Williams & Wilkins, 1996; 112-168.

68. **Larson SM.** Radionuclide Imaging. In: DeVita V, Hellman S, Rosenberg S, (Eds) Cancer: Principles and Practice of Oncology. Philadelphia: Lippincott-Raven, 1996;pp. 31-37.

69. Finn R, Macapinlac H, Humm J, Pentlow K, McDevitt M, Tjuvajev J, Blasberg R, Scheinberg D, **Larson SM,** Zweit J. Application of PET radionuclides for nuclear medicine targeted therapies. In: Duggan JL, Morgan IL, eds. Application of accelerators in research and industry; proceedings of the fourteenth international conference. Woodbury, New York: American Institute of Physics; 1996: 1345-1347.

70. **Larson SM,** Sgouros G, Cheung N-K. Radiolabeled Antibodies: General Issues. In: J.R. Bertino (Ed): Encylopedia of Cancer, Vol III, Academic Press, CA 1997;pp.1420-1431.

71. Chestnut III CH, **Larson SM.** Bone and parathyroid imaging. In: BRothfeld(Ed): Nuclear Medicine: Endocrinology, J.B. Lippincott, 1998; pp.252-269.

72. Finn RD, McDevitt M, Ma D, Jurcic J, Scheinberg D, **Larson SM,** Shoner S, Link J, Krohn K, Schlyer D. Low energy cyclotron production and separation of yttrium-86 for evaluation of monoclonal antibody pharmacokinetics and dosimetry. In: Duggan JL, Morgan IL, eds. Application of accelerators in research and industry; proceedings of the fifteenth international conference, part two. Woodbury, New York: American Institute of Physics; 1999:991-993.

73. **Larson SM,** Divgi CR, Sgouros G, Cheung N-K, Scheinberg DA. Radioisotope Conjugates. In: Principles and Practice of the Biologic Therapy of Cancer, ed: Rosenberg SA. 3rd Edition, Lippincott Inc., Philadelphia, 2000.

74. Ling CC, Humm J, **Larson SM,** Amols H, Fuks Z, Leibel S, Koutcher JA. Towards multidimensional radiotherapy (MD-CRT): Biological imaging and biological conformality. Int J. Radiation Oncology Biol. Phys. 2000; 47(3): 551- 560.

75. Divgi C, **Larson SM**: Nuclear Medicine. In Dennis A Casciato, Ed. Manual of Clinical Oncology. Lippincott Williams and Wilkins Phila 2004.

76. Swift PS, **Larson SM,** Price DC: Cancer of the Thyroid In Leibel and Philips (Eds). Textbook of Radiation Oncology. Sauders, 2nd Edition. Phila. 2004.

77. **Larson, Steven M**. "The Future of Nuclear Medicine: Molecular Imaging and Radiotherapy." Nuclear Medicine 2nd Ed. Volume 2. Henkin, Robert E. Philadelphia: Mosby, 2006. 1556-1564.

78. **Larson, Steven M**., Grewal, Ravinder K., Tuttle, Michael M. "Thyroid Cancer Imaging with PET and SPECT." Molecular Anatomic Imaging PET-CT and SPECT-CT Integrated Modality Imaging 2nd Ed. Gustav K. von Schulthess. Philadelphia: LWW, 2007. 315-326.

79. **Larson, Steve M**., Rosenzweig, Kenneth, Schőder, Heiko, Humm, John. "PET and PET-CT in Radiation Treatment Planning." Molecular Anatomic Imaging PET-CT and SPECT-CT Integrated Modality Imaging 2nd Ed. Gustav K. von Schulthess. Philadelphia: LWW, 2007. 501-516.

80. **Larson SM,** Pandit-Taskar N**.** Contemporary Issues in Cancer Imaging Prostate Cancer "Nuclear medicine: Diagnostic Evaluation of Metastatic Disease." 2007. Chapter 11.

81. Robbins RJ, **Larson SM.** "The value of position emission tomography (PET) in the management of patients with thyroid cancer" Best Practice Research. Clinical Endocrinology & Metabolism. Volume 22 Number 6, Thyroid Nodules and Cancer. December 2008. Chapter 11. 1047-1059.

82. Grewal R, **Larson SM**, Carrasquillo J. "The Role of Nuclear Medicine" A Practical Manual of Thyroid and Parathyroid Disease. Wiley Blackwell. United Kingdom: 2009 Section 1.

83. Swift, P., **Larson, SM**., Clark, O., Ruan, D. "Cancer of the Thyroid" Liebel and Philips Textbook of Radiation Oncology, Third Ed. Elsevier Suanders. Philedelphia, PA: 2010 Chapter 34. 726-736.

84. Strauss, HWS., Mariani, G., Volterrani, D., **Larson, SM.** "Nuclear Oncology" Pathopysiology and Clinical Applications. Springer, New York, December 2012: 3-19.

Reviews

1. **Larson SM,** and Thorell JI. Introduction and general principles of competitive radioassay (radioreceptor assay). Lab Med 1974; 5:15.

2. **Larson SM,** and Thorell JI. Die principien vo kompetitinen radioassays. Das Medizihische Laboratoreum 1975; 28:51061.

3. **Larson SM.** Quality assurance in radioimmunoassay May/June 1977. Applied Radiology 1977; 6:224.

4. **Larson SM.** Mechanisms of localization of Gallium-67 in tumors. Semin Nucl. Med 1978; 8:193-203.

5. Hellstrom I, Hellstrom KE, Brown JP, **Larson SM.** Monoclonal antibodies to human melanoma antigens - possible clinical applications Clinical Immunology Newsletter, June 1983; vol. 8, 71-74.

6. **Larson SM,** Carrasquillo JA: Nuclear Oncology 1984. Seminars in Nuclear Medicine October 1984, vol. XIV, no. 4, pp. 268-276.

7. **Larson SM,** Carrasquillo JA: Role of labelled antibodies in tumor detection and possible treatment. Current concepts in diagnostic nuclear medicine. 13-16, Winter 1984; vol. 1, no. 4.

8. **Larson SM.** Radiolabeled monoclonal anti-tumor antibodies in diagnosis and therapy, J Nuc Med, May 1985, pp. 538-545.

9. **Larson SM,** Carrasquillo JA, Reynolds JC. Radioimmunodetection and Radioimmunotherapy. Cancer Investigation, vol. 2, no. 5, 1984; 363-381.

10. LaFrance ND, Donner MW, **Larson SM,** Scheffel U: Diagnostische anwendung monoklonaler antikorper, Dtsch MMed Wschr 1985; 110:651-653.

11. Keenan AM, Harbert J, **Larson SM.** Monoclonal antibodies in nuclear medicine. J Nucl Med 1985; 26:531-537.

12. **Larson SM,** Carrasquillo JA: An overview of diagnostic imaging of tumors with radiolabeled antibodies, Yearbook of Nuclear Medicine, 1985, pp. 17-27.

13. **Larson SM**. Cancer imaging with monoclonal antibodies. Important Adv Oncol. 1986:233-49. Review

14. **Larson SM,** Carrasquillo JA, Reynolds JC, Hellstrom I, Hellstrom KE, Mulshine JC, Mattis LE. Therapeutic applications of radiolabelled antibodies: Curent situation and prospects. Nucl Med Biol 1986 13:207-213.

15. **Larson SM,** Fishbein D, Finn RD, Baldwin GP: Assessment of functional Imaging: II. Quality control issues, J Cereb Blood Flow Metab 1987; vol. 7, no. 2, S8-10.

16. **Larson SM.** Lymphoma, Melanoma, Colon Cancer: Diagnosis and treatment with radiolabeled monoclonal antibodies, The 1986 Eugene P. Pendergrass New Horizons Lecture, Radiology 1987; 165:297-304.

17. Weinstein JN, Eger RR, Covell DG, Black CD, Mulshine J, Carrasquillo JA, **Larson SM**, Keenan AM. The pharmacology of monoclonal antibodies. Ann N Y Acad Sci. 1987;507:199-210. Review.

18. Schlom J, Greiner JW, Colcher D, **Larson SM,** Carrasquillo JA, Reynolds JC, Sugarbaker P, Siler K. Concepts in the delivery of monoclonal antibodies in the targeting of human carcinomas. Advanced Drug Delivery Reviews 1988; 2:229-251.

19. Divgi CR, **Larson SM.** Radiolabeled monoclonal antibodies in the diagnosis and treatment of malignant melanoma. Seminars in Nucl Med October 1989; vol. XIX, no. 4, pp. 252-261.

20. **Larson SM.** Advances in cancer diagnosis through Positron Emission Tomograph. Accomplishments in cancer research, J.P. Lippincott Publisher, 1990; General Motors Cancer Research Foundation 1989; pp. 177-189.

21. Mulshine JL, Avis I, Treston AM, Kaspryzyk PG, Nakanishi Y, Mobley C, Carrasquillo JA, **Larson SM**, Merchant B, Cuttitta F. In vivo diagnosis and therapy of human tumors with monoclonal antibodies: selection of antibodies and preliminary clinical studies in small cell carcinoma of the lung. Int J Rad Appl Instrum B. 1989;16(2):159-62. Review.

22. Houghton AN, **Larson S**. Monoclonal antibodies for the treatment of cancer: therapeutic strategies. Curr Opin Oncol. 1989 Dec;1(2):258-65. Review.

23. Yeh SD, **Larson SM**. Tumor imaging with monoclonal antibodies and gallium-67. Curr Opin Radiol. 1989 Dec;1(4):508-17. Review

24. **Larson SM.** Clinical Radioimmunodetection 1978-1988: Overview and suggestions for standardization of Clinical trials. Cancer Research (Suppl.) 1990; 50:892s-898s.

25. **Larson SM**. Improved tumor targeting with radiolabeled, recombinant, single-chain, antigen-binding protein. J Natl Cancer Inst. 1990 Jul 18;82(14):1173-4. Review.

26. Schlom J, Siler K, Colcher D, Carrasquillo JA, Reynolds JC, Sugarbaker P, **Larson SM.** Binding of radiolabeled MAb B72.3 administered intravenously and intraperitoneally in colorectal cancer patients. An overview. Acta Radiol Suppl. 1990;374:123-8. Review.

27. **Larson SM.** Radioimmunology: Imaging and Therapy. National Conference on Advances in Cancer Imaging. Cancer 1991; vol. 67, no. 4, pp. 1253-1260.

28. **Larson SM.** Overview of radioimmunodetection: Technical advances. Proceedings of Third Conf. on Radioimmunodetection and Radioimmunotherapy of Cancer. Antibody Immunoconjugates and Radiopharmaceuticals. 1991; vol. 4, no. 4, pp. 525-530.

29. Goldenberg DM, **Larson SM.** (Continuing Education) Radioimmunodetection in cancer identification. J Nucl Med 1992; 33:803-814.

30. Scher HI, Curley T, Yeh S, Tong W, O'Moore PV, **Larson S.** Hormone refractory prostatic cancer: the role of radiolabelled diphosphonates and growth factor inhibitors. Adv Exp Med Biol. 1992;324:115-29. Review.

31. Scott AM, **Larson SM.** Tumor imaging and therapy. Radiologic Clinics of North America 1993; 31:859-879.

32. **Larson SM**, Macapinlac HA, Scott AM, Divgi CR. Recent achievements in the development of radiolabeled monoclonal antibodies for diagnosis, therapy and biologic characterization of human tumors. Acta Oncol. 1993;32(7-8):709-15. Review.

33. Abdel-Dayem H, Scott A, Macapinlac HA, **Larson SM.** (Review Article) Tracer imaging in lung cancer. Eur J Nucl Med 1994; 21:57-81.

34. **Larson SM,** Divgi, CR, Scott AM. Overview of clinical radioimmunodetection of human tumors. Cancer (Suppl.) 1994; 73(3):832-835.

35. **Larson SM,** Macapinlac H, Scott A, Divgi C. Recent achievements in the development of radiolabeled monoclonal antibodies for diagnosis, therapy and biologic characterization of human tumors. ACTA Oncologica 1993; vol. 32, no. 7/8, pp. 709-715.

36. Macapinlac HA, Scott AW, **Larson SM,** Divgi CR, Yeh SDJ, Goldsmith SJ. Gallium-67-citrate imaging in nuclear oncology. Nucl Med Biol 1994; 21:731-738.

37. Scott AM, Macapinlac HA, Zhang J, Kalaigian H, Graham MC, Divgi CR, Sgouros G, Goldsmith SJ, **Larson SM.** Clinical applications of fusion imaging in oncology. Nucl Med Biol 1994; 21:775-784.

38. **Larson SM,** Divgi CR, Scott A, Sgouros G, Graham MC, Kostakoglu L, Scheinberg D, Cheung NKV, Schlom J, Finn RD. Current status of radioimmunotherapy. Nucl Med Biol 1994; 21:785-792.

39. **Larson SM,** Divgi C, Scott A, Daghighian F, Macapinlac HA, Welt S. Current status of radioimmunodetection. Nucl Med Biol 1994; 21:721-729.

40. **Larson SM,** Schwartz LH. Advances in Imaging. Seminars in Oncology 1994; 21(5):598-606.

41. **Larson SM**, Schwartz LH. Advances in imaging. Semin Oncol. 1994 Oct;21(5):598-606. Review.

42. Wahl RL, Hawkins RA, **Larson SM**, Hendee WR, Coleman RE, Holden RW, Frick MP, Gatsonis C, Brown GS, Shtern F. Proceedings of a National Cancer Institute workshop: PET in oncology--a clinical research agenda. Radiology. 1994 Dec;193(3):604-6. Review.

43. Scott AM, **Larson SM,** Divgi CR, Welt S. Radioimmunodetection of colorectal cancer. Diagn Oncol 1994-95; 4:115-122.

44. **Larson SM**, Tjuvajev J, Blasberg R. Triumph over mischance: a role for nuclear medicine in gene therapy. J Nucl Med. 1997 Aug;38(8):1230-3. Review.

45. Akhurst T, **Larson SM.** Positron emission tomography imaging of colorectal cancer. Semin Oncol 1999; 26(5): 577-83.

46. Ling CC, Humm J, **Larson S**, Amols H, Fuks Z, Leibel S, Koutcher JA. Towards multidimensional radiotherapy (MD-CRT): biological imaging and biological conformality. Int J Radiat Oncol Biol Phys. 2000 Jun 1;47(3):551-60. Review.

47. **Larson SM**, Akhurst T: Nuclear Imaging in the Diagnosis and Follow-up of Cancer. Surgical Oncology, contemporary principles & practice, Part I, 4/C, 2001.

48. **Larson SM,** and Robbins, R. Positron emission tomography in thyroid cancer management. Semin Roentgenol, *37:* 169-174, 2002.

49. Pandit-Taskar, N., Hamlin, P. A., Reyes, S., **Larson SM,** Divgi, C. R. New strategies in radioimmunotherapy for lymphoma. Curr Oncol Rep, *5:* 364-371, 2003.

50. Schoder, H., Erdi, Y. E., **Larson SM,** Yeung, H. W. PET/CT: a new imaging technology in nuclear medicine. Eur J Nucl Med Mol Imaging, 2003 Oct;30(10):1419-37. Epub 2003 Sep 05.

51. Sarikaya I, **Larson SM**, Freiman A, Strauss HW. What nuclear cardiology can learn from nuclear oncology. J Nucl Cardiol. 2003 May-Jun;10(3):324-8. Review.

52. Oosterweijk E, Divgi CR, Brouwers A, Boerman OC, **Larson SM,** SM, Mulders P and Lloyd Old: Monooclonal Antibody therapy for Renal Cancer. The Urologic Clinicals of North America 30(3): 663, August, 2003.

53. Tuttle M, Robbins R, **Larson SM,** Strauss HW: Challenging cases in thyroid cancer: a multidisciplinary approach. Eur J Nucl Med Mol Imaging. 2004 Apr;31(4):605-612.

54. Schoder H, **Larson SM,** Yeung HW**.** PET/CT in oncology: integration into clinical management of lymphoma, melanoma, and gastrointestinal malignancies. J Nucl Med. 2004 Jan;45 Suppl 1:72S-81S.

55. Morris MJ, Pandit-Taskar N, Divgi C, **Larson SM,** Scher HI. Targeting Osseous Metastases: Rationale and Development of Radio- immunotherapy for Prostate Cancer. CurrOncolRep.2004May;6(3):222-229.

56. **Larson SM,** Schoder H, Yeung H. Positron emission tomography/computerized tomography functional imaging of esophageal and colorectal cancer. Cancer J. 2004 Jul-Aug;10(4):243-250.

57. Schoder H, **Larson SM,** Positron emission tomography for prostate, bladder, and renal cancer. Semin Nucl Med. 2004 Oct;34(4):274-292.

58. Kelloff, G.J., J.M. Hoffman, B. Johnson, H.I. Scher, B.A. Siegel, E.Y. Cheng, B.D. Cheson, J. O'Shaughnessy, K.Z. Guyton, D.A. Mankoff, L. Shankar, S.M. **Larson SM,** C.C. Sigman, R.L. Schilsky, and D.C. Sullivan, *Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development.* Clin Cancer Res, 2005. **11**(8): p. 2785-808.

59. Morris, M.J., N. Pandit-Taskar, C. Divgi, S. **Larson SM,** and A.H. Scher, *Targeting Osseous Metastases: Rationale and Development of Radio- immunotherapy for Prostate Cancer.* Curr Urol Rep, 2005. **6**(3): p. 163-170.

60. Schoder H, Glass EC, Pecking AP, et al. Molecular targeting of the lymphovascular system for imaging and therapy. Cancer Metastasis Rev. Jun 2006;25(2):185-201.

61. Arc- C, Hsu JF, Schoder H, Shah J, **Larson SM**, Shalha AR. FDG-PET Delected Thyroid Incidentalomas: Need for Further Investigation Ann Surg Oncol. 10/06/06.

62. Flores RMRM, Akhurst TT, Gonen MM, et al. Positron emission tomography predicts survival in malignant pleural mesothelioma. Journal of thoracic and cardiovascular surgery. 2006;132(4):763-768.

63. McBride WJWJ, Zanzonico PP, Sharkey RMRM, et al. Bispecific antibody pretargeting PET (immunoPET) with an 124I-labeled hapten-peptide. The Journal of nuclear medicine. 2006;47(10):1678-1688.

64. Pal AA, Glekas AA, Doubrovin MM, et al. Molecular imaging of EGFR kinase activity in tumors with 124I-labeled small molecular tracer and positron emission tomography. Molecular imaging and biology. 2006;8(5):262-277.

65. Tuttle RMRM, Leboeuf RR, Robbins RJRJ, et al. Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer. The Journal of nuclear medicine. 2006;47(10):1587-1591.

66. Hendee WR, Banovac F, Carson PL, DeFronzo RA, Eckelman WC, Fullerton GD, **Larson SM**, McLennan G, Welch MJ. Biomedical imaging research opportunities workshop IV: a white paper. *Med Phys*. 2007; 34:673-679.

67. Schoder H, Glass EC, Pecking AP, Harness JK, Wallace AM, Hirnle P, Alberini JL, Vilain D, **Larson SM**, Hoh CK, Vera DR. Molecular targeting of the lymphovascular system for imaging and therapy. *Cancer Metastasis Rev*. 2006;25: 185-201.

68. Scher HI, Morris MJ, **Larson S**, Heller G. Validation and clinical utility of prostate cancer biomarkers. Nat Rev Clin Oncol. 2013 Apr;10(4):225-34. doi: 10.1038/nrclinonc.2013.30. Epub 2013 Mar 5. Review.

69. Buchegger F, **Larson SM**, Mach JP, Chalandon Y, Dietrich PY, Cairoli A, Prior JO, Romero P, Speiser DE. Radioimmunotherapy combined with maintenance anti-CD20 antibody may trigger long-term protective T cell immunity in follicular lymphoma patients. Clin Dev Immunol. 2013; 2013:875343. doi: 10.1155/2013/875343. Epub 2013 Nov 26. Review.

70. Pandit-Taskar N, **Larson SM**, Carrasquillo JA. Bone-seeking radiopharmaceuticals for treatment of osseous metastases, Part 1: α therapy with 223Ra-dichloride.J Nul Med. 2014 Feb;55(2);268-74. Doi: 10.297/jnumed.112.112482. Epub 2013 Dec16. Review.

71. Pirasteh, A., Riedl, C., Mayerhoefer, M. E., Giancipoli, R. G., **Larson, S**. M., Bodei, L. PET/MRI for neuroendocrine tumors: A match made in heaven or just another hype? Clinical and Translational Imaging 2019;7::405–13. Doi:10.1007/s4033619003441. 2019 Dec 1. Review.

72. Mota JM, Armstrong AJ, **Larson SM**, Fox JJ, Morris MJ. Measuring the unmeasurable: automated bone scan index as a quantitative endpoint in prostate cancer clinical trials. *Prostate Cancer and Prostatic Diseases.* 2019;22(4):522-530. Doi:10.1038/s41391-019-0151-4. 2019 Dec. 1. Review.

73. Cheal SM, Chung SK, Vaughn BA, Cheung NV, **Larson SM.** Pretargeting: A Path Forward for Radioimmunotherapy. J Nucl Med. 2022 Sep;63(9):1302-1315. doi: 10.2967/jnumed.121.262186. PMID: 36215514.

Editorials, Guidelines and Position Papers

1. **Larson SM,** Siegel BA, Robinson RG. Guidelines for the clinical evaluation of radiopharmaceutical drugs. J Nucl Med 1978; 19:1359-1362.
2. **Larson SM.** Quantitative imaging of neuroreceptors in the living human brain, The Johns Hopkins Medical Institutions, Baltimore, Maryland, March 14-15, 1985, Notes and Impressions from Meetings. J Computer Assisted Tomography September/October 1985; 9(5):997-998.
3. Plascjak P, Finn RD, Strudler P, **Larson SM,** Yamashita Y, Googins S, Sheh Y, Meyer W. The operational status of the national institutes of health cyclotron complex. Proc. Cyclotron '86 Tokyo Conference, Oct. 13-17, 1986, (IEEE, NY) 1986.
4. Strudler PK, **Larson SM:** Radiolabeled monoclonal antibodies: a "decisive" technology. J Nucl Med, March 1985, vol. 13, 1:46-52.
5. Kuhl D, Wagner HN, Alavi A, Coleman RE, KL Gould, **Larson SM,** Mintun M, Siegel BA, Strudler, P. Positron Emission tomography (PET): Clinical Status in the United States in 1987. J Nucl Med 1988; 29:1136-1143.
6. Fowler JS, Hoffman EJ, **Larson SM,** Schelbert HR, Schwaiger M, Wagner HN Jr, Wolf AP, Strudler PK. Positron emission tomography in oncology: Council on Scientific Affairs. Report of the Positron Emission Tomography Panel. JAMA 1988; 259:2126-2131.
7. Fowler JS, Hoffman EJ, **Larson SM,** Schelbert HR, Schwaiger M, Wagner HN Jr, Wolf AP. Cyclotrons and radiopharmaceuticals in Positron Emission Tomography. Council on Scientific Affairs, Report of the Positron Emission Tomography Panel. JAMA 1988; 259:1854-1860.
8. Fowler JS, Hoffman EJ, **Larson SM,** Schelbert HR, Schwaiger M, Wagner HN, Wolf AP, Hendee WR. Positron emission tomography--a new approach to brain chemistry. Council on Scientific Affairs, Report of the Positron Emission Tomography Panel. JAMA 1988; 260:2704-2710.
9. Fowler JS, Hoffman EJ, **Larson SM,** Schelbert HR, Schwaiger M, Wagner HN Jr, Wolf AP. Application of positron emission tomography in the heart. Council on Scientific Affairs, Report of the Positron Emission Tomography Panel. JAMA 1988; 259:2438-2445.
10. **Larson SM,** Britton K, Porta E, Salvatore M. In Vivo diagnosis and therapy of human tumors with monoclonal antibodies: Overview of the Symposium. Nucl Med Biol, Int J Radiat Appl Instrum Part B 1989; 16(2):VII-VIII.
11. **Larson SM.** Are we there yet? Radioimmunotherapy and 40 years of effort. Oncology, May 1989; vol. 3, no. 5, The Article Reviewed pp. 129-130.
12. Houghton AN, **Larson SM.** Monoclonal antibodies for the treatment of cancer: Therapeutic strategies. Current Opinion in Oncology 1989; 1:258-265.
13. Yeh SDJ, **Larson SM.** Tumor imaging with monoclonal antibodies and Ga-67 Citrate. Current Science/ Current Opinion in Radiology 1989; vol. 1, no. 4:508-517.

14. Al-Aish M, Coleman RE, **Larson SM.** The Workshop Panel: National Cancer Institute Workshop Statement. Advances in clinical imaging using Positron Emission Tomography, September 14-16, 1988. Arch Intern Med 1990; vol. 150, pp. 735-739.

15. **Larson SM.** Editorial: Improved tumor targeting of a recombinant single-chain antigen-binding protein. (JNCI) Journal of the National Cancer Institutes, 1990; vol. 82, no. 14, pp.1173-1174.

16. **Larson SM.** First Reports from Unexplored Seas: Radiolabeled antibodies and cancer. Editorial for Cancer Investigation 1990; vol. 8(3/4), pp. 443-444.

17. **Larson SM.** Editorial: Biologic characterization of melanoma tumors by antigen-specific targeting of radiolabeled anti-tumor antibodies. J Nucl Med 1991; vol. 32, no. 2, pp. 287-291.

18. **Larson SM.** INTRODUCTION: Second International Conference on Diagnosis and Therapy with Monoclonal Antibodies. Nucl Med Biol 1991; vol. 18, no.1, pp. 1-2.

19. **Larson SM.** Editorial: Choosing the right radionuclide and antibody for intraperitoneal radioimmunotherapy. J Natl Cancer Inst 1991; 83:1602-1604.

20. **Larson SM.** Editorial. A model for others: a strategy for improving diagnosis and therapy of human malignancies using monoclonal antibodies targeting and TAG-72 oncofetal antigen. Cancer Invest 1993; 11, no. 2, pp. 235-238.

21. **Larson, SM**. Commentary on the Goldenberg Article. New perspectives in cancer diagnosis and management (Scientific Publication). 1993; 1(1):12.

22. Macapinlac HA, **Larson SM.** Editorial Review on Glaspy et al article: Whole Body PET in Oncology. Oncology 1993; 7:52-53.

23. Eckelman WC, DiChiro G, Salvatore M, **Larson SM.** Introduction: Diagnostic imaging in oncology, 28-30 April l993, Naples, Italy. Nucl Med Biol 1994; 21:681.

24. **Larson SM.** Editorial: Cancer or Inflammation?: A Holy Grail for Nuclear Medicine. J Nucl Med 1994; 35(10):1653-1655.

25. Wahl RL, Hawkins RA, **Larson SM,** Hendee WR, Coleman RE, Holden RW, Frick MP, Gatsonis C, Brown GS, Shtern F. Proceedings of a National Cancer Institute Workshop: PET in oncology- A clinical research agenda. Radiology 1994; 193:604-606.

26. Katzenellenbogen JA, Coleman RE, Hawkins RA, Krohn KA, **Larson SM,** Mendelsohn J, Osborne CK, Piwnica-Worms D, Reba RC, Siegel BA, et al. Tumor receptor imaging: proceedings of the National Cancer Institute Workshop, review of current work, and prospective for further investigations. Clin Cancer Res 1995;1(8): 921-932.

27. **Larson SM.** RIGS: Surgery. Talking the talk and (just possibly) walking the walk. Cancer Investigation 1996; 14(6):637-639.

28. Eckelman WC, **Larson SM,** Budinger T, Salvatore M. Preface: New trends in nuclear oncology 27-29 September 1995, Naples, Italy. Nucl Med Biol 1996; 23.

29. **Larson SM.** Triumph over mischance: a role for nuclear medicine in gene therapy [Editorial]. J Nucl Med 1997; 38:1230-1233.

30. Macapinlac HA, **Larson SM.** Positron Emission Tomography (PET)—measured biochemical response top radiotherapy of laryngeal tumors. Cancer J Sci Am 1997 Nov-Dec;3(6):333-335.

31. **Larson SM.** Molecular imaging in oncology: The diagnostic imaging "revolution". 2000 Clinical Cancer Research 2000; 6: 2125.

32. **Larson SM**, Editorial: Positron Emission Tomography (PET) and the Changing Face of China. Clinical Positron Imaging, 3(6) 2000:221-222.

33. Chapman, J. D., Bradley, J. D., Eary, J. F., Haubner, R., **Larson SM,** Michalski, J. M., Okunieff, P. G., Strauss, H. W., Ung, Y. C. and Welch, M. J. Molecular (functional) imaging for radiotherapy applications: an RTOG symposium. Int J Radiat Oncol Biol Phys, 2003. *55:* 294-301.

34. Sarikaya, I., **Larson SM,** Freiman, A. and Strauss, H. W. What nuclear cardiology can learn from nuclear oncology. J Nucl Cardiol, 2003. *10:* 324-328.

35. **Larson SM**: Positron Emission Tomography-Based Molecular Imaging in Human Cancer: Exploring the Link between Hypoxia and Accelerated Glucose Metabolism. Clin Cancer Res. 2004 Apr 1;10(7):2203-2204.

36. Miyahira AK, Pienta KJ, Babich JW, Bander NH, Calais J, Choyke P, Hofman MS, **Larson SM**, Lin FI, Morris MJ, Pomper MG, Sandhu S, Scher HI, Tagawa ST, Williams S, Soule HR. Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting. Prostate. 2020 Nov;80(15):1273-1296.

Date: 02/04/2021

Signature: